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ABSTRACT 
Mupirocin (Pseudomonic acid A, PA-A), produced by Pseudomonas fluorescens is the 
antibacterial active component in the skin cream Bactoban. The effect of this 
compound is to inhibit the isoleucyl t-RNA synthase involved in protein synthesis in 
bacteria. Previous isotope labelling studies indicate that pseudomonic acid A is 
polyketide in origin and is formed from an unusual polyketide moiety, monic acid, 
esterified with 9-hydroxynonanoic acid. The biosynthetic gene cluster responsible for 
PA-A biosynthesis has been cloned and sequenced and this has allowed investigation of 
the biosynthetic pathway by targeted gene disruptions. These result in the isolation of a 
new metabolite named mupirocin W which contains an extra methyl group and lacks the 
characteristic tetrahydropyran ring of other pseudomonic acid metabolites. This 
indicates the role of the mup W gene which encodes a dioxygenase is in activation of the 
methyl group which becomes part of the tetrahydropyran ring. Mutations of the mupO, 
mupU and mupV genes all result in the production of pseudomonic acid B, normally a 
minor metabolite in the fermentation. MupO encodes a cytochrome P450, mupU an 
acyl CoA synthase and mup Va NADH-dependent oxidoreductase. They are proposed 
to function together in a common step in the pathway which controls the flux of 
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The MupT and MupW biosynthetic proteins have been expressed and purified as 
his6-tagged fusion proteins. Both proteins were found to be mainly in the insoluble 
form but some MupT was in the soluble fraction. This was purified to near 
homogeneity. Attempts to refold the insoluble fractions were not successful. 
Mensacarcin is an aromatic polyketide antibiotic produced by Streptomyces 
C414. In order to isolate the polyketide synthase gene cluster, genomic libraries were 
constructed and screened with a fragment of the actl Type II PKS gene probe. No 
significant regions with similarity to any PKS genes were isolated. 
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CHAPTER 1 
INTRODUCTION 
Chapter 1 Introduction 
1.1 Primary and Secondary Metabolites 
Primary metabolism, for example respiration and photosynthesis, is the process, which 
produces compounds such as the common sugars, fatty acids, a-amino acids, proteins 
and nucleic acids. These compounds are classified as primary metabolites, the essential 
substances for living organisms. ' In contrast, compounds which have no apparent 
essential function for the organism are termed secondary metabolites or natural 
products, and are produced from the process called secondary metabolism. These 
metabolites are found in many organisms and are themselves derived from primary 
metabolites. Secondary metabolites have been used as medicines, poisons, spices and 
stimulants. 2 
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Scheme 1.1 Links between primary and secondary metabolites. 3 
rates 
pentose phosphate pathway 
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As shown in Scheme 1.1 primary and secondary metabolites are related by common 
metabolic pathways. 3 Primary metabolism produces a small number of starter units: 
acetate, mevalonate, and shikimate. Acetic acid, which is produced from pyruvic acid, 
has a central position in the form of acetyl CoA (coenzyme A). This compound is a 
precursor of secondary products in microorganisms, plants and animals. From acetic 
acid, mevalonic acid, polyketides, fatty acids and amino acids are derived. Mevalonate 
is the precursor for terpenoids and steroids, whereas alkaloids originate from aromatic 
amino acids, which have shikimate as precursor, and aliphatic amino acids. 
1.2 Polyketides 
Polyketides, first named by Collie, are one of the largest and most diverse groups of 
secondary metabolites, consist of a poly-ß-carbonyl and/or hydroxyl group separated by 
a methylene group. 4 They show huge structural diversity: polyketide molecules vary 
from the small molecule, 6-methylsalicylic acid 1, which contains only eight carbon 
atoms to the largest, e. g. brevitoxin B, containing fifty carbon atoms in its chain. 5 
Therefore, these metabolites are classified as aromatic and non-aromatic polyketides 
including macrolides, polyenes and polyethers. 6 
Many polyketides are valuable for their medicinal activities: anticancer, 
antiviral, antibacterial, antitumor, antifungal; and in agriculture as pesticides with 
insecticidal, antifungal and plant pathogenic properties (Fig. 1.1). Some of these 
metabolites show more than one biological effect. For example the antifungal 
compound thysanone 2 is also an inhibitor of rhinovirus protease, while the 
immunosuppressive agent FK 506 4 was originally isolated as the bases of its antifungal 
activity. 7 Microorganisms such as fungi, algae, filamentous bacteria (the 
actinomycetes), marine organisms and various plants are important sources of these 
metabolites. Actinomycetes, in particular Streptomyces sp. produces a variety of 
polyketide metabolites. However, other bacterial families are known to synthesise 
diverse polyketides, for exmple; myxobacteria such as Sorangium sp., Pseudomonas sp. 
and Mycobacteria. 6 
2 

























Figure 1.1 Examples of structure and biological activities of polyketide metabolites. 
1.3 Polyketide Biosynthesis 
Polyketide metabolites are derived from the Claisen condensation of acetyl CoA or 
related CoA thioesters in a head to tail fashion. The mechanism of polyketide 
biosynthesis is similar to fatty acid biosynthesis. The formation of linear carbon chains 
in both cases is programmed by adding C2 units. Additionally, the enzymes involved in 
both pathways, are closely related in structure and function. In fatty acid biosynthesis 
(Scheme 1.2) formation of the carbon skeleton is initiated by the condensation of a 
starter unit (usually acetate in the form of acetyl CoA) and an extender unit (usually 
malonyl CoA), which is transferred from CoA to the phosphopantethiene arm of acyl 
carrier protein (ACP) by the malonyl transferase (MT). 8 A decarboxylative 
condensation reaction is catalysed by ß-ketosynthase (KS) results in the ß-keto 
compound. This intermediate undergoes ß-ketoreduction by ketoreductase (KR) to 
form a compound containing a hydroxyl group. Subsequent dehydration by dehydratase 
(DH) and an enoylreduction by enoylreductase (ER) convert the unsaturated product to 
a saturated product. Once complete the cycle is repeated by returning the intermediate 
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chain length is reached. 8 Then the final product is released from the FAS by 
thioesterase (TE) in the free acid form. 
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Scheme 1.2 The assembly of fatty acids, polyketides and reduced polyketides (Adapted from Simpson) 
Although the mechanism of polyketide carbon chain formation is analogous 
fatty acid biosynthesis, there are some significant differences. Most fatty acids are 
derived from acetate as starter unit and very occasionally propionate with malonyl CoA 
as extender units. During fatty acid biosynthesis, C2 units are added to the growing 
chain after reduction of the previous ß-carbonyl unit to a methylene group. In contrast 
the ß-keto compound in polyketide biosynthesis may be left either unreduced or 
converted to a hydroxyl, olefin or methylene functionality. 9 Also the starter units, used 
in the pathways, are drawn from a wide pool, for example; acetate, propionate, butyrate, 
benzoate, cinnamate, salicylic acid and amino acids. 1° Apart from starter unit, the 
extender units are not limited to just malonyl CoA. Methylmalonyl CoA, or 
ethylmalonyl CoA or propylmalonyl CoA may also be used and this can vary from 
cycle to cycle. Moreover, the resulting polyketides are controlled to form the correct 
stereochemistry by the enzymes in the pathway. 5 
All polyketide metabolites are produced by enzymes called polyketide synthases 
(PKSs). These enzymes assemble the carbon skeleton of polyketides and display 
similar activities to fatty acid synthases (FASs). FASs are divided into Type I and Type 
II systems depending on the type of organism. All FASs consist of a set of enzymes 
4 
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encoding a KS, AT/MAT, ACP, KR, DH, ER as well as TE. 11 Type I FASs (found in 
fungi and vertebrates) are multifunctional proteins containing the active sites for all the 
enzyme activities linked together. On the other hand, Type II FASs, found in bacteria 
and plants, contain each catalytic site on a separate protein. 7 The classification of 
polyketide synthases is related to fatty acid synthases but with some additional features. 
Currently polyketide synthases are classified as Type I, Type II, and Type III systems. 
1.3.1 Type I Polyketide Synthases 
Type I PKSs consist of large multifunctional polypeptides, each of which contains the 
catalytic domains, which are necessary for biosynthesis. 9 There are two main 
categories. 
Type I modular PKSs 
In bacteria, this type of enzymes found are known as Type I modular PKSs, which 
resemble Type I FASs in vertebrates. The active sites are clustered into modules, with 
each module containing a full complement of sites where required for one condensation 
and an associated reduction cycle. These enzymes were first discovered from studies on 
the 6-deoxyerythronolide B synthase (DEBS) 12,13 that catalyses the formation of the 
macrolactone portion of erythromycin A7 (Scheme 1.3), an antibiotic produced by 
Saccharopolyspora eryhraea. 
Erythromycin A7 is synthesised from decarboxylative condensation reactions 
between one molecule of propionate and six molecules of methylmalonyl CoA (Scheme 
1.3). 14 The growth of the polyketide chain is started from a propionyl CoA, starter unit, 
condensed with an extender unit, 2-methylmalonyl CoA, to produce a keto intermediate, 
followed by reduction reaction catalysed by KR. 13,15 After each cycle, the polyketide 
chain is transferred from the ACP domain to the KS domain of the next module, where 
a new extender unit and other modifications are introduced. Reduction of the keto 
group occurs following each chain extension, except for module 3, where there is no 
KR domain. Additionally, dehydration and enoyl reduction occur only in module 4. 
The polyketide intermediate is released from module 6 by TE to form 6- 
5 
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deoxyerythronolide B6 (6-dEB). 6-dEB is further converted to form erythromycin A 
by further modification enzymes. 
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Scheme 1.3 Biosynthetic pathway of erythromycin A (Adapted from Hopwood' a) 
Investigation of the genes involved in the erythromycin biosynthetic pathway 
showed that DEBS is composed of three large genes: eryl, eryll, eryIII, each 
approximately 10 kb in length. 5 These three proteins, each of which contains over 
3,300 amino acids carrying two modules of PKS active sites, are 6-deoxyerythronolide 
B synthase (DEBS) 1,2 and 3.13 In general each module consists of KS, AT and ACP 
domain for one round of chain elongation and a set of domains encoding KR, DH 
and/or ER for keto group modification. 14 An acyl transferase (AT) in each module is 
responsible for introducing extender units and specifically accepts a 2S-methylmalonyl 
CoA isomer in each cycle. 16 Separate AT and ACP domains in an individual loading 
6 
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module located before module 1 of DEBS 1 are used for loading the propionyl CoA 
starter unit. During the final round of biosynthesis the linear heptaketide intermediate 
attached to module 6 is released and cyclised to form 6-dEB by thioesterase (TE) in 
DEBS3 after module 6.1 1'14 Additionally, the erythromycin gene cluster contains some 
non PKS genes encoding activities such as cytochrome P-450 hydroxylase, glycosidase, 
methyl transferase5'" (Fig. 1.2) that were proposed to be involved in post-PKS 
modifications converting 6-dEB to erythromycin A. 
0 10 20 30 40 50 60 kb 
190 - 40 110 40 
eryAlll eryA11 er , AI 
Non PKS genes ery PKS genes 
Non PKS genes 
Figure 1.2 Map of gene cluster of 6-deoxyerythronolide B synthase (Adapted from Staunton and 
Weissman''). 
Generally, DEBS has been an archetypal model for Type I modular PKSs in 
which each module contains at least three domains encoding specific KS, AT and ACP 
activities for chain extension in each step. Chang et al. (2003), reported that the 
leinamycin biosynthetic gene cluster from Streptomyces atroolivaceus S-140 is 
composed of two PKS genes, encoding six extension modules none of which contain an 
AT domain. 17 However, one AT domain is found in a separate gene and this acts as an 
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Rapamycin synthase (RAPS) involved in the formation of rapamycin 5 is 
another example of a modular Type I PKS. Rapamycin isolated from Streptomyces 
hygroscopicus, shows antitumour, antifungal and immunosuppressant activities and is a 
hybrid of a polyketide and polypeptide structure. '8 Rapamycin is derived from a 
cyclohexane carboxyl CoA starter unit to form the long chain intermediate and pipecolic 
7 
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acid 9, a lysine derived piperidine-2-carboxylic acid. 6"4 The long chain intermediate is 
first reacted with the nitrogen of pipecolate and then the carboxyl group of the 
pipecolate is esterified with the C-34 hydroxyl group to give the rapamycin macrolide 
(Scheme 1.4). " 
C-ODO 
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Scheme 1.4 Formation of the rapamycin. (Adapted from Staunton and WeissmanI I) 
The RAPS gene cluster consists of three large open reading frames (ORFs) 
encoded by rapA (4 modules), rapB (6 modules), rapC (4 modules). 18 The rapA gene 
consists of four modules, each encodes KS, AT and ACP domains for chain elongation 
and one loading domain containing coenzyme A (CoA) ligase, ER and ACP that are 
involved in formation of the reduced starter unit and transfer of it to the KS domain of 
the first module. ' 8A TE domain has not been found, so the final step intermediate is 
directly formed by the addition of pipecolic acid to produce rapamycin (Scheme 1.4). 
Type I iterative PKSs 
On the other hand, the Type I PKSs that are responsible for the biosynthesis of fungal 
polyketide metabolites are Type I iterative PKSs. 11 These enzymes consist of a single 
module, which is used iteratively to assemble a polyketide from the beginning until it is 
complete. For instance 6-methylsalicylic acid synthase (6-MSAS), found in Penicillium 
patulum catalyses the formation of 6-methylsalicylic acid (6-MSA) 1, which is derived 
from one molecule of acetyl CoA and three of malonyl CoA 11 (Scheme 1.5). 
8 
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Scheme 1.5 The biosynthetic pathway for the fungal polyketide 6-methylsalicylic acid (6-MSA) 
(Adapted from Beck et al. 19). 
DNA sequencing indicated that 6-MSAS consists of a single open reading frame 
carrying five active sites encoding KS, AT, KR, DH and ACP activities arranged in a 
similar fashion to mammalian FASs. 19 This set of enzymes will act three times for 
chain elongation, but with a different level of reductive processing at each stage. 
Following the third cycle, the chain is cyclised, dehydrated and enolised to give 6- 
MSA. 19 
Lovastatin polyketide synthase is a second example of a Type I iterative PKS. It 
is involved in the biosynthesis of lovastatin 3, produced by Aspergillus terreus, which 
shows significant activity for the inhibition of cholesterol biosynthesis. 20 This 
compound is derived from a nonaketide intermediate, dihydromonacolin L 10 that is 
formed from one acetate and eight malonate units, and a diketide, 2-methylbutyrate 11 
(Scheme 1.6). 21 Therefore, those enzymes, which catalyse the formation of lovastatin 
compose of two portions; the lovastatin nonaketide synthase (LNKS) essential for 
assembly of dihydromonacolin L, and lovastatin diketide synthase (LDKS), which 
catalyses the formation of the diketide. Both catalyse the formation of polyketide 
products from acetate and malonate units and add the methyl groups from S- 
adenosylmethionine by methyltransferase domains. 20 LNKS contains seven active 
sites: KS, AT, DH, MeT, ER, KR and ACP, which are used iteratively while the LDKS 
9 
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Scheme 1.6 Proposed pathway for the biosynthesis of the fungal metabolite lovastatin 
(Adapted from Hutchinson et al. 21). 
1.3.2 Type II Polyketide Synthases 
Unlike bacterial Type I PKSs, Type II PKSs consist of discrete monofunctional proteins 
essential for the assembly of aromatic polyketides. 6 These enzymes contain separate 
active sites and catalyse condensation reactions to form linear polyketide intermediates 
that only rarely undergo reduction prior to cyclisation or aromatisation. Genetic studies 
found that the genes responsible for assembly of aromatic polyketides in bacteria are 
clustered and consist of at least a minimal gene set encoding a KS, (ketosynthase/acyl 
transferase), a KSß or CLF (chain length factor) and an ACP. 22 KSß, which is also 
known as chain length factor (CLF)23 has a very similar sequence to KS,, but lacks the 
cysteine residue essential for KS active site. The minimal PKS is involved in the 
production of ß -polyketone compounds, and is believed to control the formation of 
polyketo chain length and the cyclisation of the first ring. 14,24 Additionally these 
10 
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clusters also contain post-PKS modification enzymes such as cytochrome P-450 for 
oxidation, glycosylation, etc. 24 
The first Type II PKS to be characterised was the actinorhodin polyketide 
synthase (act PKS), isolated from Streptomyces coelicolor A3(2)25 which produces 
actinorhodin 16, an isochromanequinone pigment and antibiotic. Feeding studies with 
isotopically labelled precursors showed that actinorhodin is derived from acetyl CoA 
and seven malonyl CoAs condensed to form a 16-carbon acyl chain (Scheme 1.7). 26 
The octaketide intermediate further undergoes reduction by ketoreductase (KR), 
followed by aromatisation and cyclisation by aromatase (ARO) and cyclase (CYC). 
Genetic studies found act PKS contained a minimal set of genes, which was 
designated as act minimal PKS (actl). This minimal PKS consisted of KS,,,, KSP and 
ACP encoded by actl-ORF1, actl-ORF2 and actl-ORF3 respectively. 27 Typically, 
Type II PKS gene clusters lack a gene encoding the malonyl transferase (MAT) activity 
that normally catalyses the transfer of malonyl CoA to malonyl ACP while actl ORF2 
or KSß is thought to be involved in the decarboxylation of malonyl ACP to form the 
starter unit, acetyl ACP, which will be transferred to KS, active site. In vivo studies 
indicated that the MAT of FASs may catalyse this reaction. In vitro studies, however, 
suggested that ACP could undergo self-malonylation. 28-30 The KR, ARO and CYC 
carry out the essential modification of the initially cyclised octaketide for actinorhodin 
production. 
The product of act minimal PKS is SEK 4 12, an unreduced octaketide in which 
the first cyclisation has taken place as in actinorhodin. 14 Thus, the minimal PKS 
appears to be able to control the first cyclisation and the chain length in the absence of 
either KR or CYC. The addition of act KR (actlll) results in reduction at C-9 with the 
formation of mutactin 13.23 Note that as a result of this reduction, a different 
cyclisation takes place. The act VII protein, an aromatase carries out two dehydrations 
on the first ring to form SEK34 14 while actlV encodes a cyclase, which catalyses the 
formation of the second ring to give DMAC 15.31,32 Following isolation of the act gene 
cluster, further gene clusters from different Streptomyces were isolated and identified, 
for example; oxytetracycline (otc) from Streptomyces rimosus, the anthracycline, 
tetracenomycin (tcm) from Streptomyces glaucescens. 14 All of them were found to 
encode homologues of actl ORF1, actl ORF2, actl ORF3 genes, however, the 
11 
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mechanism by which the minimal PKS controls the chain length and the first ring 
formation remains unclear. 
(a) 
acta 
act III a act VII actl V 
KS KS 
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Actinorhodin 16 
Scheme 1.7 (a) Organization of act gene cluster and (b) the proposed actinorhodin biosynthetic 
pathway (Adapted from Hopwood14). 
1.3.3 Type III Polyketide Synthases 
Type III PKSs such as chalcone synthases (CHSs) and stilbene synthases (STSs) are 
involved in the formation of polyketides in plant, pigmentation in fruits via compounds 
such as chalcone 17, stilbene 18, resveratrol 19 and pterostilbene 20.33 These 
compounds, which are found in parsley, grapes, blueberry and so on, show valuable 
biological activities, for example, as antioxidants and anticancer agent. CHSs and STSs 
are dimeric enzymes each of which contains a single active site. 32 Chalcone synthase 
12 
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genes were first cloned from parsley Petroselinum hortense. 14 The synthases contain a 
single active site, which carries out all the necessary reactions; decarboxylation, 
condensation, cyclisation. 34 The stilbene synthase gene was cloned from Vitis vinifera 
(grape) and found to encode a large multifunctional protein with a very similar sequence 
of amino acid to CHSs. 6 
Chalcone and stilbene are assembled from ß-coumaroyl CoA, an aromatic starter 
unit condensed with three extender units of malonyl CoA to form a tetraketide 
intermediate (Scheme 1.8). 33 During the biosynthesis there are no reductions or 
dehydrations. Moreover, this type of enzyme lacks an acyl carrier protein (ACP), 
therefore the linear polyketide intermediate is directly released from CoA. The final 
product, chalcone or stilbene, depends on the cyclisation reaction taking place at C6-C 1 
or C2-C7 respectively. 33 The recent determination of CHS35 and STS36 crystal 
structures has helped to elucidate the mechanism involved in Type III polyketide 
biosynthesis. Base on this structure and mutagenic data, the Aldol-Switch mechanism 
has been proposed where aldol cyclisation specificity may be caused by electronic 
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R= OH, R' =H Resvertrol 19 
R= OH, R' = CH3 Pterostibene 20 
Scheme 1.8 Proposed biosynthetic pathway to chalcones and stilbenes via Type III PKSs 
(Adapted from Tsai 33) 
Recently, chalcone synthase-like enzymes have been found in bacteria. 37'38 
These enzymes also use free CoA thioesters as substrates without an acyl carrier 
R 
13 
Chapter 1 Introduction 
protein. A CHS-related synthase encoded by the rppA gene, first isolated from 
Streptomyces griseus, is involved in the biosynthesis of 1,3,6,8-tetrahydroxynapthalene 
(THN) and uses malonyl CoA as a starter unit. 37 THN biosynthesis (Scheme 1.9) is 
driven by five molecules of malonyl CoA, which undergo four elongations to produce a 
pentaketide intermediate. The resulting ketide is further released to cyclise via a 
decarboxylation of a carboxyl group of the malonyl CoA to form THN 21. Furthermore 
THN is continuously converted to flaviolin 22, a precursor of melanin pigment, by air 
oxidation. 37 
RppA 
5 malonyl CoA 
O0 OH O 











Scheme 1.9 Proposed biosynthesis of THN in Streptomyces griseus (Adapted from Funa37) 
Additionally, the gene clusters, found in Pseudomonas fluorescens Q2-87 
involved in 2,4-diacetylphloroglucinol (DAPG) 2338 biosynthesis and in Amycolatopis 
orientalis, involved in 3,5-dihydroxy phenylglycine (DHPG) 24 biosynthesis encode 
genes homologous to rppA gene of THN35 suggesting a common mechanism. 





1.3.4 Polyketide Modification Enzymes 
HO 
COOH 
NH2 DHPG 24 
The observed structural diversity and complexity of polyketide metabolites and their 
biological activity are often due to modifications, which take place after the formation 
of the PKS derived skeleton. Therefore, intermediates, released from the PKSs after the 
14 
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final round of assembly, are often further modified by the addition of functional groups 
by tailoring enzymes to produce biologically active compounds. Enzymes frequently 
involved in this are typically oxidoreductases, oxygenases and transferases, which 
catalyse oxidation, reduction or methylation reactions. 39 
Oxidoreductases are a large group of enzymes that consist of oxygenases, 
oxidases, peroxidases, reductases and dehydrogenases. 39 These enzymes are 
responsible for oxidation-reduction reactions adding or removing of hydrogens, 
oxygens or introducing hydroxyl groups to the carbon backbone. Additionally, some 
functionalities may be converted to others by these enzymes, for example, aldehydes or 
ketones to alcohols. The difference of each enzyme in this group depends on the type of 
reaction, which they catalyse. For instance, dehydrogenase removes /adds protons and 
electrons to substrate but do not utilise molecular oxygen as a hydrogen/electron 
acceptor. Conversely, the oxidases involved in releasing the substrate electrons to 
molecular oxygen (equation 1.1), or such as in peroxidase, to hydrogen peroxide 
(equation 1.2)39,40, after dehydrogenating the substrate. 
AH2 + '/z 02 





On the other hand oxidations when an oxygen atom is inserted into the substrate 
to form a hydroxyl or epoxy group are catalysed by oxygenases (Fig. 1.3 ). 39 This 
group of enyzymes, which are often found in polyketide pathways, include cytochrome 
P-450 monooxygenases, dioxygenases including hydroxylases and epoxidases. 
oxygenase 






Figure 1.3 Examples of oxidation reactions by oxygenases. 
Another important group of tailoring enzymes are the transferases, for example, 
aminotransferase, methyltransferase, acyltranferase and glycosyltransferase. These 
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enzymes are involved in transferring amino, alkyl, acetyl or acyl and sugars. Among 
them, methyltransferases always uses S-adenosylmethionine as cofactor and 
glycosyltransferases, which are commonly found in macrolide biosyntheses, are 
important in post-PKS modification. 39 For example in erythromycin A biosynthesis the 
ery PKS gene cluster is composed of PKS genes and non-PKS genes (Fig. 1.2). The 
non-PKS gene, eryF corresponds to a cytochrome P-450 monooxygenase type 
hydroxylase involved in a post-PKS modification step, catalysing the first hydroxylation 
at C-6 of 6-dEB converting it to erythronolide B 25 before conversion to erythromycin 
D 26 (Scheme 1.10). 5 Erythromycin D, the first bioactive compound in the pathway, 
contains two deoxysugars, L-cladinose and D-desosamine, which are introduced onto 
carbon skeleton after PKS assembly by the glycosyltransferases, which are products of 
eryB and eryC genes. The second hydroxylation at C-12 is controlled by the eryK gene, 
which encodes another hydroxylase, to form erythromycin C 27 before conversion to 
the final erythromycin A product. 39 Further gene clusters, responsible for other 
macrolide polyketide metabolites such as oleandomycin and polyene antibiotics are also 
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7 
Scheme 1.10 The role of ery genes involved in erythromycin biosynthesis (Adapted from Katz5) 
Oleandomycin 29, a macrolide polyketide containing fourteen carbons and two 
molecules of deoxysugar42 is formed from one acetyl CoA condensed with six 
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methylmalonyl CoAs to form the 8,8a-deoxyoleandolide intermediate 28. The final 
product is formed by the addition of two deoxysugars by glycosyltransferases followed 
by epoxidation at C8/C8a, which occurs very late in the pathway. The epoxidation is 
proposed to take place by having the oleP gene encoded cytochrome P-450 involved in 
the reaction (Scheme 1.11). However, the mechanism of epoxidation is still unclear. It 
might involve an exo-methylene double bond. 42 On co-overexpression of OleP and 
DEBS in Streptomyces lividans, the 8,8a-dihydroxy-6-deoxyerythronolide B 30 was 
obtained. Moreover, oleMl gene corresponding to a methyltransferase was observed. It 
was reported that this gene might be responsible for introduction of a methyl group onto 
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Scheme 1.11 The role of ole gene product in oleandomycin biosynthesis. 
Recently Gaitatzis et al. (2002) reported that the biosynthetic gene cluster of the 
aromatic electron transport inhibitor, stigmatellin 31 produced by Stigmatella 
aurantiaca contained two unusual O-methyltransferases and a cytochrome P-450 
monooxygenase for post-PKS modification. 46 The monooxygenase was proposed to 
catalyse a hydroxylation of the aromatic ring whereas the two methyltransferases 
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47 Post polyketide processing is also observed in Type II biosynthetic pathways-49 
The griseorhodin gene cluster, cloned from the marine Streptomyces sp. JP95 consists 
of Type II PKS genes encoding a minimal PKS, a cyclase, an aromatase and additional 
genes corresponding to various oxidation-reduction enzymes such as FAD-dependent 
monooxygenases, a cytochrome P-450 and ferredoxin. 48 GrhO3, which encodes a 
cytochrome P-450 and GrhO4, which encodes a ferredoxin are believed to be involved 






Another example was found by the Moore group (2000) in the enterocin 
biosynthesis gene cluster, isolated from the marine Streptomyces maritimus. 50 They 
reported that the biosynthetic gene cluster consisted of the essential genes for Type II 
PKSs and genes encoding a cytochrome P-450 hydroxylase, FAD-dependent oxygenase 
and a methyltransferase. The proposed biosynthetic pathway showed that this 
compound was derived from a benzoyl CoA starter unit and seven malonyl CoA 
extender units. The absence of cyclase and aromatase, suggests the linear polyketide 
intermediate must spontaneous cyclise to form the ring. Prior to enterocin 34, two post- 
PKS reactions occur, one O-methylation by methyltransferase, and an oxidation to 
convert 5-deoxyenterocin 33 to enterocin may be catalysed by either a cytochrome P- 
450 hydroxylase from the encQ gene or a FAD-dependent oxygenase from the encM 
gene. 50 
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1.4 Elucidation of Biosynthetic Pathways 
Natural products have been known since the eighteenth century. As these compounds 
show important pharmacological properties, chemists have been separating, purifying 
and characterising these compounds from living organisms and to date many thousand 
of natural products have been isolated and their structures determined. The isolation of 
natural products has become much simpler with the advent of chromatographic 
techniques, such as column chromatography, thin layer chromatography (TLC), high 
performance liquid chromatography (HPLC), gas chromatography (GC) and liquid 
chromatography-mass spectrometry (LC-MS). Advances in separation techniques, 
coupled with the development in powerful characterisation techniques such as nuclear 
magnetic resonance (NMR), infrared spectroscopy (IR), mass spectrometry (MS) and 
X-ray crystallography mean that structural elucidation of complex natural products is 
now normally simple. To find out how these compounds are built up, the biosynthetic 
pathways have been investigated. Many methods have been used for this purpose such 
as: use of isotopically labelled compounds as tracers, extraction and purification of 
enzymes for testing in vitro, or using genetic mutation techniques to block the 
biosynthetic pathway. 40 
1.4.1 Isotopically Labelling Method 
Before the development of NMR for structural elucidation, the most powerful method 
for the metabolic pathway investigation involved use of radioisotopes as tracers. 
Radioactive labels such 3H and 14C were used by the pioneers of biosynthetic studies. 
These ß-emitters are analysed by assaying the radioactivity of the isolated metabolite by 
19 
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liquid scintillation counting. Label incorporations of much less than 1% can be 
detected. However, the site of incorporation can only be determined by laborious 
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The use of radionuclides has been superseded by the use of stable isotopes such 
as 2H, ' 3C, 180 and 15N. For studies involving the use of 13C, enrichments of at least 1% 
have to be achieved in order to offset the 1.1 % natural abundance background. The site 
of incorporation is determined simply by observing enhancement of a signal in the 13C 
NMR spectrum of the enriched metabolite (Fig. 1.4). 51 For instance, singly 13C 
labelled precursors result in an increase in the intensity of natural abundance signals 
(Fig. 1.4). Therefore, the use of [1-13C]-acetate and [2-13C]-acetate results in 
complementary results in the labelling patterns for acetogenic metabolites. 
Unfortunately unlike 1H NMR the intensities of signal in 13C spectra are variable even 
in natural abundance spectra and cannot be used to accurately quantify the number of 
13C atoms. This is because of the different in spin lattice relaxation times, nuclear 
Overhauser enhancements (nOe) and instrumental fluctuations. To overcome this 
problem 13 C enriched and natural abundance samples need to be compared under 
identical conditions. 
20 
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The sensitivity of stable isotopes can be further increased and the level of 
incorporation determined more accurately by the use of double isotopic labelling, 
normally 13C with another 2H, 13C, 180.5' For example, when two adjacent labelled 
carbons are incorporated intact, then doublets of coupling constant (typically 35-70 Hz) 
are observed. In acetate studies, signal due to two adjacent labelled carbons (C1 and C2) 
appear as pairs of doublets with identical coupling constants (J1,2) equidistant about 
each natural abundance signal. Similarly, signals due to another set of adjacent labelled 
carbon C and Cn+1 in a different chemical environment have similar Jvalues (Jn, n+1) but 
these are not usually the same as J1,2. If on the other hand, the bond is broken during the 
biosynthetic pathway, then each natural abundance signal in the metabolite is enhanced 
in intensity (Fig. 1.4). 
ý 0 
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Figure 1.5 The use of 2H and 180 in isotope labelling studies. 
When use in conjunction with 2H and 180,13C NMR can be used to determine 
their fate (Fig. 1.5 ). 51 When 13C is directly attached to 2H a lower frequency shift of 
0.3-0.6 ppm is observed in the 13C NMR signal due to each 2H. This phenomenon is 
known as an a-isotopic shift. The multiplicity of 13C is an indication of how many 
deuterium atoms are attached to that carbon. Thus CD, CD2 and CD3 give a triplet, 
quintet and septet respectively. A smaller ß-isotope shift (0.01-0.1) is observed when 
the deuterium is on the carbon adjacent that which is 13C labelled. In the latter case, the 
coupling between 
13C and deuterium is too small to be resolved, and thus the signal 
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always appears as a singlet. Similar but smaller shift to lower frequency (0.01-0.05 for 
180) are observed in 13C NMR spectra with 180 and 15N directly to a 13C nucleus. 2H 
has a relative natural abundance of (0.012%) consequently 2H NMR is more sensitive 
than 13C NMR for detection of relative enrichments. 5' 
1.4.2 Genetic Techniques 
Within the past decade, knowledge of gene cloning has advanced rapidly. This has led 
to the understanding of how the assembly of metabolites is controlled in living 
organisms. In addition, we can classify the type of protein from the degree of similarity 
between genes from different sources. Therefore, genetic techniques that are used to 
investigate biosynthetic genes provide an alternative way to study the biosynthetic 
pathway. The general aim is the isolation of the complete set of genes involved in the 
biosynthesis by cloning a library of large DNA fragments. These fragments are probed 
with a homologous gene to select those containing target genes, 14 followed by DNA 
sequencing. The next step is to assign functions to these genes by comparison with 
gene sequences in the databases. Furthermore, gene mutation can be carried out to find 
out how mutation in each gene effects the pathways. Thus some genes can be knocked 
out and then the compounds, which are produced by these mutants, can be isolated. 
As mentioned earlier Hopwood and co-workers initiated polyketide gene studies 
by cloning a library of DNA fragments for actinorhodin biosynthesis from its producer 
Streptomyces coelicolor A3(2). 25 The cloned DNA was screened using an antibiotic 
resistance selection method, and a 35 kb biosynthetic gene cluster later known as the 
Type II PKS gene cluster was isolated (Scheme 1.7 a). Following the discovery of 
Type II PKS, the first modular PKS gene, for erythromycin biosynthesis, was isolated 
from Saccharopolyspora erythraea. Katz and co-workers carried out gene mutations by 
deleting the KR domain in module 5 of DEBS3, which is involved in reduction of a keto 
group to form a hydroxyl group. 15 The result clearly showed the predicted compound 
35 retaining a keto group was produced. Further mutations, to inactivate the ER domain 
of module 4 at the NADPH binding site resulted in alkene functionality appearing in the 
isolated compound 36.15 
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Additional evidence from mutagenic studies of ery genes for post-PKS 
modification in erythromycin biosynthesis by Weber et al. found that the absence of the 
eryF gene encoding a cytochrome P-450 monooxygenase type hydroxylase, resulted in 
an accumulation of 6-deoxyerythromycin A 37 instead of erythromycin A (Scheme 
41 1.12) 
propionyl CoA 
6x methylmalonyl CoA 
en T, 
hIdroxýlase 















Scheme 1.12 The 6-deoxyeythromycin A (left) and erythromycin A (right) biosynthetic pathway. A 
mutation of eryF gene led to the production of 6-deoxyerythromycin A (Adapted from 
Weber et al. 41). 
The typical and novel polyketide biosynthetic genes of numerous bioactive 
compounds have been cloned and sequenced from a variety of producers and also some 
genes including post-PKS modification genes have been mutated in order to investigate 
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1.4.3 Enzymology 
Although genetic studies are able to help describe how the metabolites are assembled, 
the mechanisms that take place remain unclear; therefore more direct methods are 
needed to investigate the function of enzymes, involved in the biosynthetic pathway. 
Such target proteins are expressed and purified for in vitro studies. Recent advances of 
NMR and X-ray crystallography make it possible to determine the three-dimensional 
structure of proteins. 
1.5 Aims 
The aims of this project were to investigate the polyketide biosynthetic pathways of 
mupirocin (pseudomonic acid A) and mensacarcin. 
Following the discovery of the mupirocin gene cluster, a set of genes, which are 
involved in the polyketide synthases and post-PKS modification were knocked out in 
order to determine how the metabolic pathway was affected. Thus, the intermediates 
that were produced by these mutant strains were investigated. Therefore, the approach 
used in these studies involved: 
1) Isolation and identification of compounds from the Pseudomonasfluorescens 
NCIMB 10586 mutant strains and comparison of these with the wild type 
products. 
2) Expression and purification of mupirocin proteins from Pseudomonas 
fluorescens NCIMB 10586 mutants to get a better understanding of enzyme 
functions. 
For mensacarcin, genetic techniques were used to study the biosynthetic 
pathway and the mode of biological activity. Therefore, the PKS genes that are 
involved in the metabolic process have been searched for using: 
1) Extraction and purification of genomic DNA 
2) Construction of genomic library by cloning into lambda vectors. 
3) Screening of PKS gene using a homologous probe. 
4) Identification of gene functions from DNA sequences and comparison with 
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2.1 Introduction 
2.1.1 Discovery of mupirocin (pseudomonic acid A) 
On the basis of their biological activities, several compounds have been extracted and 
purified from Pseudomonas fluorescens, a Gram-negative bacterium. In 1971, Fuller et 
al. reported a metabolite, which was isolated from the fermentation of Pseudomonas 
fluorescens NCIB 10586.57 This metabolite, which was named pseudomonic acid A 
40, showed important antibacterial activity. Later, structural elucidation studies were 
performed by Chain and Mellows. 58,59 Further X-ray crystallography and NMR studies 
by Clayton and Everett confirmed the structure. 60,61 Pseudomonic acid A (PA-A), 
consists of a9 carbon aliphatic chain, 9-hydroxynonanoic acid 39, which esterifies the 
17 carbon monic acid 38, which contains epoxide, alcohol and tetrahydropyran 





J 9-Hydroxynonanoic acid 39 
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Scheme 2.1 Assembly of pseudomonic acid A from monic acid and 9-hydroxynonanoic acid. 
PA-A was the major metabolite, but further isolation studies found other 
members of the pseudomonic acid family: pseudomonic acid B, 
62 C63,64 and D65 (Fig. 
2.1). All of them are structurally related to PA-A. Structural elucidation studies 
showed that pseudomonic acid B (PA-B) 41, differed from PA-A in that it contained an 
extra hydroxyl at C-8, which made it more polar than PA-A. 62 On the other hand 
pseudomonic acid C (PA-C) 42 had a double bond at C 10-C 11 rather than the epoxide. 
This compound was less polar than PA-A and PA-B and (in contrast) it was more stable 
than PA-A at high pH (ý 10). 64 Pseudomonic acid D (PA-D) 43 differed from PA-A in 
the side chain ester where C4'-C5' contained an olefenic function. 65 In general, relative 
25 
OH Monic acid 38 
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amounts of pseudomonic acid A: B: C: D in submerged fermentation was 93: 5: 2: 2.66 
A fifth metabolite, pseudomonic acid E 44 has also been extracted from the culture 
broth of Pseudomonas fluorescens. 67 
aliphatic acid chain. 
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Figure 2.1 Other members of the pseudomonic acid family. 
In recent years, two novel antimicrobial antibiotics 45 and 46 were reported to 
have structural analogy to pseudomonic acid. 68 These metabolites were isolated from 
an Alteromonas sp. bacterium, which is isolated from the marine sponge Darwinella 
rosacea. Unlike PA-A, both metabolites contain an 8-hydroxyoctanamide instead of a 
9-hydroxynonanoic acid moiety. 
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Moreover, an antimicrobial, named thiomarinol A (TMA) 47, isolated from the 
culture broth of a marine bacterium, Alteromonas rava sp. nov. SANK 73390 was found 
to be a pseudomonic acid analogue. 69 Its structure is a hybrid of a PA-C analogue and 
the antibiotic holothin. The side chain 9-hydroxynonanoic acid in PA-C is replaced by 
8-hydroxyoctanoylholothin. TMA shows stronger activity against Gram-positive and 
Gram-negative bacteria than its parents. Further isolation found further thiomarinol 
derivatives, thiomarinol B (TMB) 48 and C (TMC) 49.70 TMB has two more oxygen 
atoms than TMA where the additional two oxygen atoms are contained in the holothin 
moiety. TMC lacks the 4-hydroxyl group present in TMA. Other minor components; 
thiomarinol D (TMD) 50, E (TME) 51, F (TMF) 52 and G (TMG) 53 were isolated and 
characterised. 7' All metabolites show similar biological activities to TMA. 
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2.1.2 Biological activity and mode of action 
Currently, pseudomonic acid A or mupirocin (generic name) is used clinically as an 
antibiotic for treatment of skin infection. It is marketed as the active component (2% 
PA-A in a polyethylene glycol) in the topical skin cream Bactroban. This compound 
showed high activity against bacteria such as Staphylococci especially Staphylococcus 
aureus, Streptococci sp. 65 and Escherichia coli. 72 PA-A was found to inhibit bacterial 
protein synthesis by binding to isoleucyl t-RNA synthetase, which catalyses the 
formation of isoleucyl t-RNA. 73 The active part is the terminus of the C-8 side chain 
containing the epoxide moiety whose carbon backbone is thought to resemble L- 
isoleucine 54 (Fig. 2.2). Thus PA-A is an analogue, which competes with isoleucine for 
binding on the enzyme. 
..... OH 
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Figure 2.2 Structural similarity of pseudomonic acid and isoleucine. 
Additionally, Kawakami's group studied the effect of PA-A in E. coli and 
suggested that PA-A was a bifunctional inhibitor since it could compete both isoleucine 
and ATP, for example, as an analogue of isoleucyl adenylate. 74 This was supported 
from the studies of crystal structures by Nakama et al. (2001), which showed that PA-A 
inhibited the enzyme activity by blocking the binding site of the high energy 
intermediate, isoleucyl adenylate (Ile-AMP) (Fig. 2.3). 75 
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Figure 2.3 (a), Crystal structure of the complex of Thermus thermophilus isoleucyl-tRNA synthetase 
(IIeRS) with mupirocin. The bound mupirocin is shown in red. (b), Mupirocin bound to the 
catalytic site of the IleRS. The mupirocin molecule is shown in green. 75 
Further in vitro studies showed that the activity of PA-A was affected by the pH 
of medium used for testing. 72 PA-A was more active in acid medium than in neutral or 
alkaline media. For instance, at pH 6.0 it was four to eightfold more active than at pH 
7.0. In contrast activity in medium at pH 7.0 was twofold higher than at pH 8.0. Its 
activity was lost outside the pH range 4-9.57 This arises from the instability of PA-A to 
strong acid and base. At the lower or higher ends of this pH range, the epoxide ring is 
opened and then a rapid rearrangement occurs which leads to the formation of two 
isomeric compounds 55 and 56 (Scheme 2.2). 76 The minor metabolites (PA-B, C and 
D) also showed similar activities but lower activity than PA-A. 72 
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Scheme 2.2 Rearrangement of pseudomonic acid in strong acid and base. ' 
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2.1.3 Pseudomonic acid biosynthetic studies using isotopic labelling 
Initially, the biosynthetic pathway to pseudomonic acid was studied using isotopic 
labelling. The precursors to the carbon skeleton were investigated by feeding 
radioisotopically labelled substances such as acetate, propionate, formate, mevalonate 
and methionine to the culture of Pseudomonas fluorescens. 77 It was found that both [I - 
14C] acetate and [2-14C] propionate were well incorporated whereas [14C] formate was 
poorly incorporated. [2-14C] Mevalonic acid was not incorporated. These indicated that 
pseudomonic acid structure would be generated from acetate and propionate but does 
not contain an isoprenoid residue, which would be derived from mevalonate. However, 
some conclusions were unclear because of the possible occurrence of chemical 
degradation of the labelled precursors. 
Later the biosynthesis of pseudomonic acid was confirmed by feeding studies 
with stable isotopically labelled precursors, for example; [1_13 C] acetate, [ 1-13C] 
propionate and [Me-13C] methionine. The results of these incorporation studies (Fig. 
2.4) showed that pseudomonic acid was polyketide in origin. 77 The carbon skeleton 
was derived from acetate, except for C-7', which was labelled from both acetate and 
propionate. Also C-16 and C-17 were found to derive from the methyl of methionine, 
thus indicating methylation from S-adenosylmethionine 57, whilst the branched C-15 








+ [1_13C] acetate 






" [2-13C] acetate 
- [1,2_13C] acetate 
[methyl-13C] -L -methionine 
Figure 2.4 Isotope labelling pattern in pseudomonic acid from feeding labelled precursors to 
Pseudomonasfluorescens (Adapted from Feline et a!. 77). 
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These studies led to the conclusion that PA-A was derived from three different 
units (Scheme 2.3). '7 A C12 pentaketide moiety derived from five acetate units in the 
form of one acetyl CoA and four units of malonyl CoA. Further oxidation/reduction 
occurred to give the modified functionalities. It was suggested that the C9 9- 
hydroxynonanoic acid moiety could be derived from either ß-hydroxy-ß-methylglutaryl 
CoA (HMG-CoA) or via fatty acid biosynthesis with a C3 starter unit. The C5 unit was 
also proposed to be generated from HMG-CoA. The pyran ring was probably generated 



























Scheme 2.3 Proposed biosynthetic pathway of pseudomonic acid from isotopic labelling studies. 77 
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Chapter 2 Mupirocin Biosynthesis 
1802 labelling studies using [1-13C, 1802] acetate by Martin and Simpson showed 
that the oxygens on C-1, C-5, C-7, C- 13 and C-9' were derived from acetate whereas the 
epoxide oxygen and the hydroxyl group on C-6 originated either from water or more 
likely the atmosphere (Scheme 2.4). 78 Also the mechanism of tetrahydropyran ring 
formation was proposed to be via intramolecular addition of 5-OH to a conjugated 
alkene (Scheme 2.5 route (a)) or by an intramolecular displacement from the 
hydroxymethyl intermediate (Scheme 2.5 route (b)). However, 13C-labelled HMG was 
not incorporated intact to suggest that previous proposal of its involvement in the 
pathway was unlikely. 79 
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Scheme 2.5 Proposed mechanism of tetrahydropyran ring formation. 79 
This hypothesis was confirmed by feeding [I- 13C 5 
2H3] acetate to culture broth 
of P. fluorescens. 79 The resulting incorporation showed no ß-shift at C-7 was observed 
in the 13C NMR spectrum, showing that deuterium from acetate was not present at C-8 
(Scheme 2.4). This would be consistent with a 8,16-alkene. 
2.1.4 Mupirocin gene cluster 
Initial studies on the biosynthetic gene by Whatling et al. from mutagenesis studies 
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Chapter 2 Mupirocin Biosynthesis 
Subsequently, the 74 kb biosynthetic gene cluster, involved in mupirocin biosynthesis 
has been isolated and sequenced by Thomas and co-workers (Fig. 2.5). 81 The 
enzymatic functions have been analysed. The cluster consists of six multifunctional 
genes, mmpA-F with predicted Type I modular polyketide synthase and fatty acid 
synthase sequences, and individual genes: mupA-X and macpA-E. Some of these 
individual genes such as mupB, mupD, mupG and mupS were like these from Type II 
PKS systems. Therefore, the PKS essential for assembly of mupirocin seems to be a 
combination of Type I and Type II system. Only the first 40.5 kb, which contained four 
large single ORF genes, mmpA-D, and two discrete genes, mupA and mupB were 
identified as mupirocin multifunction proteins (Mmp). 8' 
The large four proteins controlled the formation of the polyketide chain. MmpA 
contained two modules of active sites, which is fronted by loading or transferring 
module encoding KS and ACP domains. MmpD carried four modules, each contained 
KS and ACP units, and a set of domains encoding MeT, KR and DH for further 
methylation, reduction and/or dehydration. In addition, two AT domains were found 
together in MmpC whereas MmpB consisted of KS, KR, DH, three ACP and TE 
domains. Notably, this is an unusual Type I modular PKS system as no AT for malonyl 
transfer was found in each module. 81 
2.1.5 Proposed mupirocin biosynthetic pathway 
2.1.5.1 Formation of polyketide skeleton 
Based on the sequences in the gene cluster, a biosynthetic model for mupirocin was 
proposed (Fig. 2.6). 81 The biosynthesis of mupirocin is suggested to start with the 
production of the C 12 pentaketide moiety by MmpD, which then acts as a primer for 
biosynthesis of the remainder of the monic acid polyketide precursor directed by 
MmpA, and possibly MupH. MmpD encodes sequential modules that catalyse the first 
four condensations. Starter and extender units would be activated by MupU and MupQ, 
which show similarity to acyl-CoA synthases that activate substrates by linking their 
carboxyl group to the phosphoryl group of AMP. The activated substrate is then 
transferred to CoA. Mupirocin biosynthesis could start with one of the ATs transferring 
an activated acetate starter unit from CoA to the 4-phosphopantetheine arm of the ACP 
in module 1 of MmpD and then to the thiol group of the active cysteine of KS in the 
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same module. An activated malonyl extender could then be transferred to the vacant 
ACP. Alternatively, an activated acetyl unit may be transferred directly to KS. KS in 
module 1 of MmpD is proposed to catalyse the first decarboxylative condensation step 
of acetate and malonate, followed by the addition of a methyl group from S- 
adenosylmethionine (SAM) at C-12 by methyl trans ferase 1 (MeT 1) and ketoreduction 
catalysed by KR3 in the same module to produce a C5 structure. 81 
The second cycle of condensation is predicted to be catalysed by the KS in 
module 2 of MmpD and followed by ketoreduction and then dehydration catalysed by 
KR and DH in the same module respectively to produce a C7 structure. The third 
condensation corresponds to KS in module 3 of MmpD, followed by addition of a 
methyl group from SAM at C-8 by MeT2, reduction, and dehydration of keto group by 
KR and DH respectively to produce a Clo structure. The fourth condensation catalysed 
by KS in module 4 of MmpD, followed by the reduction by KR in the same module 
produces the C12 structure. Further assembly of monic acid is proposed to be continued 
by MmpA. The fifth condensation catalysed by KS in module 5 of MmpA, followed by 
ketoreduction by KR in the same module produces a C14 structure. The sixth 
condensation catalysed by KS in module 6 of MmpA and leaving the keto unreduced, 
8 produces a C16 (3-ketothioester. ' 
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Figure 2.6 Proposed biosynthetic pathway to pseudomonic acid. ' 
34 
Chapter 2 Mupirocin Biosynthesis 
In addition MupH encoding a putative HMG-CoA synthase was predicted to be 
involved in the formation of the branch chain C-15 methyl group, which was derived 
from the condensation of an acetate unit at the (3-keto group of the C 16 intermediate, 
followed by decarboxylation and dehydration (Scheme 2.6). 81 









Scheme 2.6 Proposed mechanism of C-15 methyl group formation in monic acid! ' 
The C9 moiety, 9-hydroxynonanoic acid, was proposed to derived from the 
condensation of a 3-hydroxypropionate starter unit and three malonates, and probably 
has MmpB as well as an enoyl transferase (ER) domain of MupE associated in this step 
(Scheme 2.7). 81 This suggestion was consistent with previous feeding studies using [I - 
13C] 








Scheme 2.7 Proposed 9-hydroxynonanoic acid model. 8' 
2.1.5.2 Auxiliary genes in mupirocin biosynthesis 
Many individual genes have been found and identified in the mupirocin gene cluster. 
Some of these genes were predicted to assist the PKS in some stages. For instance 
MupQ and MupU, which show similarity to acyl CoA synthases were suggested to 
activate starter and extender units prior to condensation. 8' MupH was proposed to be 
involved in the formation of branch chain C-15 methyl as it is similar to HGM-CoA 
synthase. MupE, which showed a good similarity to an enoyl reductase was thought to 
associate in the formation of C9 moiety together with MmpB. In addition, some 
individual genes were thought to be essential for post-PKS modification to form the 
active antibiotic. For example, MupO a cytochrome P-450, MupC a NADH-dependent 
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oxidoreductase, MupT a ferredoxin dioxygenase and MupW a dioxygenase, which 
basically catalyse oxidation-reduction reactions could be involved in the formation of 
the epoxide, tetrahydropyran ring and C-6 hydroxyl groups. 8' 
2.1.6 Proposed function and involvement of genes in mupirocin biosynthesis 
Following the discovery of mupirocin gene cluster, we have collaborated with Professor 
C. M. Thomas, Department of Bioscience, University of Birmingham UK to carry out 
mutagenesis studies to obtain evidence for the mupirocin biosynthetic pathway 
described above and to determine the function of all the genes present in the 
biosynthetic gene cluster. Therefore, a first set of genes was chosen for study. Most of 
these genes are thought to be involved in the post-PKS modification. 
2.1.6.1 Proposed function and involvement of MupO 
MupO is a protein containing 454 amino acids, identical to the Cp51 from 
Mycobacterium tuberculosis encoding cytochrome a P-450 monooxygenase activity. 81 
These enzymes are responsible for oxygenation by insertion of one oxygen atom into a 
substrate, and the other is reduced to water and typically have NADPH 58 as cofactor 
(Scheme 2.8). 83 
RH + 02 + NADPH + H+ º ROH + H2O + NADP+ 
Scheme 2.8 General reaction catalysed by cytochrome P-450.83 
The cytochrome P-450s, heure proteins that are found in eukaryotic and bacterial 
mitochondrial membranes are classified as Class I. They work together with an iron- 
sulfur protein to mediate electron transfer to P-450 from NADH via FAD and FMN 
prosthetic groups. Class II enzymes, which are found in the endoplasmic reticulum of 
eukaryotes, are involved in metabolism of drugs substances, synthesis of steroid 
hormones and so on, and require single redox partners. 84 
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In polyketide biosyntheses, cytochrome P-450 monooxygenases are common 
enzymes, which are involved in oxidative reactions such as hydroxylation and 
epoxidation. In erythromycin biosynthesis, there are two genes, eryF and eryK, that 
encode cytochrome P-450 monooxygenase. These two tailoring enzymes were found to 
catalyse the hydroxylation at C-6 of 6-deoxyerythronolide B6 to erythronolide B 25 
and at C-12 to provide the active erythromycin 7 (Scheme 1.10). The conversion of 
double bond to epoxide in epothilone B 59, a macrolide antibiotic from Sorangium 
cellulosum, was found to be catalysed by cytochrome P-450 monooxygenase encoded 
by the epoK gene. 85'86 In mupirocin biosynthesis, a putative cytochrome P-450 
monooxygenase encoded by the mupO gene was suggested to be involved in 
hydroxylation to form the C-6 hydroxyl group or epoxidation to give the epoxide 
function at C-10,11, or to be involved in formation of the tetrahydropyran ring. 
2.1.6.2 Proposed function and involvement of MupQ and MupU 
According to the sequence comparison, MupQ was similar to the LucI protein in 
Luciola cruciata whilst MupU showed similarity to LcfA found in Haemophilus 
influenzae. Therefore, both MupQ and MupU were proposed to be acyl-CoA synthases. 
Coenzyme A (HSCoA) is an essential cofactor in many metabolic pathways including 
polyketide biosynthesis. The role of CoA is to activate substrates such as starter and 
extender units and transport into cell in the form of a CoA ester to start the reaction. 87 
Also acyl-CoA synthase, known as acyl-CoA ligase in fatty acid biosynthesis, is an 
enzyme that is used to activate fatty acids prior to ß-oxidation, a pathway of fatty acid 
degradation, in fatty acid catabolism. This enzyme forms the thioester bond between 
the carboxyl group and coenzyme A (CoA) together with the hydrolysis of ATP to 
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AMP and PPi (Scheme 2.9). 88 Putative acyl CoA synthases, involved in activation of 
starter units and/or transportation across the membrane are also found in PKS gene 
clusters, 89-92 e. g. the fumonisin fatty acyl CoA synthase FUM10 and FUM16 in 
Gibberella moniliformis, 89 AurE from Streptomyces thioluteus HKI-227, which was 
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Scheme 2.9 The mechanism of fatty acid activation by acyl CoA synthase. 
MupQ and MupU found in the mupirocin gene cluster were proposed to be 
essential for activation of substrates before undergoing reaction. As these proteins are 
homologous to different sources of acyl-CoA synthase and only 24% identical to each 
other, 8' they might recognise and activate different substrates in the pathway. 
2.1.6.3 Proposed function and involvement of MupV 
MupV, encoded by the mupV gene, contains 662 amino acids, and is located 
downstream next to the mupU gene. Alignment of MupV sequence showed similarity 
to the F4re protein in Methylobacterium organophilum, which corresponds to an 
oxidoreductase activity. Many post-PKS modifications involve oxidation-reduction to 
form the active functions such as alcohols, epoxides, etc. However, the exact 
involvement of MupV in mupirocin biosynthesis is not yet established. 
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2.1.6.4 Proposed function and involvement of MupT and MupW 
MupT is a small gene in size, similar to the ndoA gene in Pseudomonas putida. NdoA 
protein, encoding ferredoxin, is a component of naphthalene 1,2-dioxygenase, which is 
involved in the conversion of naphthalene to cis- 1,2-dihydroxy- 1,2-dihydronaphthalene. 
The ferredoxin is an electron transfer protein, which contains a Rieske-type [2Fe-2S] 
cluster. 93 Therefore, the proposed function of MupT protein is a putative ferredoxin 
dioxygenase. MupW is similar to the BnzA encoding the benzene 1,2-dioxygenase 
alpha subunit, which is a part of the terminal oxygenase of benzene dioxygenase. This 
enzyme catalyses the formation of benzene cis-1,2-dihydroxydiol from benzene, and is 
also found in Pseudomonas putida. 94 Thus, MupW was supposed to be a dioxygenase 
enzyme. 
In general dioxygenases are members of the oxygenase family of enzymes, 
which are typically involved in dihydroxylation of aromatic compounds such as 
anthracene, benzene, toluene, naphthalene, etc to form cis-1,2-dihydrocyclohexadiene 
compounds by insertion two oxygen atoms into the substrates using NADH or NADPH 
as cofactor (Scheme 2.10 (a)). Dioxygenase systems consist of two or three proteins 
linked together. For instance, benzene dioxygenase in Pseudomonas putida ML2 
contains three components; flavoprotein reductase, a ferredoxin and a terminal iron- 
sulfur protein. 95'96 In this system, electrons are transferred from NADH via 
flavoprotein and ferredoxin to the terminal dioxygenase (Scheme 2.10 (b)). Although 
mupirocin is not aromatic, MupT and MupW were predicted to be possible candidates 
for the oxidation reactions for forming the epoxide and tetrahydropyran ring. More 
details of MupT and MupW proteins are discussed in chapter 3. 
(a) 
dioxygenase OH 





Reductase Site Electron transfer chain 
NADH FAD or FMN º Ferredoxin 
[Fe2S2] 
Oxygenase Site 
Fe --º 02 
[Fe2S2], Fe 
Scheme 2.10 (a) Ring dihydroxylation catalyses by dioxygenase, (b) summary of electron transfer in 
ring hydroxylation. 96 
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2.1.6.5 Proposed function and involvement of MupS 
The mupS gene, located upstream of mmpF, encodes a protein of 257 amino acids. It 
shows similarity to 3-oxoacyl-ACP reductase encoded by the nodG gene in Rhizobium 
sp. 8' This enzyme is a component of fatty acid synthase corresponding to FabG2 in E. 
coli. and generally catalyses the reduction of ß-keto-ACP to form ß-hydroxyacyl ACP 
having NADPH as cofactor (Scheme 2.1 1). 97 A homologous 3-oxoacyl-ACP reductase 
has been found in the PKS gene cluster involved in griseorhodin A biosynthesis. 48 
However, the involvement of this enzyme in the pathway was unclear. Similarly, the 
role of MupS protein in mupirocin biosynthesis is not yet known but one possibility is 
to be involved in the formation of the 9-hydroxynonanoic acid moiety, which may be 
assembled from a different fatty acid related pathway. 
O0 OH O 




Scheme 2.11 Reduction reaction to form ß-hydroxyacyl ACP catalyses by ß-ketoacyl-[ACP]-reductase. 
2.1.6.6 Proposed function and involvement of MupX 
The mupX gene is located near the end of the cluster. It codes for a protein of 512 amino 
acids and 37% identical to ami2 gene in Mycobacterium tuberculosis. The proposed 
function of this gene is as an amidase or hydrolase. However, the role of this protein in 
mupirocin biosynthesis is not yet assigned. 
2.1.6.7 Proposed function and involvement of McT1 domain of MmpD 
From sequence alignment MeT 1, a domain in module 1 of MmpD, was similar to PksM 
of Bacillus subtillis corresponding to methyltransferase. Basically, a methyltransferase 
is responsible for transferring, the methyl group of S-adenosylmethionine to carbon, 
oxygen or nitrogen centres. The methylation at an oxygen results in formation of 
methyl ether (Scheme 2.12 (a)) whereas methylation at carbon or nitrogen creates a C-C 
or C-N bond respectively (Scheme 2.12 (b) and (c)). 98 
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Scheme 2.12 Mechanism of (a) O-methylation; (b) C-methylation and (c) N-methylation. 
Comparison of gene sequences indicated that methyltransferasel (MeT 1) in 
mupirocin gene cluster could be involved in C-methylation as in lovastatin and 
yersiniabactin biosyntheses. 8' This enzyme was proposed to introduce a methyl group 
onto the carbon chain after forming the diketide intermediate in the first cycle of 
mupirocin biosynthesis. 
2.1.7 Mutation of genes in mupirocin biosynthesis 
As the purpose of this work is to investigate the mupirocin biosynthetic pathway using 
mutagenic studies, the relevant genes were deleted from the cluster. The deletions of 
mup genes were performed by S. Cooper" for use in these studies. The specific 
deletions in the target gene were obtained between two arms, each at least 500 bp in 
length. Either of the following two methods was used to make an in-frame 
chromosomal gene deletion. In the first method, internal restriction sites on the target 
gene were chosen. The fragment including those two sites was amplified by extending 
the same distance from each site. The deletion was carried out by digestion of the gene 
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at the selected restriction sites and then the two arms were religated. The method is 






Two restriction sites 
located in the middle of 
target gene 
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Gene T 








Gene T lacking the 
central region 
Figure 2.7 The methods of gene deletion. (a) by excising a region from the centre of the target DNA 
using specific restriction sites. (b) by PCR. A, B, C represent restriction sites used for 
cloning. 99 
restriction sites, which encompassed a significant portion of the target genes. The 
knockouts would be unsuccessful if the gene function was not removed. In the second 
method, regions of target gene were deleted by amplifying two PCR products, which 
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amplified fragments were then connected together. This would create a product, which 
lacks the DNA between the regions not covered. 
Deletion fragments from either method were constructed into pGEM-T Easy, 
which is a standard vector for PCR product. The fragment was further subcloned into 
the suicide vector, pAKE604. This vector possesses two genes that are important for 
the final step of mutant construction. These genes are a kanamycin resistance gene and 
the sacB gene encoding the levansucrase enzyme that catalyses sucrose hydrolysis and 
levan synthesis. It is thought that the accumulation of these levan can encumber the 
periplasm of the host cell resulting in its death. The recombinant plasmid was 
transformed to E. coli S17-1 and mobilised into the P. fluorescens strain. The 
recombinant clones were then screened by antibiotic selection for kanamycin. As the 
suicide vector cannot replicate in the P. fluorescens host, thus, the results of 
recombination should be from the plasmid integration. The colonies were further 
checked for sucrose sensitivity by plating onto 5% sucrose L-agar. 
The aim of this project was to investigate the mupirocin biosynthetic pathway. 
Following the discovery of the mupirocin gene cluster, a set of genes, which are 
involved in the polyketide synthases and post-PKS modification were knocked out in 
order to determine how the metabolic pathway was affected. Thus, the intermediates 
that were produced by these mutant strains were investigated. Therefore, the approach 
used in these studies involved: 
1) Isolation and identification of compounds from the Pseudomonasfluorescens 
NCIMB 10586 mutant strains and comparison of these with the wild type 
products. 
2) Expression and purification of mupirocin proteins from Pseudomonas 
fluorescens NCIMB 10586 mutants to get a better understanding of enzyme 
functions. 
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2.2 Results and Discussion 
As mentioned earlier, we have collaborated with Professor Thomas's research group to 
study the role of each gene and whether the biosynthetic pathway is affected as a result 
of the gene knockout studies. Thus, a first set of genes (mup genes) (Table 2.1) whose 
proposed functions were likely to be of significance in mupirocin biosynthesis, were 
deleted from the cluster. The intermediates, produced by these mutants and any other 
changes from wild type, were investigated and characterised. These may lead to a better 
understanding of biosynthetic pathway, which in turn would provide valuable 
information for the pharmaceutical industry. Since the mutations may increase the 
amount of products or provide modified new drugs. 
Table 2.1 Organisation of mup mutants 
Gene / mmp Proposed function / domain 
mup0 Cytochrome P450 
mupQ Acyl-CoA-synthase 
mupS 3-oxoacyl (ACP) reductase 




mupX Amidase / hydrolase 
mupQ: U Acyl-CoA-synthase 
mmpD MeT 1 
2.2.1 Production of pseudomonic acid by P. fluorescens NCIMB 10586 wild type 
and mup mutants 
Initially, the bacterial strains including the mutant strains were grown following 
standard conditions from Professor Thomas's research group. Therefore, a single 
colony of P. fluorescens NCIMB 10586 wild type (WT) and each mup mutant, on agar 
plates, were inoculated to 25 ml of seed medium (LB medium containing 0.11% 
glucose) and grown on a shaker at 200 rpm, 25°C for 24 hours. 5% volume of seed 
culture was used to inoculate 100 ml mupirocin production medium (MPM) in 500 ml 
conical flasks and grown on a shaker at 200 rpm, 22°C for 50 hours. After this time, the 
cultures were harvested by centrifugation. A 50 µl aliquot from each supernatant was 
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analysed by HPLC. Due to small amount of production from some mutants, the 
remaining supernatants were then extracted with ethyl acetate. Each crude extract, in 1 
ml methanol, was also checked for production of pseudomonic acid and other 
compounds by HPLC and LC-MS. For HPLC analysis, water-acetonitrile containing 
0.05% trifluoroacetic acid (TFA) was used as mobile phase. The compounds were 
eluted from the column by a linear gradient of 5-95 % acetonitrile in 50 minutes at flow 
rate 1 ml min-' at UV 233 nm. 
HPLC trace of crude extract from wild type (WT) (Fig. 2.8 (a)) showed the peak 
corresponding to PA-A at a retention time (RT) of 23.3 minutes in this system by 
comparison with the standard PA-A. LC-MS trace of crude extract from WT (Fig. 2.8 
(b)) showed two significant signals with molecular ions (m/z) 501 and 517 that 
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Figure 2.8 Analysis of crude extract from P. fluorescens NCIMB 10586 wild type in MPM. (a) By 
HPLC, and (b) by LC-MS. 
The production of pseudomonic acid from either culture broths or crude extracts 
of mup mutants analysed by HPLC (Fig. 2.9) and LC-MS was compared with WT. The 
results are summarised in Table 2.2. HPLC analysis of production by mupO mutant 
showed no peak corresponding to PA-A but one significant peak was detected at RT 
22.5 minutes. In addition, LC-MS trace showed the peak with the molecular ion (m/z) 
517. Therefore, it was thought that this would be PA-B. Identical results were detected 
from the productions by mupU and mupV mutants. 
HPLC analysis of compounds produced by mupQ and mupS mutants showed 
small peaks, which differed from PA-A. However, no significant peak was seen on the 
LC-MS trace. HPLC analysis of compounds produced by mupT and mupW mutants 
45 
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Chapter 2 Mupirocin Biosynthesis 
showed some small peaks, which differed from WT. In addition, these two mutants 
showed similar results in which one significant peak near PA-A was observed at time 
23.5-23.6 minutes but LC-MS analysis gave different results. The LC-MS trace of 
mupT mutant showed no PA-A peak or any other significant peak whereas that from 
mupW mutant clearly showed a peak with molecular ion (m/z) 503. 
Table 2.2 HPLC and LC-MS analysis of compounds that were produced by P. fluorescens NCIMB 
10586 mup mutant. 
mmp/mup Results 
mutants 
0 HPLC showed a significant peak, which did not correspond to PA-A whereas LC- 
MS showed peak with molecular ion 517. 
Q HPLC showed a small peak near PA-A and a small peak that differed from WT. 
But no peak was significant on LC-MS trace. 
S HPLC showed small peak near PA-A but no peak was significant on LC-MS 
trace. 
T HPLC showed small peaks near PA-A. No peak at 501 which corresponded to 
PA-A or significant peak were shown on LC-MS trace. 
U HPLC showed some peaks, which were different from WT. LC-MS showed peak 
with molecular ion 517. 
V HPLC showed a significant peak and LC-MS showed peak with molecular ion 
517. 
W HPLC showed a peak near PA-A and small peak, which differed from WT. LC- 
MS showed peak with molecular ion 503 but no peak at 501. 
X HPLC trace was similar to WT and LC-MS also showed the peak with molecular 
ion 501 and 517. 
D (MT I) HPLC trace showed peaks, which differed from WT. No peak was significant on 
LC-MS trace. 
Q: U HPLC showed small peak, which differed from WT. LC-MS showed peak with 
molecular ion 517. 
HPLC and LC-MS traces of extracts of the mupX mutant showed identical 
signals to those from WT. The major peak corresponding to PA-A was observed at RT 
23.3 minutes but it was smaller than found in WT. Also LC-MS analysis showed peaks 
at molecular ions (m/z) 501 and 517. By HPLC, no significant peak was observed from 
crude extract of the mupQ: U mutant but LC-MS trace showed a peak with molecular 
ion (m/z) 517. As this might be the same peak, which was detected from mupO or 
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mupU or mupV mutants, the analysis of crude extract of the mupQ: U mutant was 
repeated and compared with the results from mupU mutant. Unfortunately, the 
particular peak was not clearly observed. The HPLC trace of crude extract of the MeT 1 
mutant showed small peaks that differed from WT but no significant peak was observed 
by LC-MS. 
From the above initial results it can be seen that the mutations of mup genes led 
to the production of compounds, which were identical or different from WT. Although 
some mutants produced the same compounds as WT, the quantities were different. 
However, for further analysis the production from these mutants had to be scaled up. 
The compounds of interest would be isolated and characterised in order to confirm the 
structure and also to confirm some small peaks, which were observed. 
2.2.2 Isolation of compounds produced by P. fluorescens NCIMB 10586 wild type 
and mup mutants in mupirocin production medium (MPM) 
As described above the HPLC traces indicated the presence of interesting compounds 
from some mutant fermentation broths. Those compounds needed to be purified and 
characterised. Two methods were used to purify the compounds, column 
chromatography and HPLC. 
To isolate PA-A, P. fluorescens NCIMB 10586 was grown in 100 ml MIPM in 
50 x 500 ml conical flasks at 22°C for 50 hours. The cultures were harvested and 
centrifuged to separate the cells. Before extraction, the combined supernatants were 
acidified to pH 4.5 with dilute HCl and saturated with NaCl. The supernatants were 
extracted with 3x2.5 litres of ethyl acetate. The organic phases were combined and 
evaporated to dryness to give an orange oil. The crude extract was taken in 10 ml 
methanol and was methylated with diazomethane for separation by column chroma- 
tography as the corresponding methyl esters e. g. methyl pseudomonate A 60 prior to 
being loaded on column. Dichloromethane (CH2C12)-methanol (MeOH) in ratio 12: 1 
was used as elution buffer. By HPLC, the crude extract was injected into the HPLC 
using a 4.6 x 250 mm column at flow rate 1 ml min-'. Water-acetonitrile containing 
0.05% TFA was used as mobile phase at UV detection 233 nm. The collected fractions 
corresponding to PA-A from both methods were characterised by 1H NMR. 
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OH Methyl pseudomonate A 60 
The amount of PA-A from isolation and purification by column chromatography 
and HPLC were 7 mg and 4.3 mg in 5 litre media respectively. Unfortunately, the 1H 
NMR spectrum did not clearly show the signals of PA-A because the signals were 
rather weak and had some impurity signals. 
Similar isolations were carried out with some mup mutants such as mupO, mupV 
and MeT 1 mutants using the same conditions for growing and isolating. The mutant 
extracts, which showed the presence of interesting compounds were also methylated 
with diazomethane for separation by column chromatography. Similar results were 
observed from these mutants, the production was low and we could not get any 
information from 1H NMR as the signals were very weak. 
Due to the low production level, no compounds could be isolated and purified. 
Thus to achieve higher production, the growth conditions were studied and optimised. 
Also, due to the small amount of compounds that are produced by the mutant strains, 
HPLC was used to separate the compounds during this study. 
2.2.3 Optimisation of growth condition for pseudomonic acid production in 
P. fluorescens NCIMB 10586 wild type and derived mutants 
As described above, initially, P. fluorescens NCIMB 10586, the wild type strain used in 
these studies, was grown following the conditions that were developed in 
Birmingham. 99 The maximum production of PA-A, which was monitored by HPLC 
from aliquots of broth was 2.0 mg 1-1 after 50 hours. Thus, all the parameters, which 
might effect the production, e. g. media composition, temperature, culture flask, volume 
of medium and speed of shaking, were studied in order to increase the yield. 
Based on previous studies of PA-A in P. fluorescens sp. 66'67'82 two other media, 
production medium (PM) and secondary stage medium (SSM) were chosen to compare 
with MPM. Both media are richer in glucose and mineral salts. PM was developed in 
Mantle's group and contains 6% glucose66 whereas SSM, which was developed at 
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SmithKline Beecham and employed by Sugden82 and Donlevy, 67 contains 10% glucose. 
It was reported by Donlevy that the production of PA-A in P. fluorescens NCIB 10586 
was 200 mg in 0.5 litre fermentation according to HPLC. However, only 60 mg, at 
most, of PA-A was actually isolated. Previous experience for extraction of PA-A in PM 
and SSM found that the emulsion formation occurred during the extraction when SSM 
was used more than in cases when PM was used. This led to a more difficult extraction 
and some yield was lost. Therefore, PM was the first medium of choice and was 
compared with MPM. 
Two sets of experiments were carried out. Firstly, P. fluorescens NCIMB 10586 
was grown at 22°C, 200 rpm in different media, MPM and PM. Secondly, the growing 
conditions were changed to 25°C, 240 rpm in the different media as above. The 
production of PA-A was monitored by HPLC from aliquots of each broth as shown in 
Table 2.3 
Table 2.3 Comparison of PA-A production by P. fluorescens NCIMB 10586 in MPM and PM 
Concentration of PA-A (mgl-1) 
Medium 22°C, 200 rpm 25°C, 240 rpm 
MPM 2.1 3.7 
PM 1.5 1.5 
Table 2.3 shows that the production of PA-A by P. fluorescens NCIMB 10586 
grown in MPM at 25°C, 240 rpm was slightly higher than growth at 22°C, 200 rpm and 
was also better than growth in PM. But the level of production was still low. However, 
the temperature and the speed of shaking had only small affects on production. 
In the meantime the effect of medium volume for PA-A production was studied. 
The wild type strain was grown in 100 ml and 200 ml MPM in 500 ml conical flask at 
22°C, 200 rpm for 50 hours. An aliquot was taken then to determine the concentration 
of PA-A. It was found that the production of PA-A in 100 ml medium was three to four 
fold higher than in 200 ml (Fig. 2.10). This might be due to increased area for aeration 
in the flask. Thus it seemed that the volume of medium affected the production of PA- 
A. 
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Figure 2.10 HPLC trace of crude extract from P. fluorescenNCIMB 10586 fermentation. (a) in 100 ml 
MPM and (b) in 200 ml MPM. 
In addition to the effect of medium volume, it was though that the shape of flask 
for growing the strain could affect the production of PA-A. Thus, another experiment 
was carried out. The strain was grown in 100 ml MPM in 500 ml conical flask and in 
500 ml baffle flask using the same condition as above. The production of PA-A in 
baffle flasks was two fold higher than in conical flasks. Such a result indicated that the 
availability of oxygen in fermentation was important for metabolite production. 
However, we could not overcome the problem of low production by using PM. 
Therefore, the SSM was also investigated. 
To overcome the problem of low yield, SSM was used as production medium 
for comparison with MPM. Therefore, P. fluorescens NCIMB 10586 was grown in 100 
ml MPM and in 100 ml SSM in 500 ml baffle flask at 22°C and 25°C, 250 rpm for 50 
hours. It was found that the concentration of PA-A in this medium was 42 mg 1-1 at 
22°C whereas the production at 25°C was lower. The experiments were repeated to 
confirm the production of PA-A in SSM. It was observed that the production was not 
constant. Also we thought that it might be due to loss of activity in the producer strain. 
Thus, to check the activity of microorganism, a fresh strain (P. fluorescens NCIMB 
10586) was purchased from National Collection of Industrial and Marine Bacteria 
(NCIMB, UK) and grown using the same condition in SSM. The production was higher 
than the previous strain but the results were variable. The yield was approximately 70- 
100 mg 1-l At this stage, we thought that the SSM could be used as production medium 
to grow the wild type and the coup mutant strains for isolation. 
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2.2.4 Isolation of pseudomonic acid produced by P. fluorescens NCIMB 10586 in 
secondary stage medium (SSM) 
P. fluorescens NCIMB 10586 was grown in 100 ml SSM in 5x 500 ml baffle flasks at 
22°C for 50 hours. The media were combined and centrifuged at 10,000 rpm, 4°C for 
15 minutes. An aliquot (50 µl) from combined supernatant was taken to determine the 
production of PA-A, present in the medium at that time by HPLC using a linear gradient 
of 5-95% acetonitrile containing 0.05% TFA in 50 minutes at flow rate 1 ml min-'. The 
remaining supernatant was acidified to pH 4.5, and then extracted with ethyl acetate. 
The organic layers were combined and evaporated to dryness to give the crude PA-A, 
which was dissolved in 5 ml methanol. 20 µl of this solution was analysed by LC-MS. 
HPLC analysis of aliquot from combined supernatant (Fig. 2.11 (a)) showed 
peak 1 corresponding to PA-A at RT 22.1 minutes and peak 2, which was thought to be 
PA-B at RT 21.2 minutes. By area comparison, the predicted production of PA-A was 
70 mg 1-1 and the area of peak 2 was 3% of peak 1. Analysis of the crude extract by LC- 
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Figure 2.11 HPLC analysis of PA-A production by P. fluorescens NCIMB 10586 wild type (a) 
analytical HPLC trace of aliquot from combined supernatant using linear gradient and (b) 
HPLC trace of crude extract using separation method. 
For separation by HPLC, the methanol solution of the crude extract was diluted 
fourfold with HPLC grade water to give a total volume 20 ml. A 480 µl aliquot was 
injected into the HPLC and eluted using a step gradient mobile phase of water- 
acetonitrile containing 0.05% TFA. PA-A was eluted at RT 20.0 minutes in this system 
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(Fig. 2.11 (b)). One major and two minor components eluted at 19.5-20.5,17.0-17.5 
and 16.5-16.9 minutes respectively were collected. The remaining solution was 
similarly separated by repeated injection and the collected fractions were evaporated to 
dryness. The purified compound from each fraction was characterised by NMR 
spectroscopy. 
Unfortunately, the 1H NMR spectrum of fraction 1 that corresponded to PA-A 
did not show all the signals expected for PA-A. The signals at 2.65-2.75 ppm for the 
epoxide protons at C- 10 and C-11 were missing and new signals were observed. Thus, 
the sample was reinjected into HPLC. The HPLC trace now showed two peaks close 
together at 16.5 and 17.2 min (Fig. 2.12 (b)) whereas the PA-A peak had almost 
disappeared. We thought that this would probably be caused by the TFA contained in 
the fraction during purification and evaporation. This would cause PA-A to be unstable 
as the pH of water containing 0.01-0.05% TFA is 2.0-3.0. This would lead to the 
opening of epoxide ring to give the rearrangement products 55 and 56.76 Thus, the use 
of formic acid as an alternative was studied because this acid is weaker than TFA. 
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Figure 2.12 (a) HPLC trace of PA-A and (b) after in strong acid or base shows two peaks of isomers. 
Therefore, the extraction of PA-A from P. fluorescens NCIMB 10586 was 
repeated as described above. The crude extract was prepared for purification by HPLC. 
But now the water-acetonitrile mobile phase contained 0.005% formic acid instead of 
TFA. After separation, an aliquot from each collected fraction was confirmed by 
repeated injection and then evaporated to remove the acetonitrile. To avoid the 
rearrangement of PA-A under strong acid conditions, the evaporation was performed at 
low temperature and in a short time. The remaining aqueous phase was extracted with 
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ethyl acetate and the extract was evaporated to dryness. The purified compound from 
each fraction was characterised by NMR spectroscopy. 
As expected, 1H and 13 C NMR spectra of fraction 1 (10 mg) (Fig. 2.12 and 2.13) 
corresponded to those of PA-A, the spectra are first assigned in 1977 by Mellows and 
co-workers58'59 and confirmed by Tyler and Everett in 1985.60'61 Tables 2.4 and 2.5 
summarise the 1H and 13C NMR assignment of PA-A respectively. The 1H NMR 
spectrum of fraction 2 which had been assumed to be PA-B was clearly not consistent 
with this, e. g. the characteristic signals at chemical shift at 2.65 and 2.75 ppm due to the 
10,11 epoxide were not present. The 1H NMR spectrum of fraction 3 was very similar 
to fraction 2 and it appeared that these 1H NMR spectra were similar to the 'H NMR 
spectra of the PA-A rearrangement products described above. This was presumably 
again due to the mild acid condition during the extraction process. Interestingly, the 
LC-MS analysis trace of fraction 2 always showed the presence of molecular ions at 
501 and 517, which suggested that there was some PA-B in this fraction but the amount 
was too small to show up in the 1H NMR spectrum. 
2.2.5 Isolation and purification of compounds produced by P. fluorescens 
NCIMB 10586 mup mutants 
In order to understand the mupirocin biosynthetic pathway, some of mup genes shown 
in Table 2.1 were knocked out. Most of these genes are supposed to be involved in 
post-PKS modification. The compounds produced by these mutants were isolated and 
identified to see how they related to the pathway. The mutant strains were grown using 
the same optimised medium and conditions as for the wild type strain. The compounds 
were extracted and analysed by HPLC. The HPLC traces of some of the mutants 
seemed to be identical to that of wild type. However, the actual structures of the 
compounds needed to be confirmed. Therefore, the compounds from mutants that 
showed significant HPLC signals, which were either the same as or different from wild 
type were purified by HPLC. Further structural elucidations were carried out by NMR 
spectroscopy and mass spectrometry. 
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Figure 2.12 11-1 NMR spectrum of pseudomonic acid Ain CD3OD. 
Table 2.4 1H nmr spectral assignment of pseudomonic acid A. 
8H, ppm Multiplicity J, Hz 1H assignment 
0.94 d 7 17-H 
1.20 d 6.5 14-H 
1.32-1.38 br s 4'-H, 5'-H, 6'-H, 7'-H 
1.38-1.42 m 12-H 
1.60-1.68 br s 3'-H, 8'-H, 9-H 
1.95 m 8-H 
2.17 s 15-H 
2.21 dd 13,9 4a-H 
2.27 t 7.5 2'-H 
2.64 dd 13,2 4b-H 
2.72 dd 7,2 11-H 
2.80 ddd 6,6,2 10-H 
3.34 dd 9,3 6-H 
3.55 d 12 16a-H 
3.75 ddd 9,9,3 5-H 
3.80 dq 6,5 13-H 
3.85 d 12 16b-H 
3.88 dd 3,3 7-H 
4.08 t 7 9'-H 
5.75 s 2-H 
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Figure 2.13 13C NMR spectrum of pseudomonic acid A in CD3OD. 
Table 2.5 13C nmr spectral assignment of pseudomonic acid A. 
6c, ppm 13C assignment 8c, ppm 13C assignment 
11.5 C-17 43.2 C-12 
18.4 C-15 56.2 C-10 
19.5 C-14 60.5 C-11 
25.3 C-3' 64.0 C-9' 
26.3 C-7' 65.6 C-16 
29.0 C-8' 69.2 C-6 
29.3 C-4' 70.1 C-13 
29.4 C-5' 71.0 C-7 
29.5 C-6' 75.4 C-5 
32.2 C-9 117.5 C-2 
34.3 C-2' 158.3 C-3 
40.9 C-8 167.5 C-1 
43.0 C-4 177.0 C-1 
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2.2.5.1 Isolation of compounds produced by P. fluorescens NCIMB 10586 mupW 
mutant 
MupW encodes a protein, which from sequence conservation could be a dioxygenase. 
This should then be a possibility for one of a number of reactions such as; epoxidation, 
hydroxylation at C-6 or formation of the tetrahydropyran ring. Mutation could thus 
















The mupW strain was grown in 100 ml SSM in 20 x 500 ml baffle flasks using 
the same condition as above. HPLC analysis of aliquot from the combined supernatant 
showed a peak near PA-A at RT 22.3 minutes in this system (Fig. 2.14 (a)). The peak 
area was about 18% of PA-A of WT. The crude extracts were separated by HPLC as in 
2.2.4. The fraction corresponding to the peak of interest at 20.2-21.0 minutes was 
collected (Fig. 2.14 (b)) and worked up as in 2.2.4. The LC-MS trace of crude extract 
showed a significant peak at molecular ion (m/z) 503, two units mass higher than PA-A, 
but no peak at m/z 501 corresponding to PA-A itself (Fig. 2.15), to suggest that the new 
compound is a formal dihydro derivative of PA-A. 
56 











UV 233 nm 
1.0 
10 15 20 25 min 
Figure 2.14 HPLC analysis of compound by P. fluorescens NCIMB 10586 mupW mutant (a) HPLC 
trace of aliquot from combined supernatant using linear gradient and (b) HPLC trace of 
crude extraction by separation method. 
503.81 
m/z 
Figure 2.15 LC-MS trace of purified fraction from crude extract produced by P. fluorescens NCIMB 
10586 mupW mutant. 
The lH and 13C NMR spectra of this compound (5 mg) (Fig. 2.16 and Fig. 2.17 
respectively) are rather similar to PA-A. However, the 1H NMR spectrum in CD3OD 
showed three signals for methyl doublets in contrast to the two methyl doublets in the 
other pseudomonic acid metabolites. The signals at 2.65-2.85 ppm corresponding to the 
protons of the epoxide at C- 10 and 11 had disappeared. Also, the signals at 3.55 and 
3.85 ppm corresponding to the methylene in the tetrahydropyran ring were no longer 
present, and this along with the extra methyl doublet signal strongly suggested that the 
compound lacked the tetrahydropyran ring. 
To investigation how many hydroxyls group were present, the compound was 
methylated with diazomethane to form the methyl ester and then the structure was 
elucidated in deuterochloroform (CDC13) at 400 and 600 MHz NMR. The 1H NMR 
spectrum (Fig. 2.18 (b)) showed four signals of hydroxyl groups at 2.14,2.43,2.85 and 
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Figure 2.18 'H NMR spectra of compound isolated from P. fluorescens NCIMB 10586 mupW mutant. 
(a) in acid form, (b) in methylated form and (c) in acetylated form. 
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3.90 ppm. In addition, high resolution mass analysis of methyl ester 64 gave the 
molecular formula of C27144809. The presence of four hydroxyl groups was further 
confirmed on the formation of a tetra-acetate 65 by treatment with acetic anhydride in 
pyridine at room temperature, and the tetramethylsilylether (C39Hg0O9Si4). The lH 
NMR spectrum of 65 (Fig. 2.18 (c)) showed four new signals for methyl singlets at 
1.98,2.03,2.08 and 2.09 ppm corresponding to the four acetate methyl groups. Also 
four signals at 170.6 (2C), 170.7 and 170.8 were observed on the 13C NMR spectrum. 












Figure 2.19 COSY spectrum of compound 64 in CDC13. 
The appearance of an extra methyl doublet in the 1H NMR spectrum 
immediately suggested a structure lacking the tetrahydropyran ring and this was 
confirmed by a full analysis of the COSY spectrum of the methyl ester (Fig. 2.19), 
which showed the connectivities summarised in Fig. 2.20. The remaining problems 
were the exact positions of the four secondary hydroxyl groups and thus the exact 
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resolved by further examination of the COSY spectrum and changes observed in the 1D 
spectrum following D20 exchange. ' 00 
Direct correlations were seen between H-5 and the hydroxyl group proton at 
3.95 and 2.43 ppm respectively, H-6 and OH at 3.62 and 2.14 ppm, and H-11 and OH at 
3.76 and 2.85 ppm (Fig. 2.19). On addition of D20, no change was observed on either 
H-7 or H-10 at 4.12 or 3.76 ppm respectively, whereas, H-13 at 3.84 ppm sharpened 
from an apparent broad pentet with coupling of 7 Hz to a sharp doublet of quartets with 
coupling of 8 and 6 Hz respectively. Full analysis of the COSY spectrum provided the 
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Figure 2.20 Summarised proton connectivities. 'oo 
Thus, the observations are entirely consistent with the presence of a 
tetrahydrofuran ring in 64, with C-7 and C-10 being linked by the ether oxygen. The 
relative configuration around the tetrahydrofuran ring was established by observation of 
the NOEs shown in Fig. 2.21 and summarised in Fig. 2.22. These indicated that H-8, H- 
9a and H-10 showed mutual relaxations, whereas irradiation of H-9b gave enhancement 
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Figure 2.21 NOEs spectrum of compound 64 
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Figure 2.22 NOEs observed for methyl ester 64. 
Thus we can propose structure 63 for the new metabolite, which we have called 
mupirocin W, and structure 64 and 65 for the methyl ester and tetra-acetate respectively. 
The absolute configuration is assumed from that present in PA-A. The full assignment 
of the 1H and 13C NMR spectra are summarised in Tables 2.5 and 2.6. 
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R1 =R2=R3=R4=R5=H 63 
R, = OMe, R2 = R3 = R4 = R5 =H 64 
Rl = OMe, R2 = R3 = R4 = RS =CO-Me 65 
It is now clear that the mupW gene encodes a dioxygenase responsible for the C- 
16 hydroxylation to form a hydroxy intermediate, which may further undergo 












Scheme 2.13 Proposed mechanism of tetrahydropyran ring formation by mupW gene. 
It is known that PA-A is sensitive to pH and on either mild acid or mild base 
treatment, it is converted to structures containing either of the 5 or 6-membered cyclic 
ethers arising from attack of the 7-hydroxyl group at C-10 or C-11 of the epoxide ring. 
Thus one can propose that mupirocin W is formed from the biosynthetic intermediate 62 
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Table 2.5 'H nmr spectral assignment of compound 63 isolated from P. fluorescens NCIMB 10586 
mupW mutant fermentation in CD3OD. 
8H, ppm Multiplicity J, Hz 'H assignment 
0.75 d 7 17-H 
1.01 d 6 16-H 
1.07 d 6.5 14-H 
1.25-1.27 br s 4'-H, 5'-H, 6'-H, 7'-H 
1.45-1.48 m 12-H 
1.50-1.60 br s 3'-H, 8'-H, 9a-H 
1.96 ddd 12,8,6 9b-H 
2.10 d 1 15-H 
2.13 dd 13,8 4a-H 
2.18 t 7.5 2'-H 
2.21-2.26 m 8-H 
2.51 dd 13,2 4b-H 
3.40 t 6 6-H 
3.51 dd 8,6 7-H 
3.54 dd 8,3 11-H 
3.78 ddd 13,4,3,2 5-H 
3.89 dq 8,6 13-H 
3.98 t 6.4 9'-H 
4.00 ddd 11,7,2 10-H 
5.67 s 2-H 
Table 2.6 13C nmr spectral assignment of compound 63 isolated from P. fluorescens NCIMB 10586 
mup W mutant fermentation in CD3OD. 
8c, ppm 13C assignment Sc, ppm 13C assignment 
10.2 C-17 43.9 C-4 
18.0 C-16 63.8 C-9' 
18.2 C-14, C-15 69.2 C-6 
25.1 C-3' 71.1 C-7 
26.1 C-7' 74.9 C-13 
28.8 C-8' 77.0 C-5 
29.2 C-4', C-5' 80.4 C-10 
29.3 C-6' 86.2 C-11 
34.0 C-2' 117.5 C-2 
35.6 C-9 158.5 C-3 
37.6 C-8 167.5 C-1 
43.3 C-12 176.8 C-1' 
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by analogous opening of a 10-11 epoxide at C-10 by 7-OH (Scheme 2.14). Mutation of 
MupW blocks hydroxylation, but it is clear that the other presumably late stage 
modifications, 6-hydroxylation, 10,11-epoxidation and esterification with 9- 
hydroxynonanoic acid take place. This may imply that 16-hydroxylation and 
subsequent tetrahydropyran ring formation occurs as the last step in the biosynthesis of 
PA-A. 100 Alternatively, the enzymes responsible for the other late modifications may 
have sufficiently relaxed substrate specificity to accept non-THP containing 
intermediates. It is possible that greater conformational mobility of 62 compared to 40 
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Scheme 2.14 The involvement of mup W gene in mupirocin biosynthetic pathway. 
2.2.5.2 Isolation of compounds produced by P. fluorescens NCIMB 10586 
mupO, mupU, mupV mutants 
The proposed functions of mupO, mupU and mupV genes were cytochrome P-450, acyl 
CoA synthase and oxidoreductase respectively. MupO and MupV could catalyse 
oxidation reactions whilst MupU could be an activator of starter and extender units. 
MupO was predicted to be involved in an epoxide formation. Therefore, in the absence 
of this protein, PA-C 42 that contains an olefin function instead of epoxide might 
expected to be found. The 
'H NMR spectrum would be expected to show a signal at a 
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chemical shift of 5.2-5.4 ppm corresponding to olefinic proton and the epoxide signals 




OH Pseudomonic acid C 42 
Interestingly, HPLC analysis of culture broth (Fig. 2.23) or crude extract from 
all three mutants, mupO, mupU, and mupV gave very similar UV traces. Significant 
peaks were detected at RT 21.4,21.3 and 21.3 minutes from production of mupO, 
mupU, and mupV respectively. These peak areas were 25%, 40% and 74% of PA-A of 
WT. To prove that these were the same compound, the crude extracts from each mutant 
was separated by HPLC using the step gradient as shown for mupU mutant in Fig. 2.24. 


















Figure 2.23 HPLC analysis of culture broths from P. fluorescens NCIMB 10586 (a) mupO, (b) mupU 
and mupV mutants using linear gradient. 
The fraction at 16.8-17.5 minute was collected and worked-up as described in 2.2.4. 
The mass spectrum of the partially purified fraction of the crude extract showed peaks at 
molecular ion (m/z) 517 [M]H+ and two fragments at m/z 499[M-H2O]H+, 481 [M- 
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2H2O]H+, corresponding to loss of one and two molecules of water respectively and at 
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Figure 2.24 HPLC analysis of compound by P. fluorescens NCIMB 10586 mupU mutant using 
separation method. 
The 1H and 13C NMR spectra of the compounds isolated from the mupO, mupU 
and mupV mutants showed the same signals indicating that they were indeed the same 
compound. The spectra showed that the compound was pseudomonic acid B 41. The 
1H and 13C NMR spectra of PA-B (Fig. 2.25,2.26 and Table 2.7,2.8) were first 
assigned by Chain and Mellows. 62 They are similar to that of PA-A but the signal of 
the C-8 proton at (SH 1.95 in PA-A) was absent and the C-10 proton (6H 2.78 in PA-A) 
was shifted to 2.98 ppm. In addition the C-8 signal of PA-B appears at 71.4 ppm 
instead of 40.9 ppm in PA-A. Pseudomonic acid B 41, C26H44010, was reported as one 
of the minor products in P. fluorescens fermentation. 62 
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It is clear that the disruption of mupO, mupU and mupV genes affected the 
mupirocin biosynthetic pathway. The production of PA-A was blocked and an 
equivalent or greater amount of PA-B was produced. This suggests that these gene 
products are all involved in the same biosynthetic step. 
99°l0l The mupO gene encodes a 
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Table 2.7 'H nmr spectral assignment of pseudomonic acid B. 
öH, ppm Multiplicity J, Hz 'H assignment 
0.92 d 7 17-H 
1.19 d 7 14-H 
1.32-1.36 br s 4'-H, 5'-H, 6'-H, 7'-H 
1.42-1.45 m 12-H 
1.58-1.70 br s 3'-H, 8'-H, 9a-H 
1.92 dd 14,6 9b-H 
2.16 s 15-H 
2.21 dd 14,9 4a-H 
2.25 t 7 2'-H 
2.65 dd 14,2 4b-H 
2.73 dd 7,2 11-H 
2.98 ddd 6,6,2 10-H 
3.33 dd 10,3 6-H 
3.50 s 16-H 
3.62 ddd 9,9,2 5-H 
3.72 d 3 7-H 
3.77 dq 6,5 13-H 
4.06 t 6.5 9'-H 
5.73 S 2-H 
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Figure 2.25 1H NMR spectrum ofpseudomonic acid Bin CD3OD. 
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Figure 2.26 13C NMR spectrum of pseudomonic acid B in CD3OD. 
Table 2.8 13C nmr spectral assignment of pseudomonic acid B. 
Sc, ppm 13C assignment 8c, ppm 13C assignment 
10.9 C-17 52.6 C-10 
18.2 C-15 60.0 C-11 
19.2 C-14 63.7 C-9 
24.9 C-3' 68.4 C-16 
25.9 C-7' 69.7 C-6 
28.7 C-8' 70.1 C-13 
29.0 C-4' 71.4 C-8 
29.0 C-5' 73.4 C-7 
29.1 C-6' 74.3 C-5 
33.9 C-2' 117.2 C-2 
37.6 C-9 157.5 C-3 
42.3 C-12 167.0 C-1 
42.7 C-4 176.0 C-1 
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putative P450 monooxygenase. P450s commonly catalyse reactions involving oxygen 
transfer, which are typical in post-PKS tailoring. Cytochrome P450 monooxygenases 
are often found in PKS gene clusters and there are many cases of their inactivation 
leading to a structure related to the native antibiotic but lacking a hydroxyl or epoxide 
group. For example, the disruption of pimD, a gene encoding a P450 monooxygenase 
in the pimaricin gene cluster from Streptomyces natalensis, results in the formation of 
4,5-deepoxypimaricin. 102 In erythromycin biosynthesis inactivation of eryF leads to 
the accumulation of 6-deoxyerythromycin A 37, a derivative lacking the hydroxyl group 
at C-6 (Scheme 1.12). 41 Some atypical reactions performed by P450s have been 
reported, however, including reductions, dehydrations, dehydrogenations and 
isomerisations. 103 
Another common feature of P450s is that they function as a part of a 
multicomponent system, requiring electron transport proteins to shuttle electrons from 
reactions NAD(P)H. Such a role could be provided by MupV, which is predicted to 
possess NADPH-dependent reductase activity. '0' MupU is a putative acyl-CoA ligase, 
the obvious role for which would be activation of an intermediate, prior to the action of 
MupO and MupV, via an acyl adenylate and independently of CoA. This reaction is 
similar in rapamycin initiation, occurring at the loading domain of RAPS 1.104 Recent 
data has demonstrated that the targeted gene disruption of ACP 16 also results in the 
accumulation of an intermediate with the same HPLC profile as PA-B. '°' It can be 
proposed, therefore, that the biosynthetic step being affected by these mutations is 
initiated by MupU loading ACP 16 with an intermediate, which is then modified by 
MupO supported by MupV (Scheme 2.15). 101 
Where in the biosynthetic scheme might this ACP 16-MupU-O-V complex 
work? According to the predicted mupirocin biosynthetic pathway, PA-A would result 
from epoxidation of PA-C 42. PA-B would then originate from a simple hydroxylation 
of PA-A at C-8, a commonly observed process in secondary metabolism. However, the 
accumulation of PA-B at the cost of PA-A production in the mutants reported here 
indicated that PA-B cannot be derived as previously proposed. Indeed, radio-labelling 
studies conducted by Mantle et al. were also inconsistent with the model that PA-B 
arises from the oxidation of PA-A. 1° While it is possible that PA-A maybe derived by 
direct deoxygenation of PA-B this efficient switching from PA-A to PA-B production 
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can perhaps be best explained by diversion of intermediate flux at a key branch point 
























ACP16-MupU-O-V Me OH Me 0 
Me 
OH 69 
HO OR Me 
HO / OR 
Me 
Me OH Me O Me OH Me O 
Me 
OH 70 OH 71 
MupW MupW? 
HO OR Me 
HO OR 
Me 
Me H Me O 






PA-A TMA Me 
40 47 Me /o Me o 
OH OH 73 
R= 9-HN or 8= HO 
+l 1 TMG PA-B 
53 41 
Scheme 2.15 Proposed scheme to explain a branch point in the biosynthetic pathway. In branch one the 
MupO-U-V-ACP16 complex catalyses the reduction of the C8-C9 alkene bond so that the 
subsequent action of MupW produces a hydroxyl at C-16 which then cyclises to produce 
the pyran ring. In the absence of the reduction step isomerisation leads to a C8-C16 
alkene bond that produces an epoxide ring with the action of MupW, leading to the PA-B 
structure. 1 01 
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The polyketide precursor 69 predicted from the domain structure of mupirocin 
PKS retains an olefinic double bond between C-8 and 9. This must be reduced to attain 
the correct overall oxidation level of PA-A. In a fully processive pathway, this 
reduction would be predicted to occur via an enoyl reductase (ER) catalysed reduction 
at the tetraketide stage 66 but the appropriate condensation module 3 lacks an ER 
domain. 81 The reduction must therefore be carried out by a reductase outside the PKS 
and a number of candidate genes can be identified in the mup cluster, e. g. mupC and 
mupV. '01 The timing of this essential reduction step is, however, not apparent. It is 
relevant to this that the lovastatin nonaketide synthase encoded by lovA lacks a 
functioning ER domain and this activity is supplied by a separate gene, lovC. lol 
Expression of lovA in the absence of lovC results in accumulation of non-reduced shunt 
products. 
Thus, it can be suggested that the putative MupU-O-V-ACP 16 complex is 
involved in the key reduction step and so controls the flux of intermediate down this 
channel. '°' Although there are a number of possibilities, the timing of its intervention 
would likely be at the end of PKS assembly, or conceivably after addition of 9- 
hydroxynonanoic acid (9-HN). Subsequent post-PKS tailoring step including MupW- 
initiated cyclisation (Scheme 2.14) would lead to PA-A. Disruption of the full 
functionality of this complex by any of the reported mutations would lead to PA-B. At 
this stage it is only possible to speculate on the mechanism and the genes involved, but 
an interesting possible mechanism would be isomerisation of the 8,9-olefin 69 to give 
the 8,16-isomer 71. Subsequent epoxidation, to 72, perhaps also catalysed by MupW, 
would allow an alternative mechanism of tetrahydropyran ring closure, which would 
form the tetrahydropyran ring and introduce the 8-hydroxyl in one step as shown. The 
resulting intermediate 73 would require efficient conversion by the remaining tailoring 
enzymes to produce PA-B 41 in comparable yields to those of PA-A observed in the 
WT strain. A much-reduced flux of intermediate 69 through this channel would 
produce the small amounts of PA-B observed in WT and would be consistent with this 
mechanism. ' 01 The formation of TMG 53, which lacks extra 4- and 6-hydroxyl groups, 
could be circumstantial evidence for the timing of the cyclisation. Presumably in this 
case, intermediate 73, or TMG itself, is a less suitable substrate for the tailoring 
enzymes in Altermonas rava than its counterpart in P. fluorescens. 
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2.2.5.3 Isolation of compounds produced by P. fluorescens NCIMB 10586 mupX 
mutant 
The mupX gene encodes a putative amidase or hydratase enzyme. The exact 
involvement of this gene in the biosynthetic pathway was not clear. Since this gene was 
located near the end of cluster, it might not be directly involved and so might not affect 
the pathway. 
HPLC analysis of an aliquot from the combined supernatant (one litre) from 
mupX mutant fermentation showed identical signals to WT (Fig. 2.27 (a)). Significant 
peaks were detected at RT 22.1 and 21.2 minutes, which corresponded to PA-A and PA- 
B respectively. Also the LC-MS trace showed peaks with molecular ions (m/z) 501 and 
517. By HPLC comparison, the production of PA-A by the mupX mutant was 70% of 
WT. Thus, the predicted production of PA-A was about 49 mg 1-1. The crude extract 
from one litre of SSM was separated and a major fraction at time 19.5-20.5 minutes and 
two minor fractions at time 17-17.5 and 16.5-16.9 minutes (Fig. 2.27 (b)) were 
collected and characterised. The 1H NMR spectrum of the purified fraction, 9 mg, 
showed the signals corresponding to the structure of PA-A. The 1H NMR spectra of 
fraction 2 and 3 were identical to the spectra of fraction 2 and 3 from the WT culture. 
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Figure 2.27 HPLC analysis of compound by P. fluorescns NCIMB 10586 mupX mutant in SSM. (a) 
HPLC trace of aliquot of combined supernatant using linear gradient and (b) HPLC trace 
of crude extract using separation method. 
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2.2.5.4 Isolation of compounds produced by P. fluorescens NCIMB 10586 mupT 
mutant 
The mupT gene encodes a putative ferredoxin dioxygenase that was proposed to be 
involved in oxidation reactions to form functionality such as epoxide ring, hydroxyl 
group and tetrahydropyran ring. It is possible that this protein catalyses the same 
reaction as the mupW or mupO gene product. 
HPLC analysis of an aliquot from combined supernatant (two litres) showed a 
small peak near PA-A peak at RT 22.4 minutes (Fig. 2.28), which was similar to that 
found in mupW mutant fermentation. The peak area was 13% of WT. But LC-MS 
analysis of the crude extract showed no significant peaks. However, the crude extract 
was purified by HPLC as usual, and the corresponding fraction was collected. Due to 
the small amount present, the first purification was failed. Therefore, the experiments 
were repeated. It was found that the strain had not grown well in the second and the 







Retention time (minutes) 
Figure 2.28 HPLC analysis of aliquot from P. fluorescens NCIMB 10586 mupT mutant fermentation. 
Clearly further work on this mutant is required. It is likely that the product 
should be mupirocin W if as expected the products of the mupW and mupT genes are 
both involved in the tetrahydropyran ring formation. 
2.2.5.5 Isolation of compounds produced by P. fluorescens NCIMB 10586 MT1 
mutant 
MT 1 is a domain in module 1 of mmpD gene corresponding to a methyl transferase. In 
Type I modular PKSs, methyltransferase is considered as a part of the PKS. This 
enzyme usually has SAM as cofactor. In mupirocin biosynthesis, MT1 was proposed to 
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introduce methyl group at C-12 of PA-A. Thus in the absence of this domain, C-12 
should be changed to methylene group (-CH2-) instead of having a methyl substitutent 






HPLC analyses of either aliquot from culture broth or crude extract showed 
small peaks that were different from WT such as the peak at RT 18.7 minutes (Fig. 
2.29). We tried to purify this peak but were unsuccessful. In addition, we found that 
the peak disappeared when the experiment was repeated. It was thought that the 
preparation of this mutant might be not good. Thus, the construction of this mutant was 
performed again in Birmingham. Unfortunately, such a peak was not detected from the 
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Figure 2.29 HPLC analysis of aliquot from P. fluorescens NCIMB 10586 MTImutant fermentation. 
2.2.5.6 Isolation of compounds produced by P. fluorescens NCIMB 10586 mupS, 
mupQ and mupQ: U mutants 
The proposed functions of mupS and mupQ genes are rather different. The mupS gene 
encodes a 3-oxoacyl-ACP-reductase, which is usually found in fatty acid biosynthesis, 
and catalyses the reduction of a keto to a hydroxyl group. The mupQ gene encodes a 
similar protein as the mupU gene, an acyl-CoA-synthase. Thus both of these genes 
(mupQ and mup(j) were simultaneous deleted from the cluster to see how they effected 
the pathway. They might catalyse either the same or different steps in the pathway. 
From HPLC analysis, these mutants did show some peaks differing from WT but none 
of them could be isolated in sufficient quantity to allow further characterisation. 
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2.2.6 Production of pseudomonic acid A and B and other metabolites by 
P. fluorescens NCIMB 10586 wild type and derived mutants 
The production of PA-A and PA-B by mup mutants were monitored by HPLC 
comparison with the production in WT from fermentation broths (Table 2.9) and from 
isolation (Table 2.10). The compounds, isolated from some mutants were the same as in 
WT but the quantities were different. By peak area comparison, the production of PA-B 
by mupO, U and V mutants were five, eight and fifteen fold higher than that found in 
WT respectively. On the other hand the production of PA-A by mupX mutant was 30% 
smaller than in WT. The amount of PA-A or PA-B from isolation by WT and some 
Table 2.9 Comparison of production of compounds from HPLC prediction by P. fluorescens 
NCIMB 10586 mup mutants. 
m up mutants mg 1. 
PA-A PA-Ba Other 
metabolites 
wild type 70.0 3.5 - 
0 - 17.5 - 
U - 28.0 - 
V - 52.0 
W - - 12.5 
X 49.0 2.0 - 
x Prediction by comparison of peak area with PA-A of wild type. 
Table 2.10 Comparison of production of compounds from isolation by P. fluorescens NCIMB 
10586 mup mutants. 
mup mutants mg 1"1 
PA-A PA-B Other 
metabolite 
wild type 20.0 - - 
0 - 4.0 - 
U - 6.0 - 
V - 10.0 
W - - 2.5 
X 9.0 - - 
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mutants is less than prediction by HPLC from culture broths. This might be due to the 
extraction and purification steps. During extraction, the formation of emulsions 
occurred. Therefore, it took a long time to complete extraction, and the compounds 
could be lost. Also the changing of pH in sample solutions during these steps might 
make some of the compounds rearrange or decompose. 
2.3 Conclusions and further work 
In conclusion, studies of mup mutant productions were carried out. The optimal 
conditions and the proper medium for pseudomonic acid production were determined. 
The compounds produced by the mup mutants were isolated and purified by HPLC. 
The major compound produced by mupO, mupU and mupV mutants showed the same 
retention time on HPLC, and 1H NMR confirmed that it was PA-B, normally a minor 
product in the pseudomonic acid fermentation. On the other hand, the compound, 
isolated from the mupX mutant fermentation was PA-A whilst no significant compound 
was isolated from mupQ, mupS, mupT, mupQ: U and mmpD (MT1) mutant 
fermentations. An interesting new metabolite was isolated from mupW mutant. This 
had two units mass higher than PA-A. In addition 1H NMR confirmed that this 
metabolite contained one more hydroxyl and one more methyl group but no epoxide and 
tetrahydropyran ring. Therefore, the mup W gene product, a dioxygenase, was proposed 
to be involved in an oxidation necessary for formation of the tetrahydropyran ring. 
These results led to some information on involvement of the genes in the pathway even 
if some of them were unclear. However, the isolation of compounds from other mutants 
need to be repeated, e. g. mupT, mupQ: U and mmpD (MT 1) mutants. These mutants 
have shown some significant peaks but sometimes the strains did not grow well so that 
the interesting peaks disappeared. Therefore, we may need to reconstruct these mutants. 
Also more sensitive instruments may be needed to detect the small peaks, which might 
be interesting compounds. Moreover, further gene mutations must be carried out in 
order to gain more information, which will lead to a further understanding of the 
mupirocin biosynthetic pathway. 
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Chapter 3 Mupirocin Biosynthetic Protein Studies 
3.1 Introduction 
In recent years genetic techniques have become a more useful tool for the investigation 
of biosynthetic pathways. Though gene disruptions often result in new intermediates 
accumulating, due to the altered metabolic processes, in some cases there are no 
obvious explanations as to how these products are synthesised. To understand these 
occurrences more clearly, a more direct method is to investigate the enzymes which 
catalyse each step. Consequently, the target proteins need to be isolated, purified, tested 
in in vitro reactions and structurally characterised. Such results would give informative 
explanations of how the substrates bind with the enzymes and insights into how the 
reactions are taking place. 
For mupirocin protein studies, the biosynthetic gene cluster contains some 
individual genes that are proposed to be essential for post-PKS modification to produce 
bioactive mupirocin (pseudomonic acid A). Some of these proteins were proposed to be 
involved in oxidative reactions to introduce the 6-hydroxyl, the epoxide and the 
tetrahydropyran ring. These reactions may be catalysed by an individual enzyme or by 
a combination of enzymes. Thus those enzymes, for example, dioxygenases, 
cytochrome P450s and oxidoreductases, which catalyse oxidation-reduction reactions, 
are of particular interest. In this chapter, protein studies are described that concentrate 
on two enzymes, MupT a ferredoxin dioxygenase and MupW a dioxygenase, which is 
predicted to be involved in the oxidation to form the tetrahydropyran ring (Scheme 
2.14). The objective of these studies is to isolate and purify enough of the target 
proteins for elucidation of their structures by either NMR or X-ray crystallography and 
for in vitro studies on their properties to be attempted. 
3.1.1 Function and structure of dioxygenases 
As discussed in chapter 2 (2.1.6.4), dioxygenases are non-heme and iron containing, 
which are known to be enzymes that are involved in the ring hydroxylation or ring 
cleavage of aromatic compounds. These enzymes catalyse reactions by addition of two 
atoms of oxygen to a substrate. For ring hydroxylation, the reaction requires the 
presence of cofactors such as NADH and NADPH, and a metal cofactor, usually iron 
(II) or iron (III). The catalytic reaction takes place when an electron is transferred from 
the cofactor (NADH or NADPH) to the terminal site of the dioxygenase by an electron 
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transfer chain, which contains flavin adenine dinucleotide (FAD) or flavin 
mononucleotide (FMN) and a [2Fe-2S] redox centre on either the same or a different 
protein (Scheme 2.10). In addition, the oxygen molecule and mononuclear iron are 
needed to be present in the terminal dioxygenase. To function, therefore, these 
dioxygenases consist of two or three proteins linked together as a multicomponent 
system. 96 For example, the benzoate-1,2-dioxygenase, isolated from Acinetobacter 
calcoaceticus, involved in the conversion of benzoate 75 to cis-2-hydro-1,2- 
dihydroxybenzoate (DHB) 76 is composed of two components; a terminal dioxygenase 
component, a hydroxylase encoded by the benAB gene, and an electron transfer 
component encoded by the benC gene, which contains a flavin, FAD and a [2Fe-2S] 
centre (Fig. 3.1). 1°5 
Benzoate 75 
COOH 
NADH +H+ hydroxylas 
Oc 








Figure 3.1 Ring hydroxylation of benzoate to cis-2-hydro-1,2-dihydroxy benzoate by benzoate-1,2- 
dioxygenase. 105 
Conversely, dioxygenases that are involved in ring cleavage require the presence 
of iron (Fe) and oxygen but do not require NADH or NADPH. The best example of this 
type of dioxygenase is a catechol dioxygenase isolated from Pseudomonas putida 
mt2.106 The oxidative ring cleavage of catechol 77 can occur in two ways; intradiol (or 
ortho) cleavage, which utilises mononuclear iron in the ferric state (Fe 3), to produce a 
muconic acid 78, and extradiol (or meta) cleavage, which utilises mononuclear iron in 
the ferrous state (Fe2+), to produce a hydroxymuconaldehydic acid derivative 79 
(Scheme 3.1). 107,108 A second example is the dioxygenase from Amanita muscaria, 
which catalyses the ring cleavage of 3,4-dihydroxyphenylalanine 80 at C-2 and C-3 to 
produce an acid-aldehyde derivative intermediate that forms stizolobinic acid 81 and 
muscaflavine 82 by alternative molecular ring closures (Scheme 3.2). 109 
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Scheme 3.1 Catechol ring cleavage catalyses by catechol dioxygenase (Adapted from Bugg and 
Winfield107). 
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Scheme 3.2 Oxidative ring cleavage of 3,4-dihydroxyphenylalanine. 
In addition, some dioxygenase enzymes are reported to function as 
monooxygenase enzymes by insertion of only one oxygen atom into their substrates. 
For instance, toluene dioxygenase from Pseudomonas putida which normally catalyses 
the dihydroxylation of aromatic compounds or non-aromatic indene to cis-dihydrodiol 
intermediates is found to catalyse the monooxygenation of indene 83 and indan 84 to 1- 






3.1.2 Dioxygenases in polyketide biosynthesis 
OH 
1-indanol 85 
Dioxygenases which are involved in post-polyketide modification in polyketide 
biosynthesis usually catalyse oxidative hydroxylation to form the dihydroxy 
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intermediates of the carbon skeleton. For example, the mtmOII gene from Streptomyces 
argillaceus encodes for a dioxygenase which is involved in the biosynthesis of 
mithramycin, was reported to be responsible for the addition of two hydroxyls at C-4 
and C 12a of 4-demethyl-premithramycinone 86 prior to its conversion to 
premithramycinone 87 (Scheme 3.3). 111 This enzyme shows homology to FAD and 
NADPH-dependent hydroxylases. 
OH 
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OH OH O00 87 
Scheme 3.3 Oxidative ring hydroxylation to form 4-demethyl-premithramycinone by MtmOII encoding 
dioxygenase (Adapted from Rix et al. ") 
TcmG from Streptomyces glaucescens, which is involved in tetracenomycin C 
88 biosynthesis, was suggested to encode a mixed monooxygenase-dioxygenase 
activity. '" TcmG catalyses the hydroxylation at C-4, C-4a and C-12a of 
tetracenomycin A2 89 to produce tetracenomycin C in the last step of the biosynthetic 
pathway. These three hydroxyl groups are suggested to be provided from an oxygen 
molecule and water (Scheme 3.4). This enzyme, which requires FAD and either NADH 
or NADPH as cofactors, has a molecular weight 60 kDa and appears to be monomeric 







Tetracenomycin C 88 
Scheme 3.4 Ring hydroxylation of tetracenomycin A2 to form tetracenomycin C by TcmG encoding a 
mixed monooxygenase-dioxygenase. 
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In addition to ring hydroxylation, some polyketide metabolites are formed via 
aromatic ring cleavages, which are catalysed by dioxygenases. '°7" 107,112 A dioxygenase 
from Penicillium patulum is an example of an oxidative cleavage enzyme. It is involved 
in the formation of a quinone epoxide phyllostine 90 from gentisyl alcohol 91 in patulin 
92 biosynthesis (Scheme 3.5). ' 12 Two oxygen atoms are introduced to the gentisyl 
alcohol to form an intermediate containing hydroperoxide, which undergoes 



















Scheme 3.5 Biosynthesis of patulin through the oxidative ring cleavage of gentisyl alcohol. 
A small group of new dioxygenase enzymes has been reported. ' 11,113 These 
enzymes catalyse the insertion of two oxygen atoms into their substrates but neither a 
metal ion nor cofactor NAD(P)H are needed. DpgC which is involved in the 
vancomycin biosynthetic pathway has recently been shown to be a member of this 
group. It has been proposed that this enzyme is responsible for the conversion of 3,5- 
dihydroxyphenylacetyl-CoA (DPA-CoA) 93 to 3,5-dihydroxyphenyl-glyoxylate 
(DPGx) 94 (Scheme 3.6) by undergoing oxygenation to form a carbanionic and/or 





DPA-CoA 93 DPGx 94 
Scheme 3.6 Conversion of DPA-CoA to DPGx by oxygenation of DpgC. 13 
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3.1.3 Predicted function and structure of MupT 
MupT, the mupT gene product, consists of 116 amino acids and is suggested to encode a 
ferredoxin dioxygenase. Sequence comparison indicated that this protein is similar to 
NdoA from Pseudomonas putida, 81 which forms the ferredoxin component of a 
naphthalene 1,2-dioxygenase system. Naphthalene 1,2-dioxygenase is a 
multicomponent dioxygenase which catalyses the oxidation of naphthalene to cis- 
(1R, 2S)-dihydroxy-1,2-dihydronaphthalene. 93 This enzyme consists of three 
components; a reductase site containing FAD and [2Fe-2S] centre encoded by the ndoR 
gene, a ferredoxin for electron transfer to the terminal dioxygenase encoded by the ndoA 
gene and terminal iron-sulphur protein (ISP) encoded by the ndoBC gene (Fig. 3.2). 93 
OH 
OH 
NADH +H ReductaseNAP FerredoxinNAP ISP NAP 
(oxidised) (reduced) (oxidised) 
ndoR ndoA ndoBC 
02 
NAD+ ReductaseNAP FerredoxinNAP ISPNAP NAP 
(reduced) (oxidised) (reduced) 
Figure 3.2 Proposed electron transfer of naphthalene dioxygenase (Adapted from Haigler and Gibson 93) 
FerredoxinNAP contains an iron-sulphur [2Fe-2S] cluster, which resembles a 
Rieske-type ferredoxin, 93 and is similar to ferredoxinTOL of toluene dioxygenase from 
Pseudomonas putida F 1,114 and ferredoxinBED of benzene dioxygenase from 
Pseudomonas putida ML2.1 15 Although they are similar to ferredoxinN, e, P, they cannot 
be substituted for one another. In addition, all purified ferredoxins have no activities by 
themselves requiring a reductase component for function. 
Ferredoxins are a group of iron-sulphur proteins, which function as electron 
transfer agents in many metabolic reactions. The ferredoxins of dioxygenase systems 
involved in ring hydroxylation are small acidic proteins having molecular weights in the 
12-15 kDa range. 96 Two types of [2Fe-2S] clusters contained in these ferredoxins are 
usually observed. One is assigned to the class of Rieske-type iron-sulphur proteins in 
which the iron atoms are linked to the proteins via two histidine nitrogens and two 
cysteine sulphurs (Fig. 3.3 (a)). In the oxidised form, both iron atoms are in the Fe (III) 
form. Most ferredoxins are found to be Rieske type. Other [2Fe-2S] clusters are found 
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in plant-type ferredoxins in which the iron atoms are ligated with four cysteine residues 
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Figure 3.3 The structure of [2Fe-2S] cluster ferredoxins in oxidised and reduced forms; (a), Rieske- 
type ferredoxin; (b), plant-type ferredoxin. ' 
3.1.4 Predicted function and structure of MupW 
MupW, a 463 amino acid protein, is proposed to have dioxygenase activity. Sequence 
alignment has shown that this protein shares high similarity to the bnzA gene from P. 
putida, which encodes for the benzene 1,2-dioxygenase a subunit, part of a terminal 
dioxygenase component of benzene 1,2-dioxygenase. "7 The terminal dioxygenase, 
which is the catalytic component of this enzyme, consists of large a subunit encoding 
BnzA and smaller ß subunit encoding BnzB in the a2ß2 configuration. The a subunit 
has a molecular weight of 54,500 Da and also contains a Rieske-type [2Fe-2S] cluster 
per a monomer and an iron binding site. l l7 
3.1.5 Previous overexpression of MupT and MupW studies 
In order to understand how the component domains function or associate in the 
pathway, some of the individual mupirocin gene (mup gene) products have been 
studied. S. Cooper (2003) cloned some mup genes including mupT and mupW into 
pET28a expression vectors (Fig. 3.4). 99 These two recombinant plasmids were named 
Cys-S\ 
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pETmupT and pETmupW. The overexpression of these strains was studied and it was 
reported that most of the protein expressed by pETmupT and pETmupW was insoluble. 
High levels of expression of MupT were obtained at 25°C whereas high MupW 
production was observed at 25°C, 30°C and 37°C. In addition, a small soluble fraction 















Figure 3.4 Construction of mupT and mupW genes into pET28a expression vectors at EcoRI and Sad 
sites. 9 
As mentioned earlier, the aims of work described in this chapter are to isolate 
The calculated molecular weight of MupT was less than 25,000 Da, therefore this 
protein could be characterised by NMR spectroscopy while the larger MupW would be 
characterised by X-ray crystallography. Thus the mupT gene would be cloned into an 
expression vector. The pET 15b system was selected for this purpose as this is known to 
give soluble protein. ' 18'119 This vector contains aN -terminal his6-tag, for purification 
by affinity chromatography, and a T7/lac promoter for induction by isopropyl-ß-D- 
thiogalactoside (IPTG), which makes the expression easily controlled. "8 Also this 
vector had been used successfully for production of S. coelicolor KR in our laboratory 
and soluble protein was obtained. 119 It might also be useful as pET 15b does not have 
the additional sequences which could cause problems later. In addition, the his6-tag 
could be cleaved using the protease thrombin after affinity chromatography. 
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3.2 Results and Discussion 
3.2.1 Construction and overexpression of mupT gene in pET-15b vector 
The mupT gene, which was synthesised by PCR using primers containing Mel and 
BamHI sites, yielded a DNA fragment of 351 bp (Fig. 3.5). The fragment, containing 
the 3'-deoxyadenosine (A) end, was ligated into pGEM°-T Easy vector (Fig. 3.6 a). 
The ligation product, named pGEMmupT, was transformed into E. coli TAM I 
competent cells for plasmid maintenance and propagation. Following plasmid 
purification the pGEMmupT plasmid was digested with Mel and BamHI. The 371 bp 
fragment was extracted from the agarose gel, repurified and religated into pET 15b (Fig. 
3.6 b), which was pre-digested with the same restriction enzymes. This construct was 
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Figure 3.6 Maps of mupT construction. (a) in pGEM®-T Easy vector and (b) in pET15b vector. 
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The mupT gene from E. coli TAM 1 containing pET 15bmupT was confirmed by 
PCR. The amplified product showed a band corresponding to the approximate mupT 
size on an agarose gel (Fig. 3.7). DNA from pGEMmupT and pET l 5bmupT were also 
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Figure 3.7 Gel electrophoresis of PCR product of the mupT gene cloned into pET15b vector. 
Lane B, DNA marker with size in kb. 
3.2.2 Small-scale overexpression of MupT from pET 15bmupT 
Small-scale overexpression of pET 15bmupT was carried out in E. coli BL21(DE3) 
grown in LB media containing carbenicillin at 37°C. At an OD600 0.6 the bacteria 
were induced with 1.0 mm IPTG and grown for a further 2 or 4 hours at 25°C or 37°C. 
The cultures were harvested by centrifugation and the cells were resuspended in Tris 
buffer (20 mM Tris-HCI pH 8.0 with 10% glycerol) or phosphate buffer (20 mM pH 7.5 
with 10% glycerol), and then sonicated. Soluble and insoluble fractions were analysed 
by SDS-PAGE. The estimated molecular weight of MupT including the his6-tag in this 
system is expected to be 15,077 Da. No strong band could be clearly identified 
corresponding to the expected molecular weight of MupT from induction samples at 
either 25°C or 37°C in Tris buffer (Fig. 3.8). Similar results were also observed from 
the sample resuspended in phosphate buffer. 
85 
Chapter 3 Alupirocin Biosynthetic Protein Studies 
25°C 37°C 
+ IPTG - IPTG + IPTG - It 







Figure 3.8 SDS polyacrylamide gel of the overexpression of E. coil BL21(DE3) containing pET 15b- 
mupT, uninduced (-) and induced with IPTG (+) at 25°C and 37°C. Lane A and N, 
molecular mass with size in kDa; lane D, E, J and K, induced by IPTG for 2 hours; lane F, G, 
L and M, induced by IPTG for 4 hours. 
sot = soluble fraction, ins = insoluble fraction 
3.2.3 Large-scale overexpression and purification of MupT from pET 15bmupT 
As low levels of expression may be difficult to observe, the expression of MupT was 
scaled up and the protein purified. Since the expressed proteins carried an N- terminal 
his6-tag, the proteins were directly purified by nickel affinity chromatography. This 
purification method uses metal ion (Ni2+) bound to resin. Ni2+ resin binds to the his6-tag 
attached to the target protein (Fig. 3.9). 120 The protein is eluted from the resin by 
increasing the concentration of imidazole in the buffer. As the imidazole binds strongly 
to Ni2+ resin, the target protein is displaced from the binding site. This experiment was 
carried out because if a small amount of MupT were produced, this would be bound to 













Figure 3.9 Nickel affinity chromatography; (a). His6-tag binds to nickel ion on resin; (b), conformation 
around nickel ion. 
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Thus, the cultures were grown at 37°C in 100 ml LB media containing 
carbenicillin until an OD600 - 0.6 was reached and then were induced with IPTG at a 
final concentration 1 mM. The bacteria were grown for a further 4 hours at 25°C. The 
cells were harvested by centrifugation and resuspended in Tris-buffer (20 mm pH 8.0 
with 10% glycerol). The resuspended solution was sonicated and centrifuged again. 
The supernatant (soluble fraction) was transferred to a new tube while the insoluble 
fraction was resuspended in binding buffer (20 mm Tris-HC1,50 mm NaCl, 5 mm 
imidazole, pH 7.9). Both fractions were further purified by affinity chromatography. 
The soluble fraction was filtered and loaded onto the column. The fusion 
protein bound to the Ni2+ resin was eluted from the column using an elution buffer (20 
mm Tris-HC1,50 mm NaCl, pH 7.9) containing 1M imidazole. Twenty fractions (1 ml/ 
tube) were collected at a flow rate 1 ml min -I and analysed by SDS-PAGE. However, 
the expression of MupT from pET 15bmupT was unsuccessful. No bands around 15 
kDa were seen from elution fractions on SDS gel (Fig. 3.10). 
14- 
6.5- 
Figure 3.10 SDS polyacrylamide gel of nickel affinity chromatography of E. coli BL21(DE3) 
containing pET15b mupT. Lane B, molecular mass marker with size in kDa; lane A, 
fraction collected during loading wash buffer; lane C-L, fractions collected during loading 
elution buffer. 
The insoluble fraction could be purified by nickel affinity chromatography under 
denaturing conditions by adding denaturants such as urea, guanidinium hydrochloride or 
sodium dodecyl sulphate to the buffer. Among these denaturants, 6-8 M urea and 6M 
guanidinium hydrochloride are frequently used. 121,122 Therefore, 6M urea was added 
into all buffers used for purification. After harvesting, cells were resuspended in 
binding buffer containing 6M urea and sonicated. The supernatant was separated by 
centrifugation and loaded onto the Ni2+ column. Fractions were collected and analysed 
by SDS-PAGE. Similar results were also observed from the purification of the 
insoluble fraction. No bands corresponding to MupT were seen on gel. These indicated 
that no MupT was expressed from pET 15bmupT. 
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To solve the problem of poor expression, other factors that influence 
heterologous overexpression in E. coli such as induction temperature, IPTG 
concentration and expression host strain were changed. A number of research groups 
have achieved greater expression using lower concentrations of IPTG (0.05-0.20 
wM), '22. '24 whereas other approaches have been used with the media supplemented with 
substances such as glucose, maltose, and alanine. 125,126 The E. coli BL21(DE3) 
containing pETmupT was grown and induced with 0.05,0.10,0.25 and 0.50 mm IPTG 
at 25°C, 30°C and 37°C for 4 or 6 hours. At the same time, expression was also 
induced in the presence and absence of glucose. The addition of 1% glucose to the 
expression media was suggested to prevent the occurrence of leaky expression. This 
phenomenon has been reported with the pET vectors, and could be reduced by 
decreasing cyclic AMP concentration, essential for the transcription from lacUV5 
promoter of E. coli and the T7 RNA polymerase in the vector. 127,128 Even with these 
experimental changes, no strong bands corresponding to MupT were seen by SDS- 
PAGE. 
Host strain for expression was another factor which was considered. Although 
E. coli BL21(DE3) is commonly used for production of target protein from the pET 
expression system, it might be less suitable for this expression. Thus another expression 
host strain was used to see whether it effected the expression. A new host strain, E. coli 
Rosetta(DE3) was used. This strain has been designed to enhance expression in the 
case of target proteins containing rare codon usages; AGG, AGA, ATA, CTA, GGA 
and CCC by providing the rare codon tRNAs. 118 The pET l5bmupT was transformed 
into E. coli Rosetta(DE3) and grown in LB media containing chloramphenicol and 
carbenicillin. Protein expression was by induction with varied concentrations of IPTG 
and induction temperatures as above. However, no bands obviously corresponding to 
MupT were seen on SDS gel. 
Due to the total lack of MupT expression from the pET 15bmupT construct, the 
original pET28a construct had to be utilised. This system had previously been shown 
to be successful for both mupT and mupW expression, albeit in an insoluble form. Like 
the pET 15b system, this expression vector also contains an N-terminal his6-tag, a T7/lac 
promoter, and thrombin cleavage site. In addition, it contains a C-terminal his6-tag, and 
T7-tag. T7-tag is a short polypeptide (11 amino acids) fused to the target protein of 
interest, which is useful for purification by antibody affinity chromatography. The 
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plasmid pETmupT and pETmupW, which were used in these studies, were supplied by 
Professor C. M. Thomas, Department of Bioscience, University of Birmingham, UK. 
3.2.4 Optimisation of conditions for overexpression of MupT and MupW 
In order to isolate and purify the proteins for structural elucidation, the overexpression 
of MupT and MupW was repeated. Some conditions were improved in order to obtain 
higher soluble protein production. As mentioned earlier, many factors have been 
reported to influence heterologous expression in E. coli. For instance, growth 
conditions/media, induction temperature, concentration of inducer, and host strain all 
affect the production of soluble protein. 122-124°129 In recent years, some applications 
have shown high heterologous expressions in E. coli when the inductions were achieved 
at temperatures lower than 37°C, such as 15°-30°C. Studies of kinetic competition 
between folding and aggregation indicate that the relative yield of native protein is 
inversely proportional to the rate of protein synthesis. 123,130 Therefore, aggregate is 
formed when E. coli is grown at 37°C whereas at lower cultivation temperatures, a 
higher amount of native forms were observed due to decreasing the rate of protein 
synthesis. For example, some proteins were found to be insoluble when produced from 
cultures grow at 37°C, while for cultures grown at temperatures lower than 30°C, most 
proteins were active and soluble. 123 In addition, lysis buffers have been found to affect 
the production of soluble or insoluble fractions. Some salts or glycerol contained in the 
buffer can also make the proteins more soluble and stable. 130,132 These substances can 
help prevent aggregation. 
The expression of MupT and MupW were studied at lower temperatures than 
previously used, while different buffers were also used to resuspend cells. Plasmids 
pETmupT and pETmup W were transformed into E. coli BL21(DE3), and were grown 
and induced with 1 mm IPTG at 15°C, 25°C and 37°C for four hours. The cells were 
harvested and resuspended in three different buffers; Tris buffer (20 mm pH 8.0 with 
10% glycerol), phosphate buffer (100 mm pH 7.5 with 10% glycerol) and E. coli buffer 
(50 mm Tris-HCI pH 8.0,1 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl 
fluoride and 10% glycerol) prior to lysis by sonication. Both MupT and MupW were 
expressed as the fusion (his6-tag) form. The soluble and insoluble fractions were 
analysed by SDS-PAGE. 
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The calculated molecular weight of MupT including the his6-tag and T7-tag is 
16,492 Da. The bands corresponding to MupT, which were detected on the 
polyacrylamide gel, were found in the fractions that were induced with IPTG but were 
not detected from uninduced fractions. The expression of pETmupT yielded mainly 
insoluble protein though some soluble protein could be detected. Higher protein 
production was observed at 25°C as had been shown previously. 99 In addition, the 
amount of soluble protein was slightly enhanced when the cells were resuspended in 
Tris buffer (lane H, at dark arrow) or phosphate buffer (lane I, at dark arrow) (Fig. 
3.11). 
- IPTG + IPTG 








Figure 3.11 SDS polyacrylamide gel of the overexpression of BL21 (DE3) containing pETmupT, 
uninduced (-) and induced with IPTG (+) at 25°C. Lane A, molecular mass maker with the 
size in kDa; lane B, E, H and K, in Tris buffer; lane C, F, I and L, in phosphate buffer, lane 
D, G, J and M, in E. col i buffer. 
The calculated molecular weight of MupW protein including the his6-tag and 
T7-tag is 57,000 Da. The bands, which were detected on the polyacrylamide gel (Fig. 
3.12), showed the approximate size corresponding to MupW. The correct protein was 
only observed in the insoluble fraction. High expression levels were observed at 25° 
and 37°C with IPTG induction. However, no soluble fraction was detected when the 
cells were resuspended in any buffer. 
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Figure 3.12 SDS polyacrylamide gel of the overexpression of BL21 (DE3) containing pETmupW 
induced with IPTG (+) and uninduced (-) at 15°C, 25°C and 37°C; lane A, molecular mass 
marker with the size in kDa. 
sol = soluble fraction, ins = insoluble fraction 
3.2.5 Overexpression and purification of MupT from pETmupT 
For purification, the expression of MupT was scaled up. E. coli BL21(DE3) containing 
pETmupT was grown and induced with 1 mm IPTG at 25°C four 4 hours. The cells 
were harvested and resuspended in Tris buffer (20 mM pH 8.0 with 10% glycerol). 
Since the expressed protein also carried a his6-tag, the proteins were initially purified by 
nickel affinity chromatography. As a small amount of the MupT protein was observed 
as a soluble fraction, we preferred to start with the purification of this soluble protein 
rather than refolding the insoluble protein. 
The soluble fraction was filtered and loaded onto the Ni2+ column as described 
in section 3.2.3. The fusion protein bound to the Ni2+ resin was eluted from the column 
using elution buffer containing 0.25,0.50,0.75 and 1.0 M imidazole. Twenty fractions 
(1 ml/ tube) were collected at a flow rate 1 ml min-1 and analysed by SDS-PAGE (Fig. 
3.13). From the SDS PAGE bands corresponding to fusion MupT were seen at 20 kDa, 
higher than the predicted molecular weight of 16.5 kDa. This anomalous migration of 
the recombinant protein has been observed previously in the purification of Rieske-type 
ferredoxins. 124,13' Most of the MupT was eluted when using 0.25 M of imidazole. 
While collecting the fractions, a brown colour was observed in the fractions in lanes H, 
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protein were removed by desalting on FPLC using a Hiprep 26/10 desalting column 
(Pharmacia) with Tris buffer (20 mM pH 8.0 with 10% glycerol). This purification 








Figure 3.13 SDS polyacrylamide gel of nickel affinity chromatography purification of E. coli 
BL21(DE3) expressing pETmupT. Lane A, molecular mass marker with the size in kDa; 
lane B, supernatant after sonication; lane C, sediment after sonication of the same cells; 
lane D, fraction collected during loading soluble fraction into the column; lane E, fraction 
collected during loading binding buffer; lane F, fraction collected during loading washing 
buffer; lanes G-M, fractions collected during loading elution buffer at flow rate 1 ml min"'. 
In order to see whether the host strain influenced soluble protein production, 
another host strain was used. The pETmupT was transformed into E. coli Rosetta(DE3) 
and grown and induced with IPTG as described above. The soluble fraction was also 
purified by nickel affinity chromatography. The production of MupT was similar to 
that with the E. coli BL21(DE3) strain indicating that no problems existed with respect 
to the codon usage in the target protein. Therefore, either E. coli BL21(DE3) or E. coli 
Rosetta(DE3) could be used for overexpression of soluble pETmupT. 
As our purpose was to determine the structure of this protein by NMR, E. coli 
BL21(DE3) containing pETmupT was also overexpressed in 15N enriched M9 minimal 
media to produce protein suitable for NMR using the induction conditions and the 
purification method described above. SDS-PAGE analysis of eluted fractions from Ni2+ 
column was shown in Fig. 3.14. In this medium, the production of commonly his6- 
MupT decreased to 2 mg per litre of media. This decrease in protein production occurs 
as a result of changing to a medium containing fewer nutrients. 
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Figure 3.14 SDS polyacrylamide gel of nickel affinity chromatography of E. coli BL21 (DE3) 
containing pETmupT in15N M9 minimal media. Lane A, molecular mass marker with the 
size in kDa; lane B-L, fraction collected during loading elution buffer. 
Characterisation by NMR was unsuccessful. We attempted to acquire a 'H- 15 N 
HSQC (Heteronuclear single quantum correlation) to assess if the MupT had yielded a 
spectrum characteristic of a folded protein. A correctly folded protein would show a 
well dispersed 1H and 15N chemical shifts and we would expect to observe on the order 
of 120 correlation peaks (one per amino acid plus side chain amide correlations). 
However, the first 1D slice of the 'H-15N HSQC gave no observable signals and 
acquisition of the 2D spectrum, not surprisingly, did not show an HSQC characteristic 
of a well folded protein. There are two possible explanations. First, we did not have 
correctly folded protein and perhaps it aggregated in solution leading to broads, 
unobservable peaks. Secondly, we may have less amount of protein for the NMR study. 
Clearly, preparation of more 15N-labelled protein is required. 
In addition to residues from the MupT and the N -terminal his6-tag, there are also 
additional vector derived residues encoding a thrombin cleavage site and a N-terminal 
T7-tag (Fig. 3.15). These additional unneeded residues give (i) 36 extra correlation 
peaks on the NMR spectra increasing spectral complexity and (ii) the tag residues are 
likely to be unfolded giving intense, sharp peaks that reduce spectral quality. Therefore, 
we partly solved these problems by the use of thrombin cleavage to remove some amino 
acids, e. g. his6-tag. 
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Figure 3.15 Expression region containing in MupT protein. 
3.2.6 Thrombin cleavage of MupT 
Recombinant MupT expressed from the pET28a vector, pETmupT, contains extra 
amino acids from the terminal his6-tag, the thrombin cleavage site and the T7-tag (Fig 
3.15) that may be problematical for structural determination. Thrombin cleavage was 
chosen to cleave off some of these additional residues. Thrombin is specific for the 
cleavage of the sequence between arginine (Arg) and glycine (Gly) amino acids at the 
thrombin cleavage site in fusion proteins (Fig. 3.15). Therefore, the estimated 
molecular weight of MupT would be decreased from 16,492 to 14,777 Da after 
thrombin cleavage. 
Two experiments were carried out. In the first experiment, 2 µl of thrombin was 
added to 200 µl of protein solution and subsequently purified by nickel affinity 
chromatography. In the second experiment, 2 µl of thrombin was added to 200 µl of 
protein solution in thrombin cleavage buffer along with 100 µl of His-Bind resin, which 
was precharged with NiSO4 buffer. Both reactions were incubated on a shaker at 25°C. 
Every hour for 6 hours aliquots (10 µl) from both reactions were analysed by SDS- 
PAGE. In the second experiment, after thrombin cleavage, the target protein would be 
directly observed in solution whereas the his6-tag would be bound to the resin, while the 
sample from first experiment would need further purification. 
The thrombin cleavage was achieved in solution (the first experiment) rather 
than on the resin. The band detected on the SDS gel, clearly showed a reduced protein 
molecular weight, indicating that some amino acids, which should include the N- 
terminal his-tag, were removed (Fig. 3.16). No significant difference of incubation time 
at 1-6 hour was observed. In contrast, no bands were detected on the SDS gel of 
samples that were incubated with the resin. To confirm the disappearance of protein, 
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the resin was taken and analysed by SDS-PAGE. Two bands corresponding to the 
estimated molecular weight of MupT before (- 20 kDa) and after (> 14 kDa) thrombin 
cleavage were seen on SDS gel. This indicated that the cleaved proteins were still 





Figure 3.16 SDS-polyacrylamide gel of MupT. Lane A, purified protein from Ni2+ chelating column. 
Lane B, protein after thrombin cleavage at 25°C for 6 hours. Lane C, molecular mass 
marker with the size shown in kDa. 
3.2.7 Purification of MupT by ion exchange chromatography 
After thrombin cleavage, the recombinant protein was further purified by anion 
exchange chromatography on a MonoQ column (GE Healthcare). The protein was 
eluted from the column using Tris buffer (20 mm pH 8.0) with a gradient of 0-1.0 M 
NaCl. Fractions were collected and analysed by SDS-PAGE. The chromatogram and 
the SDS gel are shown in Fig. 3.17 (a) and (b) respectively. Most of the MupT protein 
was found in fraction A6 (lane C on gel), which eluted from the column at a salt 
concentration of approximately 0.25 M NaCl. After fraction A13 (lane J on gel), no 
MupT proteins were detected. Fractions A5-A7 were combined and desalted by FPLC, 
however these proteins were almost completely lost after the desalting step. These were 
due to the monitoring at 280 nm was rather low, and also no bands corresponding to 
MupT were seen on SDS gel. As the combined fractions were in small volume and 
concentration, they might be more dilute after desalting. This might indicate that 
desalting by FPLC was unsuitable in this case even if it is a fast method. However, a 
very pale band was seen on SDS gel after concentration by spin column. 
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Figure 3.17 Purification of MupT by anion exchange. a, chromatogram showed the elution of MupT 
using a gradient of Tris buffer (20 mM pH 8.0) containing 1.0 M NaCl. b, SDS polyacryla- 
mide gel of eluted fractions in which each fraction was concentrated ten times with TCA 
prior to loading onto the gel, lane A, molecular mass marker with the size in kDa. 
3.2.8 Purification of MupT by gel filtration chromatography 
As an alternative, the recombinant protein was purified by gel filtration using a 
Superdex®-75 column and Tris buffer (20 mm pH 8.0) containing 0.15 M NaCl as 
elution buffer. A calibration curve was obtained using the following molecular weight 
markers; dextran blue (Mr = 2,000,000 Da), albumin (Mr = 66,000 Da), carbonic 
anhydrase (Mr = 29,000 Da) and cytochrome c (Mr =12,400 Da). Most of the 
recombinant protein was eluted at a volume of 13.02 ml (Fig. 3.18 (a)). The calculated 
molecular weight of this fraction was 14,793 Da, close to the molecular weight expected 
of 14,777 Da, determined by amino acid comparison after thrombin cleavage. A pale 
band on SDS gel suggested a molecular weight slightly higher than 14 kDa (Fig. 3.18 
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(b)). These results indicated that most of the MupT protein was eluted in monomeric 










Figure 3.18 Purification of MupT by gel filtration. (a), chromatogram of eluted fractions in which 
MupT was shown in monomeric form. (b), SDS polyacrylamide gel, lane B from fraction 
A 12 and lane C from fraction A 13 that were concentrated ten times by TCA prior to load 
on gel, shown the bands (dark arrow) of MupT, lane A, molecular mass maker with size in 
kDa. 
As many matrices contain charged groups, the loss of protein during gel 
filtration might be caused by protein-matrix interactions, which can happen when 
charged proteins are being resolved. This can be avoided by increasing the ionic 
strength of salts in buffer solution. 132 Thus, to investigate whether salts affected the 
purified yield, other experiments were carried out. Equal amounts of recombinant 
protein were loaded onto the column, and protein was eluted using the same buffer as 
described above but containing higher salts (0.25 M NaCl) and also without salts. With 
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elution buffer containing 0.25 M NaCl, the MupT protein was eluted in the monomeric 
form (Fig. 3.19, gray). This result was similar to using the elution buffer containing 
0.15 M NaCl but the yield of recombinant protein was lower. In contrast, the absence of 
salts led to the elution of protein in multimeric forms. Most of the proteins were found 
in an aggregate form and a small amount in dimeric form whereas the monomeric form 
was not detected (Fig. 3.19, blue and Fig. 3.20). This observation indicated that the 
concentration of salts severely affected the solubility of the protein, with lower salt 
concentration decreasing the solubility of protein. This led to the formation of 










Figure 3.19 Effect of protein and salt concentration on MupT oligmerisation state. Comparison of 
chromatograms of recombinant MupT from a gel filtration column in which the 
concentration of proteins was 4 mg/ ml, except for the dotted red line, 2 mg/ml. Samples 
eluted with Tris buffer (20 mM pH 8.0) containing; 0.15 M NaCl (green), 0.25 M NaCl 
(gray) and in absence of salt (blue and red) (the Y value was not scaled). 
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Figure 3.20 SDS polyacrylamide gel of gel filtration of BL21 (DE3) containing pETmupT; lane B-J, 
collected fractions eluted by Tris buffer (20 mm pH 8.0) in the absent of salts; fraction in 
lane B-E, corresponding to the aggregate form; fraction in lane F-G, corresponding to 
dimeric form; lane A, molecular mass marker with the size in kDa. 
To investigate the effect of the concentration of protein on the formation of 
aggregated protein, half the amount of recombinant protein was loaded onto the column 
and eluted with the same buffer in an absence of salts. Most of the eluted protein was 
observed in the aggregated form (Fig. 3.19, red). This indicated that aggregation was 
salt dependent rather than concentration dependent. 
In addition to the salt concentration of the buffer, reducing agents such as DTT 
can also effect the formation of multimeric protein forms. 133 Couture et al. (2001) have 
purified BphF, a Rieske-type ferredoxin, involved in the degradation of biphenyl, 
isolated from Burkholderia LB 400.133 These workers reported that the addition of 1 
mM DTT in the elution buffer resulted in the elution of this protein in the monomeric 
form by gel filtration, whilst in the absence of DTT, the protein was observed in 
multimeric forms. Moreover, the recombinant BphF in the multimeric form was not 
detected after incubation with DTT for one hour. The occurrence of aggregate protein 
forms in the absence of DTT was therefore caused by the formation of intermolecular 
disulfide bonds. 
To study the effect of DTT on protein oligomeristaion, two experiments were 
performed. In the first experiment, the aggregated fraction from the above experiment 
(Fig. 3.20) was incubated with 1 mm DTT at 40C overnight. In the second experiment, 
the MupT solution (4 mg/ml, 500 µl) was also incubated in the same conditions with 1 
mm DTT. Proteins in both experiments were purified by gel filtration using elution 
buffer as described above containing 1 mm DTT. It was found that the peak of the 
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aggregated form decreased following the addition of DTT. Small peaks of the 
aggregated and dimeric forms were detected but the monomeric form was not observed 






Figure 3.21 Chromatogram of gel filtration of MupT in the presence of DTT. The protein solution was 
incubated with 1 mm DTT at 4°C for overnight prior to loading onto the column, the 
fractions were eluted using elution buffer containing 1 nm DTT. 
3.2.9 Purification of insoluble MupT by affinity chromatography 
The inclusion bodies of MupT were purified by nickel affinity chromatography under 
denaturing conditions by adding 6M urea into all buffers used for purification as 
described in section 3.2.3. Fractions were collected and analysed by SDS-PAGE (Fig. 
3.22). As above, most of MupT protein was found in the fractions, which eluted with 
buffer containing 0.25 M imidazole. Fractions (E-M) that showed bands on the gel 
corresponding to MupT were combined. Salts were removed by dialysis. The ratio of 
protein solution and dialysis buffer (v/v) was 1: 50. The protein was also refolded by 
slowly decreasing the concentration of urea contained in the dialysis buffer. However, 
some of the protein precipitated during dialysis. The yield of purified protein was only 
2.5 mg per litre (Fig. 3.22 lane N). 
SDS PAGE analysis (Fig. 3.22) indicated that the recovered yields were lower 
than predicted suggesting that most of protein was lost during dialysis. This might be 
caused by too rapid a decrease in urea concentration during dialysis. During dialysis, 
aggregation can occur when the concentration of denaturants is rapidly decreased or the 
concentration of protein is too high. 
121 It has been suggested that the formation of 
aggregated protein be slowed down by refolding at low protein concentrations (10-100 
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µg/ml). Also the observation of the protein colour change might indicate the removal of 







Figure 3.22 SDS polyacrylamide gel of nickel affinity chromatography of insoluble fraction from E. 
coli BL21 (DE3) expressing pETmupT. Lane A, molecular mass marker with the size in 
kDa; lane B-M, collected fractions during loading eluting buffer; lane N, supernatant of 
purified protein after dialysis in absence of urea; lane 0, supernatant of purified protein 
after dialysis in absence of urea and concentrated 25 fold prior to loading on gel. 
3.2.10 Solubilisation of insoluble MupT 
In order to recover more soluble protein from insoluble fraction, another solubilising 
reagent was used. The expression of pETmupT in E. coli BL21(DE3) was carried out 
using the same conditions as previous described. The harvested cells were resuspended 
in wash buffer (20 mm Tris-HC1 pH 7.5) containing 10 mm EDTA and 1% Triton X- 
100. For efficient cell lysis, the resuspended solution was incubated with 100 ug/ml 
lysozyme at 30°C for 15 minutes and then sonicated. The cells were separated by 
centrifugation and then resuspended in the above buffer and sonicated again. This step 
was repeated two or three times to remove cell debris and endogenous soluble proteins. 
In the final step, pellets were solubilised in 3-[cyclohexylamino]-1-propane sulfonic 
acid (CAPS) buffer containing 0.3% N-lauroylsarcosine and 1mM DTT. The solution 
was incubated at room temperature for 15 minutes. After centrifugation, the supernatant 
(solubilised protein) was refolded by dialysis in Tris buffer (20 mm pH 8.5). Although 
some of protein precipitated during dialysis, SDS-PAGE analysis showed a band 
corresponding to recombinant MupT (Fig. 3.23). This method yielded the protein 10.5 
mg per litre. However, this protein has not yet been assayed for activity. 
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Figure 3.23 SDS polyacrylamide gel of pETmupT MupT after solubilisation in CAPSbuffer and 
refolding by dialysis in Tris buffer. Lane B, molecular mass marker with size in kDa. 
To date, the MupT encoding ferredoxin dioxygenase has been expressed and 
purified. The purified MupT is soluble protein and brown in colour, a common feature 
of ferredoxins from purified from other systems, such as the naphthalene, toluene, 
benzene and biphenyl dioxygenase. 93,114,1 93,114,115 The brown colour might indicate that the 
enzyme contains an iron-sulphur complex. The calculated molecular weight of MupT 
ferredoxin, determined by gel filtration, is approximately 14800 Da. Comparison of the 
molecular weight of this ferredoxin with ferredoxins from other dioxygenase systems is 
shown in Table 3.1 
Table 3.1 Comparison of molecular weight of ferredoxins from different dioxygenase systems. 
Ferredoxin Microorganism Dioxygenase Amino Predicted Molecular 
protein system acid Molecular weightb 
weights (Mr) 
MupT P. fluorescens Mupirocin 116 12783 14800` 
NCIMB 10586 dioxygenase 
NdoA P. sp. NCIB 9816 Naphthalene 103 11315 13600 
dioxygenase 
TodB P. putida FI Toluene 106 11758 15300 
dioxygenase 
BnzC P. putida Benzene 106 11774 12300 
dioxygenase 
" Data from database. 
b Determined by gel filtration. 
Include additional amino acids, e. g. T7-tag. 
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3.2.11 Overexpression and purification of MupW 
As with MupT, the expression of MupW in the fusion (N terminal his6-tag) form in 
pET28a was scaled up using the conditions described in 3.2.5. The plasmid, pETmupW, 
was transformed into expression host E. coli BL21(DE3), grown and induced with 
IPTG at 25°C for 4 hours. The cells were harvested and resuspended in either Tris 
buffer or phosphate buffer and sonicated. Expressed MupW occurred only in the 
insoluble fraction. The protein was purified by nickel affinity chromatography under 
denaturing conditions as described in section 3.2.9 for MupT. Thus 6M urea was added 
into all buffers, which were used for purification. The fractions were collected and 
analysed by SDS-PAGE (Fig. 3.24). 
From Fig. 3.24 it can be seen that some of protein (lane B) did not bind to the 
resin as the band corresponding to MupW, 57000 Da, were seen on the gel. This might 
be due to the concentration of sample being higher than the capacity and efficiency of 
the column. This fraction was kept and repurified. Also more than one band of protein 
was observed from each fraction. This indicated that the protein needed to be further 
purified by other methods. The collected fractions (lane D-L) were combined. The 
purified proteins were pale yellow in colour. The combined fractions were dialysed to 
slowly decrease the concentration of urea in the dialysis buffer. The total yield was 4.0 
mg protein per litre of medium. 
Figure 3.24 SDS polyacrylamide gel of nickel affinity chromatography of E. coli BL21(DE3) 
expressed pETmupW. Lane A, supernatant from insoluble fraction before loading; lane B, 
collected fraction during loading binding and washing buffer into the column; lane C-L, 
collected fraction during loading eluting buffer containing 6M urea at flow rate 1 ml min'; 
lane M, molecular mass maker with the size in kDa. 
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3.2.12 Solubilisation of insoluble MupW 
An alternative method to solubilise the insoluble fraction containing MupW was carried 
out as described in section 3.2.10 for MupT. pETmupW was expressed as previously 
described. CAPS buffer containing 0.3% N-lauroylsarcosine and 1 mm DTT was used 
to solubilise the insoluble protein, followed by dialysis in Tris buffer. After dialysis, 
solubilised protein was analysed by SDS-PAGE. Analysis by SDS-PAGE showed a 
strong band corresponding to MupW (Fig. 3.25). Overexpression of fusion MupW, 
which was obtained in E. coli Rosetta(DE3), showed similar results. In both expression 







Figure 3.25 SDS polyacrylamide gel of E. coli BL2I(DE3) expressed pETmupW after solubilisation in 
CAPS buffer and refolding by dialysis in Tris buffer. Lane B, molecular mass marker with 
the size in kDa. 
As the re-solubilised protein contained more than one band of protein on SDS 
PAGE, nickel affinity chromatography was used as an initial purification step using the 
standard conditions as described in section 3.2.3 for soluble MupT. The protein was 
eluted from the column using an elution buffer containing 0.25,0.50,0.75 and 1.0 M 
imidazole. The four fractions (5 ml/each) were collected and analysed by SDS-PAGE 
(Fig. 3.26). On SDS PAGE, the bands corresponding to MupW were detected from the 
fractions eluted with 0.25 and 0.50 M imidazole (Fig. 3.26 lane E and D). The 
concentration of protein in the first fraction (lane E) was 2 mg/ml whilst in the second 
fraction (lane D) was 0.9 mg/ml. The total yield was approximately 15.0 mg per litre. 
The protein from fraction E was further purified by ion exchange chromatography. 
104 






Figure 3.26 SDS polyacrylamide gel of affinity chromatography of E. coli BL21(DE3) expressed 
pETmupW. The collected fractions were eluted with different concentrations of imidazole, 
lane B, with 1.0 M imidazole; lane C, with 0.75 M imidazole; lane D, 0.50 M imidazole; 
lane E, with 0.25 M imidazole; lane A, molecular mass marker with the size in kDa. 
3.2.13 Purification of MupW by ion exchange chromatography 
Fusion protein (fraction E) from 3.2.12 was further purified by anion exchange 
chromatography using a MonoQ column. The protein was eluted from the column by 
Tris buffer (20 mm pH 8.0) with a gradient of 0-1.0 M NaCI (Fig. 3.27). The fractions 
(B5-B 11) containing the target protein, as judged by SDS-PAGE (Fig 3.28 lane C-I), 
eluted with 0.50-0.60 mm NaCl. The MupW proteins were eluted in a broad peak. 
However, most of this protein was not detected after desalting by FPLC. A similar 
situation as for MupT protein as discussed in section 3.2.7 may be occuring. Protein 
was buffer exchanged and concentrated using a spin column. Unfortunately, some 
precipitated was observed during concentration resulting in only a small amount of 
protein being recovered. 
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Figure 3.27 Chromatogram of anion exchange chromatography of fusion MupW. Proteins were 
eluted using Tris buffer (20 mm pH 8.0) with a gradient of 0-1 M NaCl. 
ABCDEFGHI 
Figure 3.28 SDS polyacrylamide gel of anion exchange chromatography of fusion MupW. Lane A-H, 
collected fractions corresponding to fraction B 12, B 11, B 10, B9, B8, B7, B6, B5, B4 
respectively; lane I, molecular mass marker with the size in kDa. 
3.2.14 Purification of MupW by gel filtration 
MupW was further purified by gel filtration using a SuperdexTM-200 column. A protein 
solution in Tris buffer containing 1 mM DTT was loaded onto the column and eluted 
with Tris buffer (20mM pH 8.0) containing 0.10 M NaCl and 1 mm DTT. The fractions 
were collected at a flow rate of 0.5 ml min-' and then analysed by SDS-PAGE. A 
calibration curve was obtained using the following molecular weight markers; dextran 
blue (Mr = 2,000,000 Da), amylase (Mr = 200,000 Da), alcohol dehydrogenase (Mr = 
150,000 Da), albumin (Mr = 66,000 Da), carbonic anhydride (Mr = 29,000 Da) and 
cytochrome c (Mr = 12,400 Da). 
106 
0.0 3A 10.0 13.0 70.0 23.0 30.0 35.0 
-6.5 
Chapter 3 Mupirocin Biosynthetic Protein Studies 
Fig. 3.29 shows that recombinant MupW exists in a variety of multimeric forms 
(Fig. 3.30). Most of the target protein was found in higher molecular weight 
aggregates. This indicates that a fraction of the protein was not properly refolded. 
Another experiment was carried out in which the fusion proteins were incubated with 1 
mm ferric chloride overnight prior to loading onto the gel filtration column and then 
eluted using the same elution buffer described above. Since the dioxygenase may be an 
iron-sulphur protein, the addition of ferric chloride might help to form the proper 
quaternary structure of MupW. However, the multimeric protein forms were still 
observed and no significant signal, which differed from an absence of ferric chloride, 
was detected. The unsuccessful refolding was probably caused by an unsuitable 
solubilisation reagent, which might not allow the protein to achieve in the correct form. 
The nature of protein might be another possibility as the structure of dioxygenase can 
either be aß or a subunit. Thus, the absence of the ß-subunit may have caused the a- 









Figure 3.29 Chromatogram of gel filtration of fusion MupW. The proteins were eluted using Tris 
buffer (20 mM pH 8.0) containing 0.10 M NaCl and 1 mm DTT at flow rate 0.5 ml min-' 
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Figure 3.30 SDS polyacrylamide gel of collected fractions from gel filtration of fusion MupW. Lane 
A, fraction B 13; lane B, fraction B 12; lane C, fraction B 11; lane D, fraction B 10; lane E, 
fraction B9; lane F, fraction B8; lane G, molecular mass marker with the size in kDa. 
3.3 Conclusions and further work 
Overexpression and purification of MupT and MupW for structural determination has 
been carried out. Successful cloning of the mupT gene into pET15b vector was 
achieved. However, expression of the resulting construct was unsuccessful, even 
though a variety of protocols were assessed to improve expression, including altering 
host strain, IPTG concentration, induction temperature, and the presence or absence of 
glucose. It is still unclear why the mupT gene product was not produced in this system. 
The pET15b system is one of the most common expression systems available, having 
been successfully used for the expression of numerous active or inactive 
proteins. 119,135,136 
Overexpression of pETmupT in E. coli BL21(DE3) yielded the fusion protein in 
soluble and insoluble fractions; however, the insoluble fraction predominated over the 
soluble protein. Similar results were obtained from the overexpression of pETmupT, 
which was transformed into E. coli Rosetta(DE3). Both soluble and insoluble fractions 
of protein were purified by nickel chelating affinity chromatography. The soluble 
fraction was purified using standard conditions whereas the insoluble fraction was 
obtained under denaturing conditions by addition of 6M urea. MupT predominantly 
eluted with 0.25 M imidazole to yield a soluble brown protein, typical of iron-containing 
proteins. The yield of this protein was 4 mg per litre of culture. Subsequent isotope 
labelling of MupT in M9 minimal media for NMR studies resulted in half of that 
amount. . 
HSQC indicates that the protein is partially folded or unfolded. This might be 
due to protein was denatured during concentration by freeze-dry. Thus, protein was 
concentrated and buffer exchanged by spin column. 
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The insoluble fraction was purified in a system containing 6M urea as 
denaturant. This purification protocols yielded solubilised protein, which was refolded 
by dialysis. Most of protein was lost during dialysis when the concentration of urea was 
decreased thus, the yield was rather low. A more gradual reduction of urea might allow 
the proteins to properly refold by reducing the formation of protein aggregates. Better 
results were obtained when the inclusion bodies were solubilised in CAPS buffer 
containing N-lauroylsarcosine and DTT and refolded by dialysis. By this method a four 
or five-fold increase in yield could be achieved. 
Thrombin cleavage of fusion MupT was successful, allowing the removal of N- 
terminal amino acids including his6-tag from the protein. Gel filtration indicated that 
MupT was primarily in the monomeric form with a molecular weight of 14.8 kDa, 
which agrees well with the predicted molecular weight is 14.8 kDa. Aggregation of the 
mono to higher order oligomers was found to be salt and DTT dependent. Multimeric 
forms of MupT were observed when using the elution buffer in an absence of salt. 
Overnight incubation of aggregated MupT with DTT also resulted in a decrease of the 
aggregate forms. The recombinant MupT was nearly homogeneous after purification by 
anion exchange and gel filtration though the yields have been a major problem, which 
need to be improved. 
Like MupT, the expression of MupW in E. coli BL21(DE3) yielded only 
insoluble protein of approximately 57 kDa. MupW was purified using denaturing 
conditions as described for MupT. Denaturing purification using urea gave three to four 
fold lower yields than when CAPS and N-lauroylsarcosine was used. Unfortunately, the 
protein was not properly refolded and multimeric forms were observed in gel filtration. 
The failure of the MupW refolding might be caused by; the unsuitable method for 
refolding, the absence of an essential cofactor necessary for the correct structure, such 
as an iron ion, or the absence of another subunit (ß subunit). Typically the a subunit of 
a terminal dioxygenase is found complexed with the ß subunit and this may be needed 
for the protein to correctly fold. Obviously we need to test the activity of the 
refolded/purified proteins to see if it is active. 
MupT is proposed to encode a ferredoxin dioxygenase. This might function as 
an electron transfer intermediate to transfer electrons to the active site of a terminal 
dioxygenase. Therefore, the dioxygenase system in mupirocin biosynthesis is 
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dioxygenase. Therefore, the dioxygenase system in mupirocin biosynthesis is 
presumably composed of; reductase, which would be an NADH/NADPH 
oxidoreductase encoded by the mupC gene, ferredoxin encoded by the mupT gene and a 
terminal dioxygenase encoded by the mup W gene. In addition the association of MupC 
and MupT with a cytochrome P450 monooxygenase encoded by the mupO gene would 
be another possibility. 
To date, the expression and purification of MupT and MupW has been carried 
out. The quality and quantity of proteins are still major problems, which need to be 
improved. The use of new expression vectors, containing alternative fusion proteins to 
enhance solubility, such as glutathione S-transferase (GST) or thioredoxin (TRX) might 
be an alternative way to increase the soluble yields. The purification conditions or 
method may need to be improved such as salt gradient, or pH of buffer. These would 
help to get enough homogeneous protein for structural elucidation. 
Refolding of MupT/W showed a degree of success. Improved yields of soluble 
protein could be obtained for MupT, which behaved as a monomer when analysed by 
gel filtration. Optimisation of refolding may help to improve the yields for both 
proteins. For example, altering the solvent conditions has been shown to have dramatic 
effect on the yields of correctly protein. 137,138 Alternatively, co-refolding with the ß 
subunit for MupW may be necessary for the correct conformation. Another technique 
often used for difficult to refold proteins is the use of chaperonins, such as GroEL, 
DnaK/J and GrpE to assisted refolding. ' 39-141 In this system the chaperonins capture 
folding intermediates and can maintain these metastable states in aggregation free 
states. 139 Several studies have also suggested that GroEL could also assist folding by 




Chapter 4 Mensacarcin Biosynthesis 
4.1 Introduction 
Gene cloning methods are increasingly being utilised for investigation of biosynthetic 
pathways of secondary metabolites, including polyketides. Many polyketide 
biosynthesis genes have been cloned and sequenced from a variety of producers such as 
actinomycetes (in particular Streptomyces sp. ) and other bacteria, e. g. Pseudomonas and 
Mycobacterium strains. 142'143 Similarity of the gene sequences and arrangement in 
these organisms leads to the possible prediction of the nature of the polyketide 
structures. Moreover, studies of combinatorial mutation of genes enhance our ability to 
produce novel antibiotics and other compounds valuable for drug development. 
4.1.1 Cloning of Type II PKS genes 
During the past decade and a half, the cloning of biosynthetic genes from bacterial 
PKSs has been reported using various methods. Initially, one of the methods involved 
shotgun cloning of random fragments of DNA from a wild type strain into a mutant 
blocked at a step in the biosynthesis and looking for a restoration of antibiotic 
production. The second approach uses the close linkage between genes for self- 
resistance to an antibiotic and one or more of the biosynthetic genes. These studies 
indicated that the biosynthetic genes essential for assembly of antibiotic metabolites 
typically are in a single cluster, and contained one or more genes for antibiotic self- 
resistance genes. 14 
The first example of cloning of an entire cluster of Type II PKS genes was the 
act genes involved in actinorhodin biosynthesis from Streptomyces coelicolor A3(2). 25 
This led to the establishment of two general methods that are used today to successfully 
isolate complete sets of genes. 14 The first method is to clone a library of large 
fragments of wild type DNA into any available mutant blocked in a step of metabolite 
biosynthesis, looking for the complementation of the mutation, and then finding genes 
for other steps of the pathway on the complementing fragments. This is known as the 
complementation method. The second method is cloning of a library of DNA fragment 
from an antibiotic producer into another host strain, which has an antibiotic-sensitivity. 
The cloned DNA is then selected by screening with the antibiotic. This allows location 
of the antibiotic resistance gene, which is usually closely linked to the biosynthetic 
genes themselves. '4 
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Subsequently, several gene clusters from different Streptomyces and Saccharo- 
polyspora sp. have been cloned and identified. These were cloned by different methods 
such as complementation of blocked mutants by the cloned PKS DNA to restore 
production of the relevant polyketide, gene disruption and production of antibiotic after 
transfer of cloned genes to S. lividans. All genes involved in the biosynthesis tend to be 
clustered in bacterial genomes. Each cluster contained at least three genes, which 
encoded the homolog of actI ORF 1, ORF2 and ORF3 (Fig. 4.1). 14,144 
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Figure 4.1 Organisation of the type II gene clusters in actinomycetes. The arrows represent ORFs 
showing the direction of transcription and comparative length. Key: Actinorhodin (act); 
Granaticin (gra); Frenolicin B (freu); Griseusin (gris); Tetra- cenomycin (tcm); Spore 
pigment (whiE); Oxytetracycline (otc); Daunorubicin(dps/dau); Mithramycin (mtm); 
Urdamycin A (urd); and Jadomycin B (jad) (Adapted from Hopwood 14). 
4.1.2 DNA probes for Type II PKS genes 
Proteins or enzymes that have a similar function usually contain similar amino acid 
sequences. This similarity is extended to the DNA, which encodes that enzyme. This 
suggests that if different PKSs had a common ancestor, then cloned DNA from one 
synthase could be used as a probe for isolation of other genes. 144 To test this idea, the 
DNA encoding the KS (actl gene) and KR (actIII gene) functions of act PKS were used 
as hybridisation probes for cloned DNA for tcm145 and otc146 from S. glaucescens and S. 
rimosus respectively. These resulted in strong cross-hybridisation with KS (tcm and 
otc) and KR (otc only) probes in the regions that had already been identified by 
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complementation analysis as candidates for PKS genes. The KR probe does not bind to 
the tcm PKS gene as no reduction of the tetracenomycin polyketide chain occurs. 
In the same study, the actl and actlll probes were hybridised to the Southern 
blots of restriction digests of 18 known polyketide producers and 7 non-producers. 
Hybrid bands were revealed in most, but not all, of the producers, and were absent, from 
most but not all, of the non-producers. These results appeared to establish a strong, 
although imperfect, correlation between the presence of DNA sequences hybridising 
with act PKS probes and polyketide production. With these results, it was suggested 
that the probes could be use to isolate other PKS genes. 14 
After publication of these results, 147 several act probes used to search for Type 
II PKS genes, were made. To date, many Type II PKS gene clusters have been detected 
using actl as a probe. For example, the actl fragment was used as the hybridisation 
probe for the isolation of the PKS gene cluster involved in the biosynthesis of 
aclacinomycins from S. galilaeus ATCC 31,615. Sequence analysis revealed 13 
complete open reading frames including the minimal PKS genes. 49 
4.1.3 Mensacarcin 
Actinomycetes, in particular Streptomyces sp., are a large group of microorganisms, 
which produce structurally diverse polyketide antibiotics. In recent years, a new 
polyketide antibiotic named mensacarcin 95 has been found and isolated from 
Streptomyces sp C414 by Professor Axel Zeeck's research group, University of 
Gottingen, Germany. The structure was first characterised by NMR spectroscopy and 
further confirmed by X-ray crystallography. 148 Isotopic labelling studies showed that 
mensacarcin was derived from acetate except for the methoxy groups, which were 
generated from the methyl group of methionine (Fig. 4.2). 148 
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Figure 4.2 Isotopic labelling studies of mensacarcin. 
Currently, the full details of the mensacarcin biosynthetic pathway are not 
known but the basic structure of this molecule is probably assembled by a Type II PKS. 
The biosynthetic processes may involve in the condensation of an acetyl CoA starter 
unit and malonyl CoA extender unit to produce a linear core polyketide, and then 
cyclisation and aromatisation to form an aromatic intermediate. Finally, O-methylation 
and oxidations are performed to introduce functionalities such as the methyl ethers and 
epoxide by various tailoring enzymes. The compound is interesting because of the 
partial reduction of the first few carbons of the chain. The overall structure is similar to 
that of the well studied actinorhodin 16 and the less-well studied griseusin 96 (which 








As mentioned earlier, actinorhodin is derived from the condensation of an acetyl 
CoA starter unit and 7 molecules of malonyl CoA to form an unreduced octaketide 
backbone (Scheme 1.7). This is catalysed by the minimal PKS gene in the act gene 
cluster. By analogy to actinorhodin, mensacarcin could form from the acetyl CoA 
starter unit and 9 molecules of malonyl CoA extender units to form linear decaketide 
intermediate (Scheme 4.1). Also the first cyclisation would form at C-7 and C-12 and 
further undergo reduction at C-9 by ketoreductase. The second and the third cyclisation 
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would occur by cyclase and aromatase via the decarboxylation at C-1. Further side 
chain modifications might take place by some tailoring enzymes such as oxygenases for 












Scheme 4.1 Possible proposed mensacarcin biosynthetic pathway by analogy to actinorhodin. 
Alternatively, mensacarcin might derive from an unusual starter unit as found in 
griseusin biosynthesis. Griseusin 96 is an aromatic polyketide antibiotic, isolated from 
Streptomyces griseus K-63.149 This compound is thought to be derived from starter 
units such as a butanoate or hexanoate rather than acetate, and malonate extender units. 
This is analogous to the situation in the fungus Aspergillus parasitices where hexanoate 
forms the starter unit for norsolorinic acid biosynthesis. The gris gene cluster is a Type 
II PKS, which encodes KS, CLF, ACP, KR, and CYC/ ARO and a number of other 
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ORFs, '50 although the full gene sequence has never been published. However, some 
steps of this biosynthetic pathway are unclear. By analogy to griseusin, mensacarcin 
might derive from a 6-carbon starter unit and 7 malonyl CoA to form the linear carbon 
chain with the first cyclisation by the men minimal PKS gene (Scheme 4.2). This starter 
unit might be formed from another pathway or might be built up by other enzymes, 
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Scheme 4.2 Possible proposed mensacarcin biosynthetic pathway by analogy to griseusin. 
The aim of this project was to investigate the polyketide synthase gene cluster 
involved in the assembly of this metabolite. Thus, a genomic library would be 
constructed, and then the PKS genes would be looked for using actl probes. In 
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particular we were interested in finding new genes that might be involved in starter unit 
reduction and selection, which are not present during act biosynthesis. 
4.2 Results and Discussion 
4.2.1 Production of mensacarcin by Streptomyces C414 
To isolate mensacarcin, its production was studied in order to find the optimal time for 
high production. A loopful of Streptomyces C414 (supplied by Professor Axel Zeeck 
University of Goettingen Germany) from an agar plate was grown in seed medium 
(oatmeal medium) on shaker at 250 rpm, 250C for 72 hours. 3% Volume of seed culture 
was inoculated into the production medium (the same oatmeal medium), and then 
grown under the same conditions. Two flasks were harvested twice a day for 5 days. 
After centrifugation, the supernatant was extracted with ethyl acetate and evaporated to 
dryness to give a yellow residue. The crude extract was dissolved in acetonitrile. The 
concentration of mensacarcin was monitored by LC-MS, and a growth production curve 












Figure 4.3 Time course of mensacarcin production by Streptomyces C414. 
For isolation, Streptomyces C414 was grown in 100 ml production medium in 20 
0 
x 500 ml conical flasks shaken at 250 rpm, 25 C for 72 hours. The supernatant was 
extracted with ethyl acetate. The crude extract was further purified by column 
chromatography on silica gel 60 using dichloromethane-methanol in a 98: 2 ratio. The 
fractions were collected and analysed by thin layer chromatography (TLC) using the 
same solvent system. The RF of mensacarcin in this solvent system was 0.68. Two 
spots were detected on TLC from the collected fractions. The collected fractions were 
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purified once more using CH2C12-MeOH-acetone in a ratio of 15: 1: 2 as solvent system. 
The purified compound was characterised by 1H and 13C NMR spectroscopy (Fig. 4.4, 
Table 4.1 and Fig. 4.5, Table 4.2 respectively). The isolated yield of mensacarcin was 
approximately 85 mg per litre. 
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vIe OMe OH 
1 OH 
Table 4.1 'H nmr spectral assignment of mensacarcin isolated from Streptomyces C414. 
6H9 ppm Multiplicity J, Hz 
'H assignment 
1.09 d 8.0 15-H 
1.46 d 4.0 14-H 
2.30 d 7.0,3.0 3-H 
3.05 d 5.0,2.0 13-H 
3.60 d 10.0 1-OH 
3.67 d 6.0 4-OH 
3.75 s 17-H 
3.95 d 2.0 12-H 
3.95 s 16-H 
4.45 d 10.0 1-H 
4.72 dd 5.0,3.0 4-H 
5.08 s 2-OH 
5.52 s 10-H 
7.23 dd 8.0,1.0 6-H 
7.45 dd 8.0,8.0 7-H 
7.66 dd 8.0,1.0 8-H 
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Figure 4.4 1H NMR spectrum of mensacarcin isolated from Streptomyces C414 in CDC13. 
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Figure 4.5 13C NMR spectrum of mensacarcin isolated from Streptomycesin C414 in CDC13. 
Table 4.2 13C nmr spectral assignment of mensacarcin isolated from Streptomyces C414. 
6c, ppm 13C assignment 8c, ppm 13C assignment 
10.8 C-15 70.3 C-1 
17.8 C-14 83.3 C-2 
31.7 C-3 116.9 C-8 
56.3 C-13 119.4 C-6 
56.9 C-16 127.9 C-9a 
58.4 C12 129.5 C-7 
59.4 C-17 130.3 C-5a 
63.1 C-4a 158.8 C-9 
66.3 C-10a 192.9 C-5 
68.5 C-4 208.7 C-11 
69.6 C-10 
4.2.2 Isolation and purification of genomic DNA 
To isolate genomic DNA (gDNA), a new clear liquid medium for growing the strain 
was needed. This is because it is difficult to prepare DNA from samples grown in 
suspension media such as the oatmeal media. Thus, the production of mensacarcin in 
three different media; M2, NL-1358 and R2YE, was studied. The bacteria were grown 
using the same conditions as above. After 72 hours, the cultures were harvested by 
centrifugation, and the supernatant was extracted with ethyl acetate. The crude extract 
was analysed by LC-MS. The highest production of mensacarcin was observed from 
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growth in M2 medium (Table 4.3). Therefore, the M2 medium was used as production 
medium to grow the Streptomyces C414 for this purpose. 
Table 4.3 Comparison of mensacarcin production in different media. 







Streptomyces C414 was grown in M2 media on a shaker at 25 C for four days. 
The cells were harvested by centrifugation, and then were resuspended in DNA 
extraction buffer (10 mm Tris-HCl pH 8.0,10 mm EDTA, 0.5% SDS). The 
resuspended cells were broken by incubation with lysozyme, and then treated with 
ribonuclease (RNase) to remove RNA. To isolate DNA, the solution was extracted with 
phenol-chloroform. The gDNA was recovered by ethanol precipitation at -200C 
overnight. The pellets were resuspended in TE buffer and analysed by agarose gel 
electrophoresis. This showed that the extraction of gDNA was successful. The DNA 
band, which was seen on agarose gel, was bigger than 30 kb in size (Fig. 4.6(a)). The 
gDNA was further purified by CsCl-ethidium bromide gradient centrifugation. 
ABCAB 
Figure 4.6 Gel analysis of genomic DNA isolated from Streptomyces C414. (a) after extraction; lane 
A, DNA maker with size in kb; lane B, 1 µl of extracted genomic DNA and lane C, 5 µl. 
(b) after purification; lane A, DNA maker with size in kb; lane B, 6 pl of purified gemonic 
DNA 
In CsC1-ethidium bromide gradient purification, DNA and ethidium bromide are 
mixed with a CsCI solution. When the mixture is centrifuged at high speed (100,000 
rpm), the centrifugal force is sufficient to generate and maintain a gradient of caesium 
120 
Chapter 4 Mensacarcin Biosynthesis 
(Cs) ions. Due to this, DNA of different densities will migrate to positions in the tube at 
which the density of CsCI solution equals that of the DNA. 151 Although this method 
provides a high quality of DNA, some might be lost as the DNA could be degraded 
during centrifugation and when trying to isolate the purified DNA by syringing it from 
the centrifuge tube. However, we succeeded in purifying the gDNA (Fig. 4.6 (b)). 
4.2.3 Construction of genomic library 
In order to investigate the mensacarcin production gene cluster, a genomic library, 
which would contain the fragments of the entire genome needed to be made. The 
gDNA was partially digested with appropriate restriction enzymes, Sau3A I or BamHI. 
The gDNA fragments were cloned into a replacement vector (bacteriophage lambda 
vector) and then in vitro packaged to from recombinant phages, which could be used to 
infect the host cell (E. coli). The resulting lysate contains fragments of DNA housed in 
a large number of phage particles. The method is summarised in Fig. 4.7. The cloning 
was analysed by the number of phage plaques on agar plate. 
Genomic DNA 
Partial digestion with BamHI 
Size fractionation 
left arm 20 kb 
14 - 23 kb fragments 
Ligation 
left arm 20 kb 
BamHI 
Lambda GEM-11 BamHI Arms 
right arm 9 kb 
Digest with BamHI 
right arm 9 kb 
BamHI 
left arm 20 kb 







Figure 4.7 Summarised of preparation of genomic library in Lambda GEM-11® vector. 
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Bacteriophage lambda vector was utilised for preparation of the genomic library 
due to its efficiency in carrying large fragments of DNA. This would make the 
resulting recombinants more stable and easier to screen. 152 There are several reports of 
successfully constructed genomic libraries that contain PKS genes in lambda vectors 
such as ý, EMBL4.150,153 The Bacteriophage lambda is a bacterial virus which consists 
of double-stranded linear DNA of approximately 48 kb (Fig. 4.8), which is located at 
the phage head. 152 
DNA 
I 
Figure 4.8 Structure of bacteriophage lambda. 
In order to have a library containing the overlapping fragments, the gDNA of 
Streptomyces C414 was partially digested with either Sau3A I or BamHI restriction 
enzymes. Sau3A I, which is a four base cut enzyme, will provide fragments of, on 
average, 256 bp whereas BamHI will cut, on average, every 4,096 bp. Therefore, 
Sau3A I would give more random fragments than BamHI. The digestions were studied 
at 5 different enzyme dilutions; No. l= 500 fold, No. 2= 1000 fold, No. 3= 2000 fold, 
No. 4= 4000 fold and No. 5 = no enzyme. The best digestion, at least 3 times, was 
observed from the reaction with enzyme dilution No. 1 with either Sau3A I or BamHI 
(Fig. 4.9). Before ligation, size fractionation was carried out by gel electrophoresis to 
remove the fragments outside the size range of 9-23 kb, which the vector can accept. 
The purified fragments were ligated into Lambda GEM-11® BamHI Arms vector, which 
is 43 kb in size (Fig. 4.10). 154 As Sau3A I, which recognises the sequence of four base 
pairs (GATC), generated the same single-stranded termini (GATC) as BamHI, which 
recognises the sequence GGATCC, the fragments, which were digested with Sau3A I or 
BamHI were directly insert into Lambda GEM- 11®BamHI Arms. 
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Figure 4.9 Gel analysis of partial digestion of gDNA; lane A, DNA marker with size in kb; lane B, 
digested with Sau3A I; lane C, digested with BamHI; lane D, non-digested gDNA. 
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Figure 4.10 (a) Map of Lambda GEM°-I I genomic cloning vector, 154 (b) ligation of gDNA fragments 
to Lambda GEM°-I I BamHI Arms. 
The ligation product, named XWLmscI82, was packaged in vitro into phage 
particles and used to infect the host cell, E. coli KW25 1. The infection was indicated by 
the appearance of phage plaques as clear zones on LB plates. The number of phage 
plaques was used to indicate the size of library. The probability of the number of clones 
152 needed in the library is calculated from equation 4.1. 
N =1n(1 -P) / ln(1-f) (4.1) 
where N= required number of clones, P= the probability of the library containing the 
desired piece of DNA and f= the fraction of the genome represented by an average 
clone. Therefore, the estimated size of a bacterial genomic library that has a genome 
size of 4x 106 bp with a six base pair cutter, is 4.5 x 103.152 We succeeded in 
construction of the genomic library from cloning of digested BamHI gDNA fragments 
to lambda vector, and the library contained 3x 105 clones. Theoretically, this library 
should contain all required genome information. 
123 
Chapter 4 Mensacarcin Biosynthesis 
4.2.4 Screening of the genomic library 
The next step was to screen the library by hybridisation with a suitable gene probe. The 
basis of this method is the formation of a double-stranded nucleic acid molecule by 
hydrogen bonding between wholly or partially complementary sequences of the cloned 
DNA sample and the DNA probe. Since mensacarcin is an aromatic polyketide 
metabolite, the PKS involved in the assembly of this metabolite is probably a Type II 
PKS. Therefore, actl (the homologous gene from a Type II PKS) was used as a 
heterologous probe to screen the library. The actl gene is part of the minimal PKS, 
which consists of KS, (ketosynthase), KSp (chain length factor) and ACP (Fig. 4.11 
(a)), involved in the biosynthesis of actinorhodin 16, an aromatic polyketide from S. 
coelicolor A3(2). 
The pBluescript clone, pRJCII04F, was supplied by Dr R. J. Cox, and contained 
the act KS.. KSp and ACP genes. This was grown in 3 ml LB media in a 10 ml sterile 
tube with 100 pg/ml carbenicillin at 370C overnight. The cells were harvested by 
centrifugation, and then the recombinant plasmid DNA was isolated and purified by 
MiniPrepTM kit (Novagen or Promega). The DNA was double digested with Ndel and 
BamHI at 370C for two hours. The reaction was inactivated by heat at 650C for 10 
minutes. The digestion reaction was analysed by gel electrophoresis. Three fragments; 
approximately 3.0,2.0 and 1.0 kb, were observed on agarose gel. The fragment of 2.0 
kb in size which consisted of KSa and the N-terminal portion of KSR was used in these 
experiments. This 2 kb fragment was cut from the gel and purified (Fig. 4.11 (b) lane 
C) and subsequently used as the probe DNA. 
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Figure 4.11 (a) Map of actl, the minimal PKS gene in actinorhodin biosynthetic pathway. (b) gel 
analysis after purification of actl, which double digested with Ndel and BamHI. Lane A, 
DNA marker with size in kb; lane B, C and D, DNA fragment 3 kb; 2 kb and I kb 
respectively. 
The DNA probe, which is double-stranded, was heat-denatured to single strands 
by boiling at 950C for 5 minutes and then was labelled with [a-32P]dCTP. In the 
meantime, the DNA targets, which were in the form of a number of phage plaques on 
the agar plates, were transferred and immobilised on a nitrocellulose membrane. To 
remove the DNA from phage and denature it, the membrane was soaked in a sodium 
hydroxide solution, and then was neutralised in buffer solution (Tris-HC1 pH 7.5 and 
1.5 M NaCI). The membrane was further washed with 2xSSC (Standard Saline Citrate) 
buffer (0.03 M sodium acetate and 0.3 M NaCl). The single-stranded DNA molecules 
0 
were fixed on the membrane by baking at 80 C for 30 minutes, and the membrane was 
then hybridised with the labelled probe. 
The hybridisation temperature and the concentration of salts, which would be 
used for washing after hybridisation, are important. 152 For hybridisation with 
homologous probes, high stringency (high temperature and low salt concentration) must 
be used to prevent missing some probe-target hybrids, low stringency (low temperature 
and high salt concentration) should be used. As a heterologous probe was used in these 
125 
9Z bp 1862 bp 205 bp 
Chapter 4 Mensacarcin Biosynthesis 
studies the hybridisation was obtained at low stringency (2 x SSC, 650C) in order to be 
able to select mismatch hybrids. 
As the DNA probe could bind non-specically to other materials on the 
membrane, the membrane was pre-hybridised with hybridisation solution (14% SDS 
and 0.5 M Na2HPO4 in ratio 1: 1) in the absence of the probe at 650C for 15 minutes, and 
then was hybridised with probe overnight. In this way, the labelled probe should 
hybridise to DNA target from any plaques which contained the related gene or part of it. 
The non-hybridised radioactive probe was washed away with 2x SSC buffer. The 
labelled probe-target hybrids were detected on an X-ray film. 
After incubated of the X-ray film at -800C for five hours, the pale dark spots for 
the hybrids were observed on the film. In order to see more clearly, the exposure on a 
new X-ray film was left overnight (Fig. 4.12). The film showed strong hybrid signals. 
This indicated that the screening was obtained at high density. Thus, the recombinants 
needed to be rescreened in order to be able to pick single clones uncontaminated from 
the other clones. Six phage plaques were picked from plate, resuspended in SM buffer 
and used for the next hybridization. Before plating on agar plate, the phage plaque 
solution was diluted 100 and 1,000 fold in order to make single isolated clones. The 
hybridisation was repeated as describe above until a single clone was picked. 
ý; 
Figure 4.12 X-ray film of phage hybridisation after incubation at -70°C overhight. 
4.2.5 Purification of lambda DNA from phages 
In order to purify the lambda DNA, phage lysate stock was prepared. The single phage 
plaque, which was picked after hybridisation in 4.2.4, was used. Two methods for lysis, 
were carried out, plate lysis and liquid culture lysis. 
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For plate lysis, the phage solution was infected to the E. coli KW251 host cell 
and then plated on agar as describe in 4.2.3. The plates were incubated at 370C for six 
hours. The phage plaques were removed from plates by overlaying the top agarose with 
SM buffer. The mixture including top agarose was transferred to a centrifuge tube and 
incubated at room temperature for 30 minutes on a shaker. The lysate solution was 
recovered by centrifugation. For long storage, 3% (v/v) of chloroform was added to the 
solution. This addition was to remove the bacterial debris and stabilise the phage. 
For liquid culture lysis, 20 µl of phage solution was added into 500 µl overnight 
KW251 culture grown overnight and incubated at 370C for 20 minutes to allow the 
phage to absorb. 500 µl of infected culture was inoculated into 100 ml LB media 
0 
containing 1 ml of 1M MgSO4. The culture was grown on a shaker at 37C for 5-7 
hours. The media appeared turbid after two hours of incubation but were not clear after 
cell lysis for 5 hours. Therefore, the culture was grown for a further 2 hours. After 7 
hours, chloroform was added and the bacterial debris removed from the lysate solution 
by centrifugation. 
The advantage of the plate lysis method is that it provides a higher yield and it is 
easier to know whether or not the phage have grown successfully by looking at the 
degree of confluence of lysis. But the DNA derived is usually contaminated with E. coli 
cells or sulphated polysaccharides that leach from the top agarose. This sometimes 
causes the purification in the next step to be unsuccessful, which can further lead to 
failure of digestion with restriction enzymes. For the liquid culture lysis, the phage 
lysate is cleaner and free of sulphated polysaccharides. However, it provides a lower 
yield and it is more difficult to obtain complete lysis. 
151 We succeeded in purifying 
lambda DNA from plate lysate rather than from liquid culture lysis. 
The lambda DNA was isolated and purified from phage lysate by either 
Wizard®Lambda Prep DNA purification kit (Promega) or Miniprep. 
151,155 The first 
step was to remove RNA and DNA from phage particles by addition of RNase A and 
DNase I, each to a final concentration 1 µg/ml. The reaction was incubated at room 
temperature for 30 minutes. To precipitate phage particles, 5.8 g of NaCI and 9.3 g of 
polyethylene glycol (PEG) were added to every 100 ml of phage lysate mixture. The 
mixed solution was incubated on ice for 1-2 hours. The addition of NaCl is to assist the 
separation of phage particle from the bacterial debris and is also required for efficient 
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precipitation of phage particles by PEG. 151 The precipitated phage particles were 
recovered by centrifugation and resuspended in SM buffer. The PEG and cell debris 
were removed by addition of an equal volume of chloroform. The mixture was 
centrifuged again. To isolate lambda DNA, SDS and EDTA were added to the aqueous 
phase, which contained the phage particles, and the reaction was incubated at either 
560C for one hour or 680C for 15 minutes. The solution was extracted with phenol- 
chloroform to isolate the DNA. The DNA was recovered by ethanol precipitation and 
resuspended in TE buffer. The recovered lambda DNA was analysed by gel 
electrophoresis. 
Gel analysis showed a strong band, which was close to 48 kb in size (Fig. 4.13). 
The problem in this step was the contamination from other nucleic acids because a 
band, which located on the bottom, was usually observed. This was thought to be RNA 
contamination or it might be from the E. coli DNA. Therefore, RNase A was added into 
the running buffer during run gel. This was tested because if the RNA contained in the 
target DNA, it would be easily removed and the band would not be observed. However, 
the strong band still appeared on gel. On the other hand, with addition of a higher 
amount of DNase I in the first step of purification, the pale band was seen or sometimes 
almost disappeared. However, we finally got some appropriate purified lambda DNA 
for the further step (Fig. 4.13). 
48.5 
AB 
Figure 4.13 Gel electrophoresis of purified lambda DNA; lane A, DNA marker with the size in kb; lane 
B, purified lambda DNA. 
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4.2.6 Characterisation of lambda DNA 
The confirmation of the correct lambda DNA was performed by restriction digestion 
and Southern hybridisation with the previous 2 kb probe from the actl gene. The basis 
of this method is to transfer the DNA fragment from agarose gel to membrane, and then 
was hybridised with labelled probe as previous described. 
The lambda DNA was digested with BamHI at 37"C for three hours, and the 
reaction was inactivated by heat at 650C for 10 minutes. The digestion reaction was 
analysed by gel electrophoresis. After digestion, at least three fragments should be 
observed: two fragments from the left arm (about 20 kb) and right arm (about 9 kb) of 
the vector, and the fragment of insertion DNA, which would be only one fragment or 
small multifragments. When the appropriate digestion was observed, the gel was run at 






Figure 4.14 Southern hybridisation of lambda DNA. (a), gel analysis before blotting; lane A and D, 
DNA marker with size in kb; lane B and C, different clones of lambda DNA that were 
digested with BamHI. (b) X-ray film after hybridisation. 
As shown in Fig. 4.14 (a), different results were observed from the different 
clones (lane B and C). More small fragments were detected from lambda DNA in lane 
B. Except for the left (20 kb) and right arm fragments (9 kb), fragments of about 15,6, 
4.5 and 2.5 kb were seen in lane B. On the other hand, the lambda DNA in lane C 
contained a additional fragment of about 3 kb but the fragment of about 9.0 kb was 
rather strong. After hybridisation with the actl probe, the dark signal of hybrid band of 
lambda DNA/probe was observed from the fragment about 9.0 kb on the X-ray film 
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(Fig. 4.14 (b), lane Q. In addition, the fragment about 3.0 kb was sometimes observed. 
But no hybrid bands were seen from lane B. Theoretically, the markers should not 
hybridise with the labelled probe. Why sometimes hybrid bands were observed in the 
marker lane (D) is not understood. 
4.2.7 Sequencing of lambda DNA 
As the southern hybridisation confirmed the correct clone, the lambda DNA was sent 
for sequencing by Lark Technologies using T7 and SP6 primers. DNA analysis would 
be obtained by alignment with the actl sequence from database, BLAST search 
(http: //www. ncbi. nlm. nih. gov/BLAST/)'56 and frameplot (http: //www. nih. gojp/-jun/cgi 
-bin/frameplot. pl. ). 
157 
Unfortunately, the quality of the results from sequencing sometimes were of 
variable quality. These problems were probably caused from the purity of the lambda 
DNA, which was possibly not high enough. In addition, the size of lambda DNA, 43 
kb, might cause the sequencing problems. Thus, we decided to subclone the lambda 
DNA fragments into a plasmid vector, which would be easier to purify and sequence 
than the previous. 
4.2.8 Subcloning of lambda DNA fragments to pBluescipt vector 
The previous Southern hybridisation of lambda DNA (in 4.2.6) resulted in two hybrid 
fragments of, 9.0 and 3.0 kb. These two fragments were purified from agarose gel and 
ligated into pBluescript. Unfortunately, the band corresponding to the fragment of 3.0 
kb was not seen after purification from gel even when the purification was repeated. 
Therefore, only the 9.0 kb fragment was ligated to pBluescript vector. 
The ligation product, which was designated pWLmscII3, was further 
transformed to E. coli TAM! competent cells. As the plasmid vector contains lacZ (ß- 
galactosidase), white/ blue selection was utilised to screen the recombinant plasmid. 
This works due to the action of ß-galactosidase releasing a dye in the presence of X-gal 
(5-bromo-4-chlo-3-indolyl-ß-D-galactopyranoside) and IPTG, resulting in a deep blue 
colour. Thus, the transformed plasmids were spread on an LB plate containing X-gal 
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and IPTG. The recombinant plasmids, which carried the inserts showed as white 
colonies because the lacZ gene was disrupted by insertion of DNA fragment. 
To confirm the right clone, white colonies were picked, grown and further 
characterised by digestion with restriction enzymes. From digestion, at least two bands 
of size 3.0 and 9.0 kb, which corresponding to vector and insert respectively, should be 
detected. If the DNA has an internal BamHI restriction site, fragments, which were 
smaller than 9.0 kb would be observed. As shown in Fig. 4.15, the digestion of 
recombinant DNA, which was isolated from a white colony, showed two bands of size 










Figure 4.15 Gel electrophoresis of restriction digestion of recombinant DNA, which were constructed 
in pBluescript vector; lane A, DNA marker with size in kb. 
4.2.9 DNA analysis of the lambda fragment in pBluescript vector 
The DNA was sequenced using T3 and T7 primers. The first sequencing resulted in the 
good quality sequence data. Thus, new primers were designed for further sequencing. 
The sequencing of both strands from recombinant plasmid was continued until the 
results from T3 primer strand were not good and could not go further. This resulted in 
incomplete sequencing, and the sequences from both strands did not overlap. The size 
of sequences from T3 primer end was 3.0 kb whereas from T7 primer end was 5.0 kb. 
This means that -- 1 kb of sequence was not obtained in the centre of the clone. 
Sequence analysis of each strand was performed. An individual sequence and a 
contig were aligned with actl sequences from database using vectorNTl. No similar 
sequences were observed. For T7 primer end sequences, analysis of open reading 
frames (ORF) and their transcription directions by vectorNTl found four potential ORFs 
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(Fig. 4.16). These were further analysed by BLAST search and frameplot for the 
prediction protein-coding regions in bacteria DNA with a high G+C content (Fig. 4.17). 
Figure 4.16 Analysis of open reading frames of nucleotide sequence of T7 end of lambda 
DNA fragment in pBluescript. "= Start codon, º= stop codon in frame. 
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Figure 4.17 Frame plot of contig of lambda DNA fragment in pBluescript. 
Nucleotide or amino acid sequence-comparison of orfl (Fig. 4.17) that 
contained 316 amino acids showed high similarity to putative branched-chain alpha keto 
acid dehydrogenase El beta subunit from S. coelicolor A3(2) (97% identity), and 
similar to putative 3-methyl-2-oxobutanoate dehydrogenase from S. avermitilis (96% 
identity). The orJ2 contained 177 amino acids, and showed similarity to a putative 
transcriptional regulator from S. coelicolor A3(2) (87% identity). The orf3 contained 
608 amino acids, and showed similarity to a putative 3-hydroxyacyl CoA 
dehydrogenase from S. avermitilis (84% identity) and from S. coelicolor A3(2) (75% 
identity). The orf4 contained 271 amino acids, and showed similarity to the same 
protein as orf3.79% was identical to putative 3-hydroxyacyl CoA dehydrogenase from 
S. avermitilis, 69% from S. coelicolor A3(2), and 42% identical to putative 3- 
hydroxyacyl CoA dehydrogenase PaaC from Pseudomonas putida KT 2440. 
On the other hand, BLAST search and frameplot of contig from the T3 primer 
end showed no significant ORFs. However, no significant region, which was similar to 
any PKS sequence, was observed from both strands. The unsuccessful sequencing in 
the middle of the clone might be caused by the occurrence of tandem repeat inserts. In 
any event, the unsequenced region was no bigger than 1 kb-too small to harbour a PKS. 
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4.2.10 Construction of genomic library in Lambda B1ueSTARN Vector 
Due to the low quality of gDNA library in Lambda GEM"-1 I vector, XBlueSTAR Ahoi 
Half-site Arms vector was an alternative choice for the preparation of the library. A 
size range of fragments, which is accepted by XBlueSTAR Xhol Half-site Arms, is 7-20 
kb. The advantage of this cloning vector was the ability for direct excision of plasmid 
from the lambda vector. In addition, Xhol partially filled-in arms have the theoretical 
advantage of reducing the occurrence of tandem inserts. 158 Thus the size fractionation 
step can be omitted. Also this vector provided good results for construction of fungal 
genomic libraries in our laboratory. 
To prepare for cloning, the purified gDNA was partially digested with Sau3A I. 
The experiment was carried out as in 4.2.3. After digestion, the digested gDNA was 
partially filled-in at Sau3A I end with dATP and dGTP to yield a 5'd(GA) overhang, 
which is complementary to the d(CT) overhangs created by partial fill-in of Xhol- 
digested vector (Fig. 4.18). The filled-in DNA was recovered from the reaction by 
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Figure 4.18 Xhol partial fill-in cloning. 
The ligation product, named XWLmscII12 was in vitro packaged at room 
temperature for two or three hours, and then infected to E. coli KW251 host cell. The 
infection was indicated by the appearance of plaques on LB plates as described above. 
For this library the phage titer (pfu/ml) was 3x 104, which was smaller than the 
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previous library, but was considered to be big enough for a genomic library. This was 
due to the suggestion of the estimated library size of bacterium that contains 4x 106 
bases in genome with four base cutter should be 1.0 x 103.152 
4.2.11 Excision of pB1ueSTAR-1 from Lambda B1ueSTAR vector 
The amplified library was screened by hybridisation with the actl probe as earlier 
described. Five single phage plaques were picked and resuspended in SM buffer. This 
was kept as phage stock. In the 2 BlueSTAR system, the plasmid, pB1ueSTAR-1, can be 
directly obtained from the lambda vector by plating lambda phage on E. coli BM25.8 
strain. This produces colonies that carry the inserted gDNA in a plasmid excised from 
the lambda vector. Therefore, phage solution was added into E. coli BM25.8 culture and 
then spread on LB plate containing carbenicillin. The recombinant DNA was purified 
and then transformed into TAM 1 competent cells for amplification. 
To check it was the correct clone, restriction digestion and Southern 
hybridisation were carried out. The colonies from amplification in TAM I were grown 
in LB media containing carbenicillin. The plasmid DNA was purified and then digested 
with BamHI. The digestion reaction was analysed by agarose gel electrophoresis (Fig. 
4.19 (a)). Gel analysis showed many bands including the band corresponding to vector 
size, 2.0 kb. The size of the inserted DNA was in range 9-14 kb. The appropriate gels 
were further hybridised with actl probe as previously. From hybridisation, hybrid 
bands were observed on X-ray film (Fig. 4.19 (b)). But the results were rather strange 
as most of the fragments seemed to be hybrid bands. These might indicate that the 
labelled probe would have less specific binding. Thus, the clones could be the correct 
or incorrect. The experiment was repeated with the samples from different clones but 
the similar results were observed. Hence the recombinant DNA (lane A) was sent for 
sequencing. This clone was chosen because its size was bigger than samples in lane E- 
F, and therefore might be expected to give more information. 
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Figure 4.19 Southern hybridisation of lambda DNA from pBlueSTAR-1. (a), gel analysis before 
blotting; lane A, DNA marker with size in kb; lane B-D and lane E-G; different cloned of 
lambda DNA that were digested with BamHI. (b) developed X-ray film after 
hybridisation. 
4.2.12 Sequencing of lambda DNA from Lambda B1ueSTAR system 
For pB1ueSTAR-1, T7 and T3 primers were used for sequencing. The 
sequences from both strands were individual and contig assembly alignment with actl 
sequence. DNA sequences were translated to protein sequences for comparison with 
the known sequences in databanks. Sequencing of recombinant DNA from both strands 
until complete was 9.2 kb (Fig. 4.20). 
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Figure 4.20 Assembly of nucleotide sequences from both strands of genomic library constructing in 
XBlueSTAR vector. 
Analysis of open reading frames by vector NTI showed five ORFs (Fig. 4.21). 
Nucleotide or amino acid sequence comparisons, however, showed no sequences 
corresponding to known PKS genes. DNA analysis of the whole contigs by frameplot 
for predicted protein-coding regions showed some ORFs (Fig. 4.22). For example, the 
orf7 contained 223 amino acids, and was similar to a sporulation associated protein 
from S. avermitilis (26% identity). The orJ2 contained 237 amino acids, and was 
similar to a hypothetical protein FG00205.1 from Gibberella zeae PH-1 (33% identity) 
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and was also similar to Fe-S oxidoreductase from Geobacter metallireducens GS-15 
(32% identity). The orf3 contained 264 amino acids, and was similar to orfl of 
Mycobacterium gastri (36% identity). Other ORFs corresponded to unknown protein 
product or hypothetical proteins. 
Figure 4.21 Analysis of open reading frame of contigs of lambda DNA from XB1ueSTAR library. 
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Figure 4.22 FramePlot of assembly contigs of lambda DNA from excision pBlueSTAR-1. 
So far, we have been unsuccessful in finding the PKS gene cluster, which is 
involved in the biosynthesis of mensacarcin from the genomic library. The 
heterologous probe, which was used for hybridisation could be a possible cause due to 
its low specific binding with the target samples. Therefore, a homologous probe was 
considered. This probe would be prepared from the complementary DNA (cDNA). 
Here, the messenger RNA (mRNA) would be isolated and used as the primer to amplify 
cDNA by PCR. This PCR product would be used as probe for screening the library by 
hybridisation. In addition, the cDNA library might be prepared. But there are some 
caveats that we need to consider. ' 52 These are that mRNA in bacterium is unstable as 
the half-life in vivo only 1-2 minutes and it has only a short tail polyadenylated (poly A) 
at 3' end, which is necessary for preparation of cDNA by PCR. In general, it is rather 
uncommon to produce a bacterial cDNA library. The isolation of mRNA from S. C414 
has been tried but has not been successfully carried out. 
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4.3 Conclusions and further work 
The studies of mensacarcin production from Streptomyces C414 were carried out. 
Mensacarcin was isolated and separated by column chromatography. This yielded 85 
mg 1-1 mensacarcin. To investigate the biosynthetic pathway and the biological active 
part, genetic techniques were used as tool for these studies. In an effort to find the gene 
cluster, a genomic DNA library was prepared, and the polyketide synthase genes 
searched. 
The preparation of genomic DNA was successful by extraction with phenol- 
chloroform and purification by CsC1-ethidium bromide gradient. By observation from 
agarose gel, the size of gDNA was bigger than 30 kb. To construct the genomic library, 
gDNA was partially digested with either Sau3A I or BamHI. Two lambda vectors: 
Lambda GEM-11 BamHI Site Arm and Lambda BlueSTAR Xhol Site Arm, were 
utilised for cloning. Lambda GEM-11 BamHI Site Arm is 43 kb in size and accepts the 
DNA fragments in range 14-23 kb whereas Lambda B1ueSTAR vector is 48 kb in size 
and accept the insertion fragments in range 7-20 kb. Cloning to Lambda GEM-11 
vector, the partially digested gDNA needed to do size fractionation to remove the out 
size range accepted. On the other hand, size fractionation can be omitted for cloning to 
Lambda B1ueSTAR but the nucleotide end filled-in was required. The additional 
advantage of Lambda B1ueSTAR vector is the direct excision of plasmid that carrying 
the gDNA insertion. 
The preparations of genomic libraries using both vectors were satisfactory as the 
libraries showed the appropriate size from the calculation of titre phages. Both libraries 
were screened by hybridisation with the heterologous probe. The 2 kb fragment of actl 
DNA that consists of KS,, and a portion of KSß was used as isotopically labelled probe. 
The screening of both genomic libraries was satisfied. The phage plaque stocks were 
prepared. For genomic library in Lambda GEM-11, the preparation of phage lysate was 
achieved by plate lysate as the higher yield was observed. But the quality of phage 
lysate was lower than preparation by liquid culture method because it was usually 
contaminated with E. coli cell debris. This sometimes caused the purification of lambda 
DNA in the further step to be unsuccessful. Also the purified DNA failed to digest with 
restriction enzymes. For genomic library in Lambda B1ueSTAR, the preparation of 
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lambda DNA was carried out by the excision of pBlueSTAR-1, and then the DNA was 
purified from this plasmid. 
After purification, lambda DNA was rescreened by restriction digestion and 
Southern hybridisation with actl probe. Hybrid bands were observed on the X-ray films 
from both libraries and the lambda DNA viscera were partially sequenced. DNA 
analysis by frameplot and BLAST search showed some ORFs but no sequences that 
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5.1 General experimental details 
5.1.1 Techniques 
Column chromatography 
Flash column chromatography was carried out using Merck silica gel 60 as the solid 
support. Samples were loaded in the minimum volume of the elution solvent. The 
compounds were eluted with a suitable solvent for each system. 
Thin Layer Chromatography 
Thin layer chromatography (TLC) was carried out using Merck Kieselgel 60/F254 
aluminium backed sheets with a suitable solvent system as mobile phase. Bands were 
visualized by using ultraviolet light or developing in anisaldehyde H2SO4 reagent (15 
ml of solution A (85 ml methanol, 10 ml acetic acid and 5 ml conc. sulphuric acid) and 
0.15 ml 4-methoxybenzaldehyde) and followed by heating with a hot air gun. 
Microbiological work 
Microbiological work was undertaken under sterile conditions in a Biomat Class II 
microbiological cabinet. All media and materials were sterilised prior to use by 




All chemicals and solvents were of analytical grade and purchased from BDH Chemical 
Ltd., Fluka, Adrich, Lancaster or Sigma Chemical Co. Ltd. (Sigma) unless otherwise 
stated. HPLC grade solvents were purchased from Rathburn and Fisher Scientific. 
Media ingredients were purchased from Sigma, Oxoid, Difco or Merck. 
Electrophoresis grade agarose was obtained from Invitrogen. 
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Enzymes 
Restriction enzymes were obtained from Roche, Promega and Sigma. T4 DNA ligase 
and Rapid T4 DNA ligase were purchased from Promega and Invitrogen. Red Taq 
polymerase was obtained from Sigma. 
Vectors 
Cloning vectors, LambdaGEM-11®BamH I Arms and pETGEM-T Easy were purchased 
from Promega. LambdaBlueSTAR Xhol Site Arm and pET 15b, expression vectors 
were purchased from Novagen. 
Competent Cells 
E. coli strain TAM 1 was used as the standard cloning host and was supplied by Active 
Motif. E. coli strains BL21 (DE3) and Rosetta (DE3) utilised for protein expression 
were obtained from Novagen. E. coli KW251 and BM25.8 were used as host cells 
according to Promega and Novagen manufacturer's protocols respectively. Strain 
details are shown in Table 5.1. 
Table 5.1 Competent cells and host strains 
E. coli strains Genotypes 
TAM! mcrA(mrr-hsdRMS-mcrBC)(D801acZAM15 AlacX74 recA1 
araD139 (ara-leu) 7697 galU galK rpsL endAl nupG 
BL21 (DE3) F ompT hsdSB(rB"mB-) gal dem (DE3) 
Rosetta (DE3) F ompT hsdSB(rB-mB-) gal dem (DE3) pRARE2 (Cam 2) 
KW251 F supE44, galK2 galT22 metB 1 hsdR2 mcrB 1 mcrA- argA81: Tn 10 
recD 1014 
BM25.8 supE thiA(lac-proAB) F [traD36proA+B+ lacl'ZAM] S] Ximm434P 1 
hsdR(rkl2-mkl2+)(CamR, KanR) 
Isotopic label 
Isotope that was used for hybridisation was [a-32P] dCTP, which was purchased from 
Amersham. 
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Bacterial and plasmid strains 
Pseudomonas fluorescens NCIMB 10586 wild type and mup mutant strains including 
plasmid strains for mupirocin protein studies were supplied by Professor C. M. Thomas, 
School of Biosciences, University of Birmingham, UK. Streptomyces C414 was 
donated from Professor Axel Zeeck, University of Goettingen, Germany. Plasmid 
strain (pRJCII04F) for preparation of the gene probe was supplied by Dr R. J. Cox. 
5.1.3 Instrumentation 
Nuclear Magnetic Resonance Spectroscopy (NMR) 
1H, 13C, COSY, DEPT, and HMQC spectra were recorded on a JEOL GX400, Eclipse 
400 or Varian 600 MHz NMR spectrometers as solutions in deuterochloroform or 
deuteromethanol, using CDC13 as a reference to 5H 7.25 and 6c 77.0 while CD3OD as a 
reference to 6H 3.30 and Sc 48.0. Chemical shifts are reported in parts per million 
(ppm) and the coupling constants are in Hertz (Hz). 
High Performance Liquid Chromatography 
High performance liquid chromatography (HPLC) was performed using a GILSON 750 
System on a luna C18 column (5 µ, 4.6 x 250 mm, Phenomenex). Compounds were 
separated using a linear gradient of 95% water/ 5% acetonitrile to 5% water/ 95% 
acetonitrile containing either 0.05% TFA or 0.005% formic acid at flow rate 1 ml min-' 
over 50 minutes with the UV detected at 233 nm. For purification, the HPLC was 
performed using a Beckman System Gold Samples were separated using a step 
gradient mobile phase over 30 minutes. 
Liquid Chromatography-Mass Spectrometry 
Liquid chromatography-mass spectrometry (LC-MS) analysis was undertaken on a luna 
C8 column (5 µ, 2.0 x 150 mm, Phenomenex). Compounds were separated by using a 
linear gradient of 95% water/ 5% acetonitrile to 5% water/ 95% acetonitrile containing 
0.05% TFA at flow rate 1 ml min-' over 20 minutes. 
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Mass Spectrometry 
Low and high-resolution mass spectrometry were obtained by Fisons Autospec mass 
spectrometer. Spectra were obtained using electron impact (EI) and chemical ionisation 
(CI) techniques. 
Fast Protein Liquid Chromatography 
Fast protein liquid chromatography (FPLC) analysis was carried out using an AKTA 
FPLC (Amersham, Pharmacia). HiprepTm 26/10 desalt column was used for desalting 
and buffer exchange. Superdex 75 HR 10/30 and Superdex 200 HR 10/30 columns 
were used for purification. 
5.2 Chapter 2 experimental: mupirocin biosynthesis 
5.2.1 Growth media 
(a) L-agar: 10.0 g Bacto-tryptone, 5.0 g yeast extract, 10.0 g NaCl, 1.0 g D-glucose, 
with the pH adjusted to 7.0 in 1 litre dH2O and then 15.0 g agar was added. 
(b) Seed medium: 10.0 g Bacto-tryptone, 5.0 g yeast extract, 10.0 g NaCl, 1.0 g D- 
glucose with the pH adjusted to 7.0 in 1 litre dH2O. 
(c) Mupirocin production medium (MPM): 2.3 g yeast extract, 2.6 g Na2HPO4,2.4 g 
KH2PO4,5.0 g (NH4)2SO4,1.1 g D-glucose in 1 litre dH2O. 
(d) Production medium (PM): 0.20 g soya flour, 0.50 g spray dried corn steep liquor, 
0.10 g Na2HPO4,0.15 g KH2PO4,0.10 g KC15 0.50 g (NH4)2SO4,0.625 g CaCO3,0.05 g 
MgSO4 7H20 in 85 ml dH2O. Prior to use 40% D-glucose (autoclaved, 15 ml) was 
added. 
(e) Secondary stage medium (SSM): 2.0 g soya flour, 0.25 g spray dried corn steep 
liquor, 0.25 g NaH2PO4,0.90 g (NH4)2SO4,2.0 g CaCO3,0.059 MgSO4 7H20 in 75 ml 
dH2O. Prior to use 40% D-glucose (autoclaved, 25 ml) was added. 
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5.2.2 Production of pseudomonic acid by P. fluorescens NCIMB 10586 wild type 
and mup mutants 
Seed medium (25 ml) in 250 ml conical flasks was inoculated with a single colony of P. 
fluorescens NCIMB 10586 wild type (WT) or mup mutants and incubated with shaking 
at 200 rpm, 25°C for 24 hours. MPM (100 ml in 500 ml conical flasks) was inoculated 
with 5% volume of each seed culture and incubated at 200 rpm, 22°C for 50 hours. The 
cultures were harvested by centrifugation (Sorvall® RC5C PLUS, Kendro) at 10,000 
rpm, 4°C for 15 minutes. An aliquot (50 µl) from each supernatant was taken for 
analysis by reverse phase HPLC using a C18 column (luna 5 µ, 4.6 x 250 mm, 
Phenomenex). Water/ acetonitrile containing 0.05% TFA was used as mobile phase. 
The compounds were separated using linear gradient of mobile phase at flow rate 1 ml 
min-' and detected by UV at 233 nm. 
The remaining supernatants of wild type and each mutants were acidified to pH 
4.5 by addition of HCl (1 N), saturated with NaCl and extracted with 3x 50 ml of ethyl 
acetate. The organic phases were combined, dried over magnesium sulphate and 
evaporated to dryness. Each crude extract was dissolved in methanol (1 ml) and 
analysed by HPLC and LC-MS. 
5.2.3 LC-MS analysis 
Crude extract in methanol (20 µl) was analysed by LC-MS and compounds were 
separated on a Luna C8 column (5 p, 2.0 x 150 mm, Phenomenex) using a linear 
gradient of 95% water/ 5% acetonitrile to 5% water/ 95% acetonitrile containing 0.05% 
TFA at flow rate 1 ml min"' over 20 minutes. 
5.2.4 Isolation of compounds produced by P. fluorescens NCIMB 10586 wild type 
and mup mutants in mupirocin production medium (MPM) 
To isolate compounds, MPM (100 ml in 50 x 500 ml conical flasks) was inoculated 
with 5% volume of seed cultures of P. fluorescens NCIMB 10586 wild type or the mup 
mutants, e. g. mupV, mupO, MT1 mutants. The bacteria were grown with shaking at 200 
rpm, 22°C for 50 hours. After 50 hours the cultures were harvested by centrifugation at 
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10,000 rpm, 4 °C for 15 minutes. The combined supernatant was acidified to pH 4.5, 
saturated with NaCI and extracted with 3x2.5 1 of ethyl acetate as described in 5.2.2. 
The crude extracts were dissolved in methanol (10 ml). Compounds were separated by 
either column chromatography or HPLC. The crude extracts were treated with 
diazomethane prior to purification by column chromatography. 
For column chromatography, the methylated extracts were dissolved in a small 
amount of elution solvent and loaded onto a silica gel 60 column. Compounds were 
eluted by dichrolomethane (CH2C12)-methanol (MeOH) in a ratio of 12: 1. The fractions 
of interest were collected, evaporated to dryness and characterised. 
For HPLC purification, an aliquot (480 µl) of crude extract was injected to 
HPLC using a Beckman System Gold on a C18 column (luna 5 µ, 4.6 x 250 mm, 
Phenomenex). Water and acetonitrile containing 0.05% TFA were used as solvent 
system at flow rate 1 ml min-' and compounds detected by UV at 233 nm. The 
compounds were eluted using a step gradient mobile phase (Table 5.2) and fractions of 
interest were collected. The remaining solution was similar separated by repeated 
injection. The combined fractions were evaporated to dryness and characterised. 
Table 5.2 Mobile phase for separation of compounds by HPLC 
Time (minutes) Flow rate (ml min-) %A (water) %B (acetonitrile) 
0-2 1.0 95.0 5.0 
2-4 1.0 63.0 37.0 
20-23 1.0 1.0 99.0 
25-26 1.0 95.0 5.0 
28-30 0.1 95.0 5.0 
5.2.5 Preparation of ethereal diazomethane'59 
Potassium hydroxide (14 g, 0.25 mol) in ethanol (50 ml) and water (15 ml) was cooled 
in an ice bath and a solution of diazald (N-methyl-N-nitroso-p-toluenesulphanamide) 
(43 g, 0.20 mol) in diethyl ether (250 ml) was added. The yellow distillate mixture was 
distilled at 65°C into an ice-cold conical flask until the distillate was colourless. Once 
complete, the remaining reaction mixture was quenched with 10% acetic acid in diethyl 
ether. Diazomethane was used immediately. 
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Caution: Diazomethane is a toxic, explosive, carcinogenic and corrosive substance. 
5.2.6 Preparation of methyl esters of crude extracts from P. fluorescens NCIMB 
10586 wild type and mup mutants 
Diazomethane was added dropwise to the crude extract (in methanol) until in excess. 
To test for the excess diazomethane, a few drops of acetic acid were added. The 
evolution of nitrogen indicated there was excess of diazomethane. The reaction was 
incubated at room temperature for 1-2 hours. To remove the excess diazomethane, the 
solution was quenched by addition of 10 % acetic acid in diethyl ether until no further 
nitrogen was evolved. The solution was then evaporated to dryness to yield the methyl 
ester. 
5.2.7 Optimisation of growth conditions for pseudomonic acid production in P. 
fluorescens NCIMB 10586 and derivative mutants 
Seed medium (25 ml) was inoculated with a single colony of P. fluorescens NCIMB 
10586 and incubated with shaking at 200 rpm, 25°C for 24 hours. MPM, PM or SSM 
(100 ml in either 500 ml conical flaks or baffled flasks) were inoculated with 5% of the 
volume of the broth cultures and incubated at 200 or 240 rpm and 22°C or 25°C for 50 
hours. The production of pseudomonic acid A (PA-A) was analysed by HPLC as 
described in 5.2.2. 
To study the effect of medium volume, P. fluorescens NCIMB 10586 was 
grown in 100 ml and 200 ml MPM in 500 ml conical flasks with shaking at 200 rpm, 
22°C for 50 hours. The production of PA-A was observed as described in 5.2.2. 
To study the effect of shape of shaking flask, P. fluorescens NCIMB 10586 was 
grown in 100 ml MPM in a 500 ml conical flask or a 500 ml baffled flask with shaking 
at 200 rpm, 22°C for 50 hours. The production of PA-A was observed as described in 
5.2.2. 
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5.2.8 Isolation of pseudomonic acid A produced by P. fluorescens NCIMB 10586 
in secondary stage medium (SSM) 
Secondary stage medium (SSM, 100 ml in a 500 ml baffled flask) was inoculated with 
5% of the seed culture volume and incubated with shaking at 250 rpm, 22°C for 50 
hours. After which point the cultures were harvested by centrifugation at 10,000 rpm, 
4°C for 15 minutes. An aliquot (50 µl) of the supernatant was analysed by HPLC as 
described in section 5.2.2. The remaining supernatant was extracted with ethyl acetate 
as described in 5.2.4. Crude extract was dissolved in 5 ml methanol and analysed by 
LC-MS. The remaining extract was diluted four or five fold with distilled water or 
HPLC grade water and centrifuged to remove the precipitate residue. Compounds from 
the remaining extract were separated by HPLC as described in 5.2.4 but the mobile 
phase (water/ acetonitrile) contained 0.005% formic acid instead of 0.05% TFA. 
Three fractions of interest were collected after 16.5-16.9,17.0-17.5 and 19.5- 
20.5 minutes respectively. Each combined fraction was evaporated at 30-35°C to 
remove acetonitrile. The aqueous phase was extracted three times with half the culture 
volume of ethyl acetate, dried over magnesium sulphate and evaporated to dryness. 
5.2.9 Isolation and purification of compounds produced by P. fluorescens 
NCIMB 10586 mup mutants 
Compounds, which were produced by each mup mutant, were isolated and purified as 
described in 5.2.8. Fractions of interest were collected and characterised by NMR. 
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Compound 63 was isolated from mupW mutant fermentation. 1H NMR (400 
MHz, CD3OD): b=0.75 (3H, d, J=7, H3-17), 1.01 (3H, d, J=6, H3-16), 1.07 (3H, d, J 
= 6.5, H3-14), 1.25-1.27 (8H, br s, H2-4'- 7'), 1.45-1.48 (1H, m, H-12), 1.50-1.60 (5H, 
br s, H2-3', H2-8', HH-9), 1.96 (1H, ddd, J= 12,8,6, HH-9), 2.10 (3H, d, J= 1, H3-15), 
2.13 (1 H, dd, J= 13,8, HH-4), 2.18 (2H, t, J=7.5, H2-2' ), 2.21-2.26 (1 H, m, H-8), 2.51 
(1 H, dd, J= 13,2, HH-4), 3.40 (1 H, t, J=6, H-6), 3.51 (1 H, dd, J= 8,6, H-7), 3.54 (1 H, 
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dd, J= 8,3, H-11), 3.78 (1 H, dddd, J= 13,4,3,2, H-5), 3.89 (1 H, dq, J=8,6, H-13 ), 
3.98 (2H, t, J=6.4, H2-9'), 4.00 (1 H, ddd, J= 11,7,2, H-10), 5.67 (1 H, s, H-2); ' 3C 
NMR (100 MHz, CD3OD): 6= 10.2 (C-17), 18.0 (C-16), 18.2 (2C, C-14, C-15), 25.1 
(C-3'), 26.1 (C-7'), 28.8 (C-8'), 29.2 (2C, C-4', C5'), 29.3 (C-6'), 34.0 (C-2'), 35.6 (C- 
9), 37.6 (C-8), 43.3 (C-12), 43.9 (C-4), 63.8 (C-9'), 69.2, (C-6), 71.1 (C-7), 74.9 (C-13), 
77.0 (C-5), 80.4 (C-10), 86.2 (C-11), 117.5 (C-2), 15 8.5 (C-3), 167.5 (C-1), 176.8 (C- 
1'). MS (EI): m/z (%) 503 ([M]+, 0.5). 
5.2.10 Methylation of mupW metabolite 64 
OH 
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Diazomethane, prepared as described in 5.2.5, was added dropwise to the purified 
compound (5 mg) in methanol (3 ml) whilst cooling on ice until the yellow colour of the 
solution was stable. The reaction was stirred continuously for 15 minutes. Excess 
diazomethane was removed by addition of 10% acetic acid in diethyl ether or by drying 
under a stream of nitrogen until colourless. The solution was evaporated to dryness to 
yield a pale yellow oil 64.1H NMR (600 MHz, CDC13, TMS): 8=0.79 (3H, d, J=7, 
H3-17), 1.17 (3H, d, J=6, H3-16), 1.19 (3H, d, J=6, H3-14), 1.30-1.42 (8H, br s, H2- 
4'- 7'), 1.48 (1H, ddq, J=9,8,6, H-12), 1.63 (4H, in, H2-3', H2-8'), 1.68 (1H, dt, J= 
12,11, HH-9), 2.01 (1 H, ddd, J= 12,7,5, HH-9), 2.14 (1 H, d, J=4,6-OH), 2.23 ((3H, 
d, J=1, H3-15), 2.29 (1 H, dd, J= 14,9, HH-4), 2.30 (2H, t, J=7.5, H2-2), 2.37 (1 H, 
dqdd, J= 11,7,7,7, H-8), 2.43 (1H, d, J=3,5-OH), 2.59 (1H, dd, J= 14,2, HH-4), 
2.85(1, s, 11-OH), 3.62 (1 H, ddd, J=7,6,4, H-6), 3.64 (1 H, dd, J=7,7, H-7), 3.67 
(3H, s, OCHS), 3.76 (1H, dd, J= 9,3, H-11), 3.84 (1H, dq, J= 8,6, H-13), 3.90 (1H, s, 
13-OH), 3.95 (1H, dddd, J= 13,4,3,2, H-5), 4.08 (2H, t, J= 7, H2-9'), 4.12 (1H, ddd, 
J= 11,5,3, H-10), 5.79 (1 H, s, H-2); 13C NMR (100 MHz, CDC13, TMS): b= 12.4 (C- 
17), 18.3 (C-16), 19.0 (C-15), 20.1 (C-14), 24.9 (C-3'), 25.9 (C-7'), 28.6 (C-8'), 29.0 
(C-4'), 29.1 (2C, C-5', C-6'), 33.7 (C-9), 34.1 (C-2'), 37.8 (C-8), 42.3 (C-12), 43.9 (C- 
4), 51.5 (CO2Me), 63.9 (C-9'), 70.6 (C-5), 72.0 (C-13), 76.1 (C-7), 76.7 (C-11), 80.5 
(C-10), 86.2 (C-6), 118.5 (C-2), 156.2 (C-3), 166.5 (C-1), 174.4 (C-1'). MS (Cl): m/z 
(%) 517 ([M]H+, 46), 499 ([M-H2O]H+, 25), 481 ([M-2 H2O]H+, 14), 329 ([M- 
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O(CH2)8CO2Me]+, 34), 311 ([M-O(CH2)8CO2Me-H201+, 66), 293 ([M-O(CH2)8CO2Me- 
2H2O]+, 100). HRMS (Cl, [M]H+) calcd for C27H49O9 517.3377, found 517.3378. 
5.2.11 Acetylation of methylated mupW metabolite 65 
OAc 
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The methyl ester 64 (5 mg, 0.01 mmol) was dissolved in dichloromethane (2 ml) and 
treated with pyridine (0.5 ml) and acetic anhydride (0.25 ml, 3.4 mmol) stirring at room 
temperature for overnight. The pyridine was removed by addition of dichloromethane 
(2 ml) and extraction with HC1 (1 N) three times, washed with brine, dried over 
magnesium sulphate and evaporated to dryness to yield 65 as a pale yellow oil. 1H 
NMR (600 MHz, CDC13, TMS): b=0.97 (3H, d, J=7, H3-17), 1.05 (3H, d, J=6, H3- 
16), 1.16 (3H, d, J= 7, H3-14), 1.30-1.40 (8H, br s, H2-4'-7'), 1.50 (IH, ddq, J= 12,10, 
8, H-12), 1.60 (4H, in, H2-3', H2-8')5 1.62 (IH, dd, J= 14,7, HH-9), 1.98 (3H, s, 
OCOCH3), 2.08 (3H, s, OCOCH3), 2.09 (3H, s, OCOCH3), 2.10 (1H, dd, J= 6,2, HH- 
4), 2.16 (3H, d, J= 1, H3-15), 2.30 (2H, t, J= 7.5, H2-2'), 2.44 (1H, ddd, J= 14,11,11, 
H-8), 2.51 (1 H, dd, J= 14,3, HH-4), 3.50 (IH, dd, J=8,4, H-7), 3.62 (3H, s, 
OCOCH3), 4.06 (2H, t, J=7, H2-9'), 4.15 (1 H, ddd, J= 10,6,4, H-10), 5.00 (1 H, dd, J 
= 11,4, H-11), 5.01 (1 H, dq, J= 10,6, H-13 ), 5.08 (1 H, dd, J=8,3 H-6), 5.3 5 (1 H, 
ddd, J= 11,6,3, H-5), 5.70 (1 H, s, H-2). 13C NMR (100 MHz, CDC13, TMS): b= 10.8 
(C-17), 15.7 (C-14), 17.8 (C-16), 18.4 (C-15), 20.9,20.9,21.1,21.4 (COCOCH3), 24.9 
(C-3'), 25.9 (C-7'), 28.6 (C-8'), 29.1,29.1,29.7 (C-4', C-5', C-6'), 34.1 (C-2'), 36.6 
(C-9), 38.5 (C-12), 39.4 (C-8), 40.0 (C-4), 51.8 (CO2Me), 63.8 (C-9'), 70.6 (C-5), 70.8 
(C-11), 74.9 (C-13), 75.2 (C-6), 78.2 (C-10), 83.1 (C-7), 118.5 (C-2), 155.0 (C-3), 166.5 
(C-1), 170.6 (2C, 2x OCOCH3), 170.7 (OCOCH3), 170.8 (OCOCH3), 174.3 (C-1'). 
MS (Cl): m/z (%) 685 ([M]H+, 18.7), 653 ([M-OCH3]+, 4), 625 ([M-OCOCH3]+, 94.0), 
565 ([M-(CH2)3CO-OCH3-H2O]+, 100.0), 497 ([M-O(CH2)8CO2Me]H+, 14.0). HRMS 
(Cl, [M]H+) calcd for C35H56013 685.3799, found 685.3810. 
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5.3 Chapter 3 experimental: mupirocin biosynthetic protein studies 
5.3.1 Growth media 
(a) LB-agar: 10.0 g Bacto-tryptone, 5.0 g yeast extract, 10.0 g NaCI, 15.0 g agar with 
the pH adjusted to 7.0 in 1 litre dH2O. 
(b) LB medium: 10.0 g Bacto-tryptone, 5.0 g yeast extract, 10.0 g NaCl with the pH 
adjusted to 7.0 in 1 litre dH2O. 
(c) M9 minimal media: 6.0 g Na2HPO4,3.0 g KH2PO45 0.5 g NaCI, 1.0 g NH4C1 with 
the pH adjusted to 7.0 in 1 litre dH2O. After autoclaving the solution was added IM 
MgSO4 (200 µl) 1M CaC12 (10 µl) 35% glucose (5 ml). 
(d) 2TY medium: 16.0 g Bacto-tryptone, 10.0 g yeast extract, 10.0 g NaCI with the pH 
adjusted to 7.5 in 1 litre dH2O. 
(e) SOC medium: 2TY medium (1 ml) was added glucose (10 µl, 1 mg/ml) and MgCl2 
(10 µl, 1 mg/ml). 
5.3.2 Transformation of DNA into E. coli TAM1 
Ligation product or plasmid DNA (2 µl) was added to TAM I competent cells (25 µl). 
The reaction was incubated on ice for 30 minutes, heat shocked at 42°C for 30 seconds 
and then placed on ice for 2 minutes. SOC medium (250 µl) was added to the 
transformation mixture and incubated with shaking at 37°C for 1 hour. The 
transformation product was spread on an LB plate containing an appropriate antibiotic, 
and incubated at 37°C overnight. 
5.3.3 Isolation of plasmid DNA 
LB media (3-5 ml) containing an appropriate antibiotic was inoculated with a single 
colony of E. coli carrying target plasmid and incubated with shaking at 250 rpm, 37°C 
overnight. Cells were harvested by centrifugation and plasmid DNA isolated using the 
Wizard MiniPrep (Promega) following the manufacturer's protocol. 
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5.3.4 Transformation of mup protein plasmid into E. coli 
The mup plasmid DNA (2 µl) was added to E. coli BL21 (DE3) or Rosetta(DE3) 
competent cells (20 µl) and incubated on ice for 5 minutes, heated at 42°C for 30 
seconds and immediately placed on ice again for 2 minutes. To the cell suspension was 
added 250 µd of SOC medium and the same incubated with shaking at 37°C for 1 hour. 
100 µl of culture was spread on an LB plate containing an appropriate antibiotic, and 
incubated overnight at 37°C. 
5.3.5 Preparation of overnight culture 
LB media (3-5 ml) containing an appropriate antibiotic was inoculated with a single 
colony of E. coli BL21 (DE3) or Rosetta(DE3) carrying mup protein plasmid and 
incubated with shaking at 37°C overnight. 
5.3.6 Small-scale overexpression of mup protein 
LB media (25 ml) containing an appropriate antibiotic was inoculated with overnight 
culture (250 µl) and incubated with shaking at 250 rpm, 37°C until the optical density at 
600 nm (OD6oo) reached 0.6. Protein expression was induced by the addition of 
isopropyl-, &D-thiogalactoside (IPTG) to a final concentration of 0.1-1.0 mM and 
incubated for a further 2-4 hours at a induction temperature. Cells were separated by 
taking aliquots (2 ml) and centrifuging at 13,000 rpm for 2 minutes, and the supernatant 
discarded. The cells were re-suspended in sterile water or buffer (200 µl). 
The cell walls of re-suspended cells were lysed by sonication (3 x 30 sec) on ice. 
The mixtures were centrifuged at 13,000 rpm, room temperature for 5 minutes. The 
supernatant, soluble protein, was transferred to new tubes. The pellets, which may 
contain insoluble protein, were re-suspended in 200 µl of 1% sodium dodacyl sulphate 
(SDS) in water. The samples, soluble and insoluble fractions were analysed by SDS- 
polyacrylamide gel electrophoresis (SDS-PAGE). 
150 
Chapter 5 Experimental 
5.3.7 SDS-polyacrylamide gel electrophoresis 
SDS-PAGE analysis was performed using a Mini-PROTEAN III system (Biorad). The 
solution and buffer were prepared as described below. 40% Acrylamide/ bis-acrylamide 
solution (Biorad) was used to prepare the gel. The samples were prepared by taking 10 
µl of sample to mix with 10 µl loading buffer, boiled for 10-15 minutes to denature the 
proteins and run in 10% separating gel, 4% stacking gel (Table 5.3) along with the low 
range marker (6,500-66,000 Da, Sigma). The gel was run using 30-40 mA for 20 
minutes, followed by 70-80 mA until the dye moved to an appropriate level. The gel 
was stained in the staining solution for 15-20 minutes and then destained overnight. 
The image was recorded with Kodak Digital Science camera (DC40) and processed 
using Kodak Digital Science 1D software. 
Table 5.3 Preparation of SDS polyacrylamide gel 
4% Stacking gel (10 ml) 10% Separating gel (10 ml) 
40% Acrylamide 1 ml 2.5 ml 
Gel buffer 2.5 ml 3.33 ml 
Glycerol - 1.3 ml 
dHZO 6.5 ml 2.8 ml 
10% Ammonium persulphate 50 µl 50 µl 
TEMED 20 µl 10 µl 
Gel buffer: 181.7 g Tris base, 1.5 g SDS with the pH adjusted to 8.45 in 500 ml dH2O. 
Anode buffer: 12.11 g Tris base with the pH adjusted to 8.9 in 500 ml dH2O. 
Cathod buffer: 6.06 g Tris base, 8.96 g Tricine, 0.5 g SDS with the pH adjusted to 8.25 
in 500 ml dH2O. 
Stain solution: 0.25 g Coomassie blue, 45 ml methanol, 10 ml glacial acetic acid in 
100 ml dH2O and filter before used. 
Destain solution: 45 ml methanol, 10 ml glacial acetic acid in 100 ml dH2O. 
Loading buffer: 9.46 g Tris base, 1 ml ß-mercaptoethanol, 1g SDS, 10 ml glycerol, 
0.01 g bromophenol blue with the pH adjusted to 6.8 in 100 ml dH2O. 
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5.3.8 Protein concentration assessment 
The concentration of proteins was determined using the BCATM Protein Assay Kit 
(Pierce) with bovine serum albumin (BSA) was used as a standard. A serial dilution of 
BSA dilutions: 5,25,50,125 and 250 µg/ml was prepared. Each dilution (50 µl) was 
taken and assayed alongside the unknown. The unknown sample (50 µl) was taken 
directly to assay or dilute into two or three series with sterile water (50 µl) was used as 
reference. All samples were added to reagent A (1 ml), reagent B (20 µl), mixed well 
and then incubated at 37°C for 30 minutes. The absorbance of the solution was 
measured at 562 nm and the concentration of protein was calculated comparison with 
the standard. 
Reagent A: sodium carbonate, sodium bicarbonate, bicinchoninic acid and sodium 
tartrate in 0.1 M sodium hydroxide. 
Reagent B: 4% cupric sulphate. 
5.3.9 Construction of mupT gene into pET15b vector 
5.3.9.1 Preparation of mupT gene 
The mupT gene was amplified using the polymerase chain reaction (PCR). Two 
primers were designed based on the published sequences of mupT and encoding 
restriction sites. 99 The forward primer (FW-T) sequence encoding a NdeI site was 
5'CATATGTTGGTAGAGCATCCGCCC 3whilst the reverse primer (RV-T) sequence 
encoding a BamHI site was 5'GGATCCTCACGTACCGCACTCCAG 3. The reaction, 
which contained template DNA (1 µl), 10 µM FW-T (1 µl), 10 µM RV-T (1 µl), 2 mM 
dNTPs (5 µl), 10 x Red Taq buffer (2.5 µl) and sterile water (12.5 µl), was prepared in a 
PCR tube on ice and centrifuged briefly. Red Taq polymerase (2 µl) was added and 
mixed by pipetting up and down. The tube was placed in a PCR machine (PTC-200 
Peltier Thermal Cycler, MJ Research) and run using the following conditions: 
step 1: 94°C for 2 minutes 
step 2: each cycle composed of 94°C for 30 seconds, 58-69 °C for 30 seconds, 
and 72°C for 30 seconds, for 30 cycles 
step 3: 72°C for 10 minutes 
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Once complete, 2 µd of PCR product was analysed by gel electrophoresis. The band 
corresponding to mupT gene from the remaining PCR product was purified by High 
pure PCR purification kit (Roche) following the manufacturer's protocol. 
5.3.9.2 Gel electrophoresis 
DNA was analysed by agarose gel electrophoresis, which was run on a Sigma 
horizontal gel electrophoresis apparatus. 0.4-1.0% agarose (electrophoresis grade, 
Invitrogen) in TAE buffer (40 mm Tris-acetate, 1.0 mm EDTA) was used to prepare the 
gel. 1 µl gel loading buffer (0.25% bromophenol blue, 0.25% xylenecyanol FF, 15% 
Ficoll in water) was added to every 5 µl of sample before loading on the gel. 
Hyperladder I (Bioline) was added alongside the samples to permit size identification of 
the fragments. Gels were run at 25-100 mA using TAE as the running buffer and 
stained for approximately 15 minutes in the ethidium bromide solution (5-10 µl (15 mg 
ethidium bromide in TAE buffer) in 50 ml H20), which allows the DNA to be absorbed 
by UV light. Digital images were recorded with a Kodak Digital Science camera (DC 
40) and processed using Kodak Digital Science 1D software. 
5.3.9.3 Ligation of mupT gene to pGEM®-T Easy Vector 
DNA ligation was carried out following the protocol of pGEM®-T Easy Vector Kit 
(Promega). A reaction consisted of pGEM®-T Easy vector (1 µl), 2x Rapid ligation 
buffer (5 µl), PCR product (mupT gene) (2 µl), T4 ligase (1 µl) and sterile water (1 µ1), 
was incubated at room temperature for 1 hour and then transformed into E. coli TAM! 
as described in section 5.3.2. The transformation product was screened using 
blue/white colony selection by spreading on a LB plate containing carbenicillin (50 
µg/ml), X-gal (80 µg/ml) and IPTG (0.5 mM). The plate was incubated at 37°C 
overnight and stored at 4°C until used. 
5.3.9.4 Isolation of mupT gene from pGEM-T mupT 
TAM I pGEM-T mupT was incubated overnight in LB media (5 ml) containing 
carbenicillin (50 µg/ml) with shaking at 250 rpm, 37°C. Cells were harvested and 
plasmid DNA isolated as described in section 5.3.3. Plasmid DNA was double digested 
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with Ndel and BamHI and the digestion reaction analysed by agarose gel 
electrophoresis. The band corresponding to mupT gene, 351 bp, was purified from the 
gel. The expression vector, pET15b was prepared in the same way as the mupT 
fragment. 
5.3.9.5 Purification of DNA fragments from agarose gel 
Digested DNA sample was loaded into a wide well in a 0.4-1.0% low melting point 
agarose gel (Invitrogen). To 5 µl of DNA solution, 1µl gel loading buffer was added 
and the solution mixed. Gel electrophoresis was performed at 25-100 mA as described 
in section 5.3.9.2. After staining in ethidium bromide solution, the gel was placed on a 
glass plate and briefly visualised with UV light to identify the DNA position. Target 
DNA fragment was excised from the gel using a razor blade, and extracted using High 
pure PCR product purification kit (Roche) following the manufacturer's protocol. 
5.3.9.6 Ligation of mupT fragment to pET15b Vector 
mupT and pET 15b cut fragments were ligated together. A typical reaction contained 10 
x Fast-Link ligation buffer (1.5 µl), 10 mm ATP (1.5 µl), pET 15b vector (1 µl), inserted 
DNA fragment (3 µl), Fast-Link DNA ligase (1 µl, Cambio) and sterile water (7 µl) and 
incubated at room temperature for 5 minutes. The enzyme was inactivated by heating at 
70°C for 15 minutes and the ligation product transformed into TAM 1 competent cells as 
described in section 5.3.2. 
5.3.10 Overexpression of MupT by pET15b mupT 
pET15b mupT was transformed to E. coli BL21 (DE3) as described in section 5.3.4. 
The E. coli BL21 (DE3) containing pET15b mupT was grown in LB media containing 
carbenicillin (50 µg/ml) and expressed by induction with 1 mm IPTG at 25 or 37°C for 
a further 2or 4 hours as described in section 5.3.6. Cells were separated by 
centrifugation, re-suspended in Tris buffer (20 mm pH 8.0 with 10% glycerol) or 
phosphate buffer (20 mm pH 7.5 with 10% glycerol), and sonicated as described in 
section 5.3.6. After sonication, soluble and insoluble fractions were analysed by SDS- 
PAGE. 
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As no expression of the MupT protein was observed, we attempted to optimise 
the expression conditions. Two experiments were carried out. One experiment, the 
overnight culture of transformed mupT in BL21(DE3) (250 µl) was added to LB media 
(25 ml) containing carbenicillin (50 µg/ml) and 1% glucose in 250 ml conical flask. 
The flask was incubated with shaking at 37°C until the OD600 reached 0.6. Another 
one, without glucose, was incubated under the same conditions. For induction, each 
experiment was separated into four tubes and induced with IPTG to a final 
concentration of 0.10 mM, 0.25 mM, 0.50 mM, and 1.0 mm respectively. All tubes were 
incubated with shaking at 25°C for 4 hours. After 4 hours, the cells were harvested and 
the lysis conditions performed as described in section 5.3.6. 
In addition, the pET15b mupT was transformed into E. coli Rosetta (DE3) and 
overexpression as described above. 
5.3.11 Large-scale overexpression of mup protein in LB medium 
Overnight culture of BL21 (DE3) the mup protein expression plasmid (1 ml) was added 
to LB media (100 ml) containing carbenicillin (50 µg/ml) or kanamycin (50 µg/ml) and 
incubated with shaking at 250 rpm, 37°C until the OD600 reached 0.6. Protein 
expression was induced by addition of IPTG to a final concentration of 1 mM and 
incubated at 250 rpm, 25°C for 4 hours. The cells were harvested by centrifugation at 
9,000 rpm, 4°C for 15 minutes and were re-suspended in Tris buffer (20 ml; 50 mM pH 
8.0). Cells were lysed by sonication (10 x 30 sec blasts and storing on ice for 2 minutes 
between each blast). The cell free extracts were centrifuged at 18,000 rpm, 4°C for 20 
minutes and the supernatant transferred to a new tube. The pellets, which may contain 
insoluble target protein, were re-suspended in 1% SDS (20 ml). The proteins were 
purified by affinity chromatography. 
5.3.12 Optimisation of conditions for overexpression of pETmupT and pETmupW 
Transformed BL21 (DE3) carrying mup protein expression plasmid was grown as 
described in section 5.3.6 until the OD600 reached 0.6. Protein expression was obtained 
in the presence and absence of IPTG at different induction temperatures. Therefore, one 
set of cultures was added IPTG to final concentration 1 mM and further incubated with 
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shaking at 15°C, 25°C or 37°C for 4 hours. Another set, without IPTG, was incubated 
in the same condition. Cells were separated as described in section 5.3.6. To study the 
effect of lysis buffer on protein solubility, cells were re-suspended in three different 
buffers (2O0µ1): Tris buffer (20 mm pH 8.0 and 10 % glycerol) phosphate buffer (100 
mm pH 7.5 and 10 % glycerol), and E. coli buffer (50 mM Tris-HC1 pH 8.0,1 mM 
phenylmethylsulfonyl fluoride, 1 mM dithiothreitol (DTT)and 10 % glycerol) instead of 
water. 
5.3.13 Purification of soluble proteins by nickel affinity chromatography 
His-bind resin (5-8 ml) was loaded into a glass Biorad column. Prior to running the 
column was equilibrated with distilled water (20 ml), charging buffer (20 ml, 50 mM 
NiSO4 solution) and binding buffer (20 ml; 50 mm NaCl, 20 mm Tris-HC1,5 mM 
imidazole, pH 7.9) at a flow rate of 1 ml min-'. Protein samples were filtrated through a 
0.45 µm syringe filter (Satorious) and injected onto the column. 20 ml of both binding 
buffer and washing buffer (50 mm NaCl, 20 mm Tris-HC1,60 mm imidazole, pH 7.9) 
were injected onto the column respectively. The proteins were eluted using 20 ml 
elution buffer containing 50 mm NaCl, 20 mM Tris-HCI, 0.25-1.0 M imidazole, pH 7.9. 
Fractions (1 ml) were collected during the injection of eluting buffer and analysed by 
SDS-PAGE as described in section 5.3.7. Fractions containing the target protein were 
combined and desalted by FPLC into Tris buffer (20 mm pH 8.0 with 10% glycerol). 
5.3.14 Purification of mup protein by anion exchange chromatography 
Anion exchange chromatography was performed using a MonoQ column (1 ml, 
Pharmacia). The column was first equilibrated with 5 column volumes of low salt 
buffer (20 mM Tris buffer pH 8.0), followed by 5 column volumes of high salt buffer 
(20 mM Tris buffer pH 8.0 containing 1M NaCl) and finally with 5 column volumes of 
low salt buffer. Protein solution (1 ml), which was purified by affinity chromato- 
graphy, was diluted to 10 ml with 20 mm Tris buffer pH 8.0 and injected 
into the 
column. The proteins were eluted using a linear gradient of 1M NaCl over 30 minutes 
at a flow rate of 1 ml min-'. Fractions were analysed by SDS-PAGE as 
described in 
section 5.3.7. Fractions containing the target protein were combined and 
desalted by 
FPLC into Tris buffer (20 mm pH 8.0 with 10% glycerol). 
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5.3.15 Purification of mup protein by gel filtration chromatography 
Gel filtration chromatography was used to separate the protein by size using the 
Superdex 75TH HR10/30 column (20 ml, Pharmacia) or the Superdex 200 TM HR10/30 
column (23.5 ml, Pharmacia). The column was washed with two column volumes of 
water and equilibrated with two column volumes of Tris buffer (20 mm pH 8.0) 
containing 150 mm NaCl at flow rate 0.3-0.5 ml min-. Protein solution (500 µl) in 
Tris buffer (20 mm pH 8.0) was injected to the column. The proteins were separated 
and eluted with Tris buffer (20 mm pH 8.0) containing 150 mm NaCl at flow rate 0.5 
ml min-' The fractions were collected and analysed by SDS-PAGE. By this method, 
the molecular weight of protein was also determined by calculation comparison with 
the standards: blue dextran (2,000,000 Da), amylase (200,000), alcohol dehydrogenase 
(150,000), albumin (66,000 Da), carbonic anhydride (29,000 Da) and cytochrome c 
(12400 Da). 
5.3.16 Overexpression of pETmupT in M9 minimal media 
E. coli BL21 (DE3) pETmupT was grown in LB media as described in section 5.3.11 
until the OD600 reached 0.6. Cells were harvested by centrifugation at 9,000 rpm, 4 °C 
for 15 minutes and washed with M9 minimal media (10 ml) and centrifuged. The cells 
were re-suspended in M9 minimal media (10 ml). 1 ml of this solution was inoculated 
into M9 minimal media (100 ml) and incubated with shaking at 250 rpm, 37°C for 30 
minutes and induced by addition of IPTG to a final concentration of 1 mM. Flasks were 
incubated with shaking at 250 rpm, 25°C for 4 hours. Once complete the cells were 
harvested by centrifugation at 9,000 rpm, 4°C for 15 minutes and were re-suspended in 
Tris buffer (20 mM, pH 8.0 with 10% glycerol). The re-suspended cells were lysed and 
purified as described in section 5.3.11 and 5.3.13 respectively. 
5.3.17 Purification of insoluble protein by nickel affinity chromatography 
The strains were grown and expressed as described in section 5.3.11. Cells were 
harvested by centrifugation and sonicated. After centrifugation the insoluble proteins 
were re-suspended in Tris buffer (20 ml, 20 mm pH 8.0) containing urea (6M). The 
proteins were purified by nickel affinity chromatography using His-bind resin under 
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denaturing conditions with urea (6M) added to the buffers used in the purification 
procedure. Fractions were eluted and analysed by SDS-PAGE. The fractions, which 
contained the target protein were combined and desalted by dialysis. 
5.3.18 Protein refolding 
Removal of salts and urea was carried out by dialysis. The concentration of urea was 
slowly decreased from the dialysis buffer. Protein solution was loaded into the dialysis 
tubing (Spectra) and placed into a crystallisation basin containing dialysis buffer (20 
mm Tris buffer pH 8.0 with 5M urea) at 4°C overnight. The concentration of urea was 
decreased in IM steps until the buffer contained no urea. Precipitate residue was 
removed by centrifugation and the protein solution analysed by SDS-PAGE. 
5.3.19 Protein solubilisation 
The strains were grown and expressed as described in section 5.3.11. The cells were 
harvested by centrifugation at 9,000 rpm, 4°C for 15 minutes. The supernatant was 
removed and the cells re-suspended in wash buffer (20 ml; 20 mm Tris-HC1 pH 7.5,10 
mM EDTA, 1% Triton X-100). To the solution was added lysozyme (lyophilised, 
Sigma) to a final concentration of 100 gg/ml, incubated at 30°C for 15 minutes and 
sonicated as described in section 5.3.11. The cell free extract was centrifuged at 9,000 
rpm, 4°C for 10 minutes. The above step was repeated by adding further wash buffer. 
The pellets were re-suspended in solubilisation buffer (50 mm CAPS: 3-[cyclohexy 
lamino]-1-propane sulfonic acid, pH 11.0,0.3% of N-lauroylsacocine and 1 mm DTT). 
The reaction was incubated at room temperature for 15 minutes and centrifuged at 9,000 
rpm, 4°C for 10 minutes. The supernatant containing solubilised protein, was 
transferred to a fresh tube. Solubilised proteins were refolded by dialysis as described 
in section 5.3.18. The concentration of DTT, which contained in protein solution, was 
decreased whilst changing the dialysis buffer until without DTT. 
5.3.20 Thrombin cleavage of MupT 
Two experiments were carried out. In the first experiment, thrombin cleavage was 
obtained in the solution. Protein solution (200 µl) in thrombin cleavage buffer (20 mm 
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Tris buffer pH 7.5,50 mm NaCl, 2.5 mm CaC12 and 5. O MM MgCl2) was incubated with 
a 1: 100 ratio (v/v) of thrombin (1 U/µ1). In the second experiment, protein solution 
(200 µl) in thrombin cleavage buffer was mixed with His-bind resin (100 µ1) which was 
precharged with NiSO4 buffer and thrombin. Both reactions were incubated with 
shaking at 25°C for 1,2,3,4,5,6 hours. Every hour, an aliquot (10 µl) from both 
reactions was analysed by SDS-PAGE. 
5.4 Chapter 4 experimental: mensacarcin biosynthesis 
5.4.1 Growth medium 
(a) Seed medium: 20.0 g oatmeal and 2.5 ml trace element solution with the pH 
adjusted to 7.8 in 1 litre dH2O. 
Trace element solution: 3.0 g CaC12 2H20,1.0 g FeC13,0.2 g MnSO4,0.1 g ZnC12, 
0.025 9 CuSO4 5H20,0.02 g Na2B4O7 10H20,0.01 g Na2MoO4 2H20,0.0049 CoC12 in 
100 ml dH2O. 
(b) M2 medium: 10.0 g malt extract, 4.0 g yeast extract, 4.0 g D-glucose with the pH 
adjusted to 7.0 in 1 litre dH2O. 
(c) NL-1358 medium: 30.0 g glycerol, 2.0 g caseinpeptone, 1.0 g K2HPO4,1.0 g NaCl, 
and 2.5 ml trace element solution with the pH adjusted to 7.0 in 1 litre dH2O. 
(d) R2YE medium: 103.0 g sucrose, 0.25 g K2SO49 10.12 g MgC16 6H209 10.0 g 
glucose, 0.1 g casamino acids in 800 ml dH2O. After autoclaving, to the solution (80 
ml) was added 0.5% KH2PO4 (1. Oml), 3.68% CaC12 (8.0 ml), 20.0% L-proline (1.5 ml), 
5.73% TES buffer (10.0 ml), trace element solution (0.2 ml), IN NaOH (0.5 ml), 10% 
yeast extract (5 ml). 
Seed medium was also used as production medium while LB medium and SOC medium 
were prepared as described in section 5.3.1. 
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5.4.2 Time course of mensacarcin production by Streptomyces C414 
Seed medium (50 ml) was inoculated with a 10 µl loopful of Streptomyces C 414 and 
incubated with shaking at 250 rpm 25°C for 72 hours. Production medium (100 ml) 
was inoculated with 5% volume of the seed cultures and incubated with shaking at 250 
rpm, 25°C. Two culture flasks were harvested each day by centrifugation. The 
supernatant was extracted three times with half the culture volume of ethyl acetate. The 
organic phases were combined and evaporated to dryness to yield a yellow product. 
The crude extract was dissolved in a small amount of dichloromethane and analysed by 
LC-MS. The concentration of mensacarcin was calculated comparison with the 
standard. 
5.4.3 Isolation of mensacarcin by Streptomyces C414 
Crude mensacarcin was cultured and extracted as described in section 5.4.2 and purified 
by column chromatography on silica gel 60 using dichloromethane-methanol (98: 2) as 
eluent. Fractions were collected and analysed by TLC. Fractions containing the target 
compound were combined and evaporated to dryness. The residue was dissolved in a 
small amount of dichloromethane and re-columned using a mixture of dichloromethane- 
methanol-acetone (15: 2: 1) as eluent. Fractions were collected, evaporated to dryness 
and analysed by TLC. The purified compound was characterized by 1H and 13C NMR 
spectroscopy. 
5.4.4 Preparation of genomic DNA 
5.4.4.1 Preparation of cells 
Streptomyces C414 was grown in three different media: M2, NL-1358 and R2YE as 
described in section 5.4.2 to identify the best for isolating genomic DNA. To compare 
the production, the mensacarcin was extracted from the above media and the 
concentration of mensacarcin determined by LC-MS. The best production was found 
from M2 medium. Thus, M2 media (100 ml in 5x500 ml conical flasks) were 
inoculated with 5% volume of seed cultures and incubated with shaking at 250 rpm, 
25°C for 4 days. Cells were harvested by centrifugation at 10,000 rpm, 4°C for 15 
minutes and used for isolation genomic DNA. 
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5.4.4.2 Extraction of genomic DNA 151,160 
Cells (approximately 4 g) were re-suspended in DNA extraction buffer (10 ml; 10 mM 
Tris-HC1 pH 8.0,10 mM ethylene diamine tetraacetic acid (EDTA), 0.5% sodium 
dodacyl sulphate (SDS)) on ice. To the solution was added lysozyme (lyophilised, 
Sigma) to a final concentration of 2 mg/ml, mixed well and incubated at 37°C for 1 
hour. Extraction solution (10 ml, phenol: chloroform: isoamyl alcohol = 25: 24: 1) was 
added to the solution and mixed slowly on ice for 30 minutes. The solution was 
centrifuged at 6,000 rpm, 4°C for 15 minutes to separate the phases. The aqueous layer 
was transferred to a fresh centrifuge tube and phenol-chloroform extraction was 
repeated until the interface of two layers became clear. 
Phenol was removed from the aqueous layer by extraction with chloroform- 
isoamyl alcohol solution (24: 1) 2-3 times. RibonucleaseA solution (bovine pancreas, 
20 gl-1 in water, 10 µl) was added to the solution to remove RNA and incubated at 37°C 
for 30 minutes. Phenol-chloroform extraction, followed by chloroform-isoamyl alcohol 
extraction was repeated. The genomic DNA was recovered by ethanol precipitation as 
described in section 5.4.4.3. 
5.4.4.3 Ethanol precipitation 
To the solution containing target DNA was added to 2.5 volumes of ethanol and 0.1 
volume of 4M LiCl solution and incubated at -20°C overnight. The precipitated DNA 
was separated by centrifugation at 13,000 rpm, 4°C for 10 minutes. The pellet was 
washed with 70% ethanol, dried at room temperature and re-suspended in TE buffer (1 
ml; 10 mm Tris-HC1 pH 8.0,1 mM EDTA) at 4°C overnight. 
5.4.4 4 DNA concentration assessment 
DNA concentration was quantitatively assessed by UV-VIS Spectroscopy (Pharmacia). 
10 µl of DNA solution was diluted 40 times with sterile water and the absorbance at 260 
nm was measured. The concentration of DNA was calculated according to equation 5.1. 
1 unit Abs260 = 50 ng/µl double-stranded DNA (5.1) 
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5.4.4.5 Purification of genomic DNA by CsCI-Ethidium bromide gradient 
To purify the DNA, the weight of genomic DNA solution was determined by 
transferring the solution into a new tube. Solid caesium chloride (CsCI) 1.01 g for 
every gram of DNA solution was added into DNA solution. The solution was mixed 
slowly until the CsCl dissolved. For every millilitre of genomic DNA, 80 µ1 of 
ethidium bromide solution (10 mg/ml) was added. The solution was mixed gently and 
transferred to centrifuge tubes. To balance the weight, CsCI solution (p = 1.55 g/ml) 
was used. The tubes were sealed and centrifuged using TL-100 ultracentrifuge 
(Beckman, USA) at 15°C, 100,000 rpm approximately 16 hours. The genomic DNA 
band was visualised with an UVL-21 long wave lamp (Ultra-violet Products Inc. ) and 
removed using a hypodermic needle and syringe. Genomic DNA was combined and 
centrifuged again in the same method as above for 5-6 hours. The ethidium bromide 
and CsCI were removed by precipitation of the DNA in 3 volumes of water and 4.5 
volumes of isopropanol at -20°C overnight. The pellet was separated by centrifugation 
at 13,000 rpm, 4°C for 10 minutes, washed with 70% ethanol, dried at room 
temperature and re-suspended in TE buffer at 4°C overnight. 
5.4.5 Construction of genomic library 
5.4.5.1 Partial digestion of genomic DNA 
Optimisation of restriction digestion 
Small-scale reactions were performed to optimise the enzyme concentration for 
generating the desired range of fragment sizes for construction of the genomic library. 
In these studies serial dilution of the two restriction enzymes, BamHI and Sau3A I were 
used. Therefore five enzyme dilutions (500,1000,2000,4000 fold and no enzyme) in 
enzyme dilution buffer (20 mm Tris-HC1 pH 7.5,250 mm NaCl, 5 mm 2-mercapto- 
ethanol, 0.1 % mM EDTA, 50% glycerol) were prepared. 
The digestion mixture consisted of genomic DNA solution (8 µl), 10 x enzyme 
buffer (1 µl), restriction enzyme dilution (1 µl), mixed gently. The 5 digestion reactions 
were incubated at 37°C for 1 hour. The reactions were stopped by heating at 65°C for 5 
minutes and analysed by 0.4% agarose gel electrophoresis along with HyperladderV 
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(10-48.5 kb, Bioline) as described in section 5.3.9.2. The gel was run at 25 mA for at 
least 3 hours or until the dye moved to the end. 
Large-scale preparation of partial digestion of genomic DNA 
Using the optimised conditions for digestion was scaled up. The reaction mixture 
consisted of genomic DNA solution (40 µl), 10 x enzyme buffer (5 µ1), appropriate 
BamHI or Sau3A I enzyme dilution (5 µl), mixed gently and incubated at 37°C for 2 
hours, then stopped by heating at 65°C for 10 minutes. Digested DNA was recovered 
by ethanol precipitation as described in section 5.4.4.3. The pellets were re-suspended 
in TE buffer (40 µl). 
5.4.5.2 Size fractionation of genomic DNA 
Digested DNA outside the required fragment size was removed by gel electrophoresis 
as described in section 5.3.9.2. Gel electrophoresis was performed using 0.4% agarose 
gel and gel run at 25 mA for 3 hours. The target fragment was purified from gel as 
described in section 5.3.9.5. The purified DNA was eluted into TE buffer (20 µl). 
5.4.5.3 Partial end filling in genomic DNA 
Genomic DNA (40 µl), partially digested as described in section 5.4.5.1 using Sau3A I, 
was added to 10 x polymerase buffer (6 µl), 100 mm dATP (1 µl), 100 mm dGTP (1 
µl), and Klenow enzyme (2 p1, DNA polymerase I large (Klenow) fragment, Promega), 
sterile water (10 µl). The reaction mixture was mixed gently and incubated at 30°C for 
30 minutes. The reaction was stopped by heating at 65°C for 10 minutes. DNA was 
recovered by ethanol precipitation as described in 5.4.4.3. 
5.4.5.4 Cloning of genomic DNA fragments to Lambda GEM-11® Vector 
Genomic DNA fragments from 5.4.5.2 were ligated into LambdaGEM-11®BamHI 
Arms (Promega) and BamHI Site Arm was used as positive control. To determine the 
appropriate ratio of vector to inserted DNA, the following reactions were performed. 
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Control Samples 
Reaction Positive Negative 1 2 3 
LambdaGEM-11®BamHI Arms vector 
(0.5 µg/µl), [d 
0.5 0.5 0.5 0.5 0.5 
BamHI Site Arm positive control, pl 2.0 - - - - 
Inserted DNA (0.15 µg/µ1), µl - - 1.0 2.0 5.0 
10 x T4 DNA ligase buffer, µl 1.0 1.0 1.0 1.0 1.0 
T4 DNA ligase, pl 1.0 1.0 1.0 1.0 1.0 
Sterile water, pl 5.5 7.5 6.5 5.5 2.5 
Total, pl 10.0 10.0 10.0 10.0 10.0 
The ligation reactions were incubated at 4°C overnight. 
5.4.5.5 Cloning of genomic DNA fragments to Lambda B1ueSTAR Vector 
Genomic DNA fragments, which were digested with Sau3A I and partial end filled-in, 
were ligated into Lambda BlueSTAR Xhol Half-site Arms (Novagen) with half-site 
control insert used as positive control. To optimise the ratio of vector to insert, the 
following reactions were set up. 
Reaction Control Samples 
Positive Negative 1 2 
Lambda BlueSTAR Xhol Arms vector (0.48 
µg/µl), t1 
0.5 0.5 0.5 0.5 
Half-site control insert (0.25 µg/µ1), pI 2.0 - - - 
filled-in DNA fragments, µl - - 1.0 - 
filled-in DNA fragments (diluted 10 fold), µl - - - 2.0 
10 x T4 DNA ligase buffer, . i1 1.0 1.0 1.0 1.0 
T4 DNA ligase, µl 0.5 0.5 0.5 0.5 
Sterile water, µl 6.0 8.0 7.0 6.0 
Total, µl 10.0 10.0 10.0 10.0 
The ligation reactions were incubated at 4°C overnight. 
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5.4.5.6 In vitro packaging 
Packaging extract (PackageneaExtract, Promega or PhageMaker®, Novagen) was 
thawed on ice and added to ligated DNA mixture (50 µl/10 µl ligated DNA solution) 
with gently mixing. Extract/DNA mixture was incubated at room temperature for 2-3 
hours and added to phage buffer (450 µl; 20 mm Tris-HCI pH 7.4,100 mm NaCl, 10 
mM MgSO4 7H20) or SM buffer (5.8 gl-'NaCl, 2.0 g1-1MgSO4 7H20,50 ml/1 Tris-HCI 
pH 7.5,5.0 ml 2% gelatine) and chloroform (25 µl) and mixed gently by inversion and 
stored at 4°C until used. 
5.4.5.7 Titration of recombinant phage 
Preparation of bacterial cell for infection 
E. coli KW251, from a glycerol stock solution, was spread on an LB plate containing 
tetracycline (15 µg/ml) and incubated at 37°C overnight. LB media (50 ml), 
supplemented with 0.2% maltose and MgSO4 (10 mM), was inoculated with a single 
colony of KW251 and incubated with shaking at 37°C for 5-7 hours or until the OD600 
reached 1.0. Cells were isolated by centrifugation at 2,000 rpm for 10 minutes. Cells 
were re-suspended in MgSO4 solution (20 ml, 10 mm) and stored at 4°C until used. 
Titre of packaged phage 
Serial dilutions of packaged phage in phage buffer or SM buffer (1: 10,1: 100,1: 1,000, 
1: 10,000 (v/v)) were made and then each diluted phage (100 µl) was added to the 
bacterial cell suspension (100 µl) and the phage allowed to adsorb for 30 minutes at 
37°C. Molten LB top agarose (3 ml; 1% Bacto-tryptone, 0.5% NaCl, 0.6 % agarose) 
was added and mixed by quickly inverting and immediately poured onto prewarmed LB 
plates. The plates were left at room temperature to allow LB top agarose to harden and 
then incubated at 37°C overnight. The phage plaques, which occurred on the plates were 
counted and the titre of the phage and the packaging efficiency of arms were calculated 
using equation 5.2 and 5.3. 
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The titre in plaques forming units (pfu/ml) = Number of plaques x dilution factor (5.2) 
Volume of extract plated 
and recombinants / pg DNA = pfu / ml (5.3) 
Concentration of vector DNA packaged 
5.4.6 Amplification of genomic library 
Packed phage (300 µl) was added to 2 ml of bacteria cells as described in section 
5.4.5.7. The phages were allowed to absorb for 30 minutes at 37°C. Molten LB top 
agarose (30 ml) was added to the phage/bacteria mixture. The mixture was mixed by 
quickly inverting and immediately poured onto prewarmed LB 23 x 23 cm plate. The 
LB plate was left to allow the LB top agarose to harden and the plate incubated at 37°C 
overnight. Phage plaques were eluted by covering the plate with 20 ml of SM buffer 
and incubated at 4°C for overnight. The buffer was transferred to a sterile centrifuge 
tube using a sterile pipette. Chloroform (10 ml) was then added and the sample shaken 
well. The solution was centrifuged at 6,000 rpm for 10 minutes and supernatant 
transferred to a sterile tube and stored at 4°C in chloroform (short-term storage) or at - 
20°C in DMSO (long-term storage). 
5.4.7 Screening of genomic library with gene probe 
5.4.7.1 Preparation of actl fragment probe 
A single colony of E. coli DH5a actl was inoculated into LB media (3 ml) containing 
carbenicillin (50 µg/ml) and incubated with shaking at 37°C overnight. The cells were 
harvested by centrifugation and plasmid DNA purified as described in section 5.3.3. 
The plasmid DNA was double digested with BamHI and Ndel. The digestion 
reaction contained plasmid DNA (20 µ1), BamHI (1 µl), Mel (1 µl), lOx enzyme buffer 
(2.4 µl) was incubated at 37°C for 2 hours. The reaction was stopped by heating at 
65°C for 10 minutes and analysed on a 0.7% agarose gel as described in section 5.3.9.2. 
The fragment, approximately 2 kb in size was isolated as described in section 5.3.9.5 
and used as a probe. 
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5.4.7.2 Preparation of phage plates 
1 µl of genomic library (approximately 3x 106 pfu) was added to 200 µl of E. coli 
KW251 bacterial cells. The experiment was performed as described in section 5.4.5.7 
(titre of packaged phage) and plates left at 4°C for 1-2 hours before blotting. 
5.4.7.3 Blotting of membranes 
Phage plaques were transferred using Zeta-Probe® GT membranes or nitrocellulose 
membranes (Boehringer Mannheim) cut to the same size as the plate. The membranes 
were placed on the surface of the plaques and left for 5 minutes. At which point the 
membranes were taken from the plates and denatured with 0.5m NaOH for 2 minutes by 
turning the side that touched the plaques up. To neutralise the DNA, the membranes 
were washed with a mixture of 0.5 M NaOH and 1.5 M NaCl for 2 minutes, followed by 
washing with 1.5 M NaCl and 0.5 M Tris-HC1 pH 7.5 for 2 minutes. Finally, the 
membranes were washed with 2xSSC buffer (0.30 M NaCl, 0.030 M sodium citrate pH 
7.0) for 5 minutes, dried on filter papers and put in filter paper bags. The DNA was 
fixed onto the membrane by baking at 80°C for 30 minutes and kept at room 
temperature until used. 
5.4.7.4 Preparation of labelled probe with 32P 
The DNA solution (in range 25-50 ng), which was used as the probe, was denatured in a 
95°C water bath for 5 minutes and immediately placed on ice for 2 minutes. The 
reaction mixture containing denatured DNA (2-5 µl), [a-32P] dCTP (2 µl, 300 
Ci/mmol), sterile water (45-48 µl) was prepared in Ready To GoTM DNA Labelling 
Beads (Amersham Pharmacia Biotech), mixed by gently pipetting up and down several 
times and incubated at 37°C for 15 minutes. The reaction was stopped by incubation on 
ice. The labelled DNA was purified by nick column (Pharmacia) according to the 
manufacturer's protocol, and eluted in sterile water (400 µl). Alternatively, the labelled 
DNA was purified by G-50 spin column (Amersham). 50 µl of above labelled DNA 
was loaded into the column, and centrifuged for 2 minutes. All purified labelled DNA 
was denatured by boiling for 5 minutes, cooled on ice and either used immediately or 
stored at -20°C for later used. 
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5.4.7.5 Hybridisation 
The blotting membrane from 5.4.7.3 was placed into a hybridisation tube taking care be 
avoid bubble formation, and pre-hybridised in 40 ml hybridisation buffer (20 ml 14% 
SDS, 20 ml 0.5 M Na2HPO4 pH 7.2). The tube was rotated in a hybridisation oven 
(Techne) at 65°C for 10 minutes. After 10 minutes the buffer was decanted and a 
further 10 ml of hybridisation buffer and labelled probe from 5.4.7.4 were added to the 
tube and rotated overnight at 65°C. 
The buffer was decanted from the tube and the unincorporated radioactive probe 
removed by adding a wash buffer (2xSSC buffer and 0.1% SDS) and rotating at 65°C 
for 15 minutes. The solution was decanted and the above step repeated. The 
membranes were taken out, covered with Saran wrap (Dow) and placed in a film 
cassette. X-ray film was placed on the wrapped membranes in the film cassette, snap 
shut and stored at -70°C for 5 hour. 
Once complete, the X-ray film was developed using LX-24 X-ray developer 
(Kodak) for 1 minute each side, followed by incubation in Hypam rapid fixer (Ilford) 
for 1 minute each side. The X-ray film was rinsed in running water for 10 minutes and 
dried in an oven. To confirm the result, the wrapped membranes were exposed again as 
above but stored at -70°C overnight. The dark signals, which occurred on the X-ray 
film, were marked on the original plates. The plaques of interest were picked from the 
plates using a sterile tip and the agar plug placed into 1.5 ml eppendorf tube containing 
phage buffer or SM buffer (500 µl) and chloroform (20 µl), and stored at 4°C until used. 
5.4.8 Preparation of lambda DNA from phages 
5.4.8.1 Preparation of bacteriophage lambda stocks151,154 
Liquid culture method 
LB media (3 ml), supplemented with 0.2% maltose and MgSO4 (10 mM), inoculated 
with a fresh single colony of E. coli KW251 and incubated with shaking at 37°C 
overnight. The overnight cultures (500 µl) were added to a tube containing the plaque 
plug eluted from 5.4.7.5 (10-20 µl) and incubated at 37°C for 20 minutes. The infected 
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culture (500 µl) was transferred into 250 ml conical flask containing prewarmed (37°C) 
LB medium (100 ml) supplemented with MgSO4 (1 ml, 1 M). The flask was incubated 
with shaking at 200 rpm, 37°C. After 7 hours, chloroform (500 µl) was added to the 
flask and shaked for a further 15 minutes. The cultures were then centrifuged at 8000 
rpm, 4°C for 10 minutes to remove the cellular debris and supernatant transferred to the 
new sterile tubes and stored at 4°C until used. 
Plate lysate method 
LB media (5 ml), supplemented with 0.2% maltose andMgS04 (10 MM), was 
inoculated with a fresh single colony of E. coli KW251 and incubated with shaking at 
37°C overnight. The eluted plaques from 5.4.7.5 (20 µl) were mixed with overnight 
culture (100 µl) in a 10 ml sterile tube and incubated at 37°C for 20 minutes. Molten 
top agarose (3 ml) was added to the infected cells, mixed by inversion and poured on an 
LB plate, which pre-warmed to 37°C. The LB plate was left until the top agarose was 
hard, and incubated by inversion at 37°C for 6 hours at which point the plate was 
overlaid with SM buffer (3 ml). The top agarose was scraped and broken with a 
spatula, and transferred to a centrifuge tube. The tube was incubated at room 
temperature for 30 minutes with periodically shaking and then centrifuged at 10,000 
rpm, 4°C for 10 minutes. The supernatants were transferred to a fresh tube and 
chloroform added to a final concentration 0.3% (v/v). Samples were stored at 4°C until 
used. 
5.4.8.2 Assaying the DNA content in lysate stock by gel electrophoresis 
151 
DNaseI solution (1 µl, 1 µg/ml) was added to lysate solution (10 p1). The mixture was 
incubated at 37°C for 30 minutes at which point 2.5xSDS-EDTA dye mixture (4 µl, 
0.4% v/v SDS, 30 mm EDTA, 0.25% bromophenol blue, 0.25% xylenecyanol FF, 20% 
(w/v) sucrose) was added and incubated at 65°C for 5 minutes. The reaction was 
analysed by 0.7% agarose gel electrophoresis as described in section 5.3.9.2. 
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5.4.8.3 Precipitation of phage particles 
To the lysate solutions were added DNasel and RNaseA, each to a final concentration of 
1 µg/ml and incubated 30 minutes at room temperature. Solid NaCl (5.84 g to each 100 
ml of lysate solution) was added. The solution was mixed until the salt had dissolved at 
which point the sample was placed on ice for 1 hour. The bacterial debris was removed 
by centrifugation at 8,300 rpm, 4°C for 10 minutes. To supernatant was added solid 
polyethylene glycol (PEG) 6000 to a final concentration of 10 % (w/v). The PEG was 
dissolved by slow stirring at room temperature and the solution then incubated on ice 
for 1 hour to allow the phage particles to precipitate. The precipitated particles were 
removed by centrifugation at 8,300 rpm, 4°C for 10 minutes and the precipitate dried. 
The pellets were re-suspended in SM buffer (1.6 ml to each 100 lysate solution). The 
PEG and bacterial cell debris were extracted from the phage suspension by adding an 
equal volume of chloroform and the phage particles were separated by centrifugation at 
4,300 rpm, 4°C for 15 minutes. The aqueous phase, containing phage particles was 
recovered. 
5.4.8.4 Extraction and purification of lambda DNA 
To remove the phage proteins, the re-suspended phage solution in 5.4.8.3 was treated 
with proteinase K to a final concentration 50 µg/ml and SDS to a final concentration of 
0.5 %. The solution was mixed by gently inverting the tube several times and incubated 
at 56°C for 1 hour. The solution was cooled to room temperature, an equal volume of 
phenol added and the solution mixed by gently inverting the tube several times until an 
emulsion had formed. The phage were separated by centrifugation at 5,000 rpm for 5 
minutes and the aqueous phase was transferred to a fresh tube and extracted once with 
1: 1 mixture solution of phenol and chloroform. The aqueous phase was recovered as 
described above and the extraction repeated with an equal volume of chloroform. The 
lambda DNA was recovered by ethanol precipitation as described in section 5.4.4.3, re- 
suspended in an appropriate volume of TE buffer and stored at 4°C. Alternatively, 
lambda DNA was extracted and purified from the lysate stock using Wizard® Lambda 
Preps DNA Purification System (Promega). 
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5.4.9 Preparation of lambda DNA by excision of plasmid from Lambda 
B1ueSTAR vector 
LB media (3m1), containing 0.2% maltose and MgSO4 (10 mM), was inoculated with a 
single colony of host strain E. coli BM25.8 and incubated with shaking at 37°C until the 
OD600 reached 1.0. Phage solution (3 µl) was added to host cell culture (100 µl), 
incubated at 37°C for 30 minutes and spread on LB plate containing carbenicillin (50 µg 
/ml). The plate was incubated at 37°C overnight. A single colony containing 
recombinant plasmid was picked and grown in LB media (3 ml) containing carbenicillin 
(50 µg /ml) with shaking at 37°C overnight. The plasmid was isolated as described in 
section 5.3.3. As the yield of plasmid DNA was low in the host strain BM25.8, they 
were transformed to TAM 1 as described in section 5.3.2. 
5.4.10 Characterisation of lambda DNA by southern blotting 
Lambda DNA was digested with BamHI at 37°C overnight and analysed by gel 
electrophoresis as described in 5.3.9.2. Lambda DNA on the agarose gel was 
transferred to a nitrocellulose membrane by alkaline capillary method using 0.4 M 
NaOH as transfer buffer for 5-6 hours. 148 DNA was pre-denatured in 0.25 M HCl with 
shaking for 15 minutes prior to blotting. After 5 hours, the membrane was washed 
twice with 2x SSC buffer and baked at 80°C for 30 minutes. The baked membrane was 
hybridised with the gene probe as described in section 5.4.7.5. 
5.4.11 DNA sequencing 
The DNA was sequenced by Lark Technologies using standard primers. From the 
continuously sequenced data, the contiguous sequences were assembled using Vector 
NTI. 
5.4.12 DNA analysis 
Sequence analysis was performed using the Vector NTI suite 6.0. The DNA sequences 
were aligned with the known sequences from databases. BLAST (Basic Local 
Alignment Search Tool) searches on NCBI site (http: //www. ncbi. nlm. nih. goy)l56 and 
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FramePlot (http: //www. nih. go. jp/-jun/cgi-bin/frameplot. Dl)157 for prediction protein- 
coding regions in bacterial DNA with a high G+C content were used for identification 
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